Investigating the inhibition mechanism of L,D- transpeptidase 5 from Mycobacterium tuberculosis computational methods. by Tolufashe, Gideon Femi.
  
 
 
 
 
INVESTIGATING THE INHIBITION MECHANISM OF  
L,D-TRANSPEPTIDASE 5 FROM MYCOBACTERIUM TUBERCULOSIS 
USING COMPUTATIONAL METHODS 
 
 
 
 
BY: GIDEON FEMI TOLUFASHE 
216076453 
 
 
 
Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in  
Pharmaceutical Chemistry 
School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South 
Africa. 
 
2018
i 
 
PREFACE 
The work described in this thesis was conducted at the Catalysis and Peptide Research Unit, Westville 
Campus, University of KwaZulu-Natal, Durban, South Africa, under the supervision of Dr Bahareh 
Honarparvar, Prof. H.G. Kruger and Dr G.E.M. Maguire. 
 
This work has not been submitted in any form for any degree or diploma to any institution, where use has 
been made of the work of others, it is duly acknowledged in the text. 
 
Supervisors:  
Dr B. Honarparvar    Date 30/10/2018 
Prof. H. G. Kruger________________   Date ___________ 
Dr. G.E.M Maguire_______________   Date ___________ 
 
As candidate’s supervisor I agree to the submission of this thesis. 
 
 
 
 
 
 
 
 
 
 
ii 
 
DECLARATION 
DECLARATION I- PLAGIARISM 
I, Gideon Femi Tolufashe declare that 
(i). The research reports in this thesis, except where otherwise indicated, is my original work. 
(ii). This thesis has not been submitted for any degree or examination at any other university. 
(iii). This thesis does not contain other person’s data, pictures, graphs or other information, unless 
specifically acknowledged as being sourced from other persons. 
(iv). This thesis does not contain other person’s writing, unless specifically acknowledged as being sourced 
from other researchers. Where other written sources have been quoted, then: 
a. Their words have been re-written, but the general information attributed to them has been referenced. 
b. Where their exact words have been used, then their writing has been placed in italics and inside quotation 
marks, and referenced. 
(v). This thesis does not contain text, graphics or tables copied and pasted from the internet, unless 
specifically acknowledged, and the source being detailed in the thesis and in the references sections. 
 
Signed ………………………… 
  
iii 
 
DECLARATION II-PUBLICATION  
List of publications included in this Thesis 
1. Gideon F. Tolufashe, Victor T. Sabe, Colins U. Ibeji,  Thandokuhle Ntombela,  Thavendran 
Govender,  Glenn E. M. Maguire,  Hendrik G. Kruger, Gyanu Lamichhane,  and Bahareh 
Honarparvarar. (2018). Structure and function of L,D- and D,D-transpeptidase family enzymes 
from Mycobacterium tuberculosis. Current Medicinal Chemistry. DOI: 
10.2174/0929867326666181203150231 
 
Contributions:  
Tolufashe, G.F: Main author- contributed to the project by performing all literature reviews, manuscript 
preparation and writing.   
Sabe, V.T, Ibeji, C.U, Ntombela, T., Govender, T., Lamichhane, G.: Helped with technical, 
experimental and financial supports.  
Honarparvar, B.: Supervisor  
Kruger, H. G. and Maguire, G. E.: co-supervisors with academic contribution 
2. Gideon F. Tolufashe, Thavendran Govender, Amit K. Halder, Collins U. Ibeji1,  Monsurat M. 
Lawal,  Thandokuhle Ntombela,  Glenn E. M. Maguire,  Gyanu Lamichhane,  Hendrik G. Kruger, 
and Bahareh Honarparvar.  Inhibition of Mycobacterium tuberculosis L,D-transpeptidase 5 by 
carbapenems: MD and QM/MM Mechanistic Studies, ChemistrySelect 2018, 3, 1-11. DOI: 
10.1002/slct.20180318 
 
Contributions:  
Tolufashe, G.F: Main author- contributed to the project by performing all literature reviews, manuscript 
preparation and writing.   
Halder, A.K., Ibeji, C.U, Lawal, M.M., Ntombela, T., Govender, T., Lamichhane, G.: Provided 
assistance with technical, experimental and financial supports.  
Honarparvar, B.: Supervisor  
Kruger, H. G. and Maguire, G. E.: co-supervisors with academic contribution 
 
3. Victor T. Sabe, Gideon F. Tolufashe ,  Collins U. Ibeji, Sibusiso B. Maseko, Thavendran Govender 
,  Glenn E. M. Maguire, Gyanu Lamichhane, Bahareh Honarparvar and Hendrik G. Kruger.  
Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as 
potential anti-TB leads: Virtual Screening and Molecular Dynamics Simulations  
Manuscript Submitted to Journal of molecular modelling on 5 October 2018 
iv 
 
 
Contributions:  
Victor T. Sabe: Principal investigator in the design of this project and first author responsible for writing 
and preparation of this manuscript. 
Gideon F. Tolufashe and Collins U. Ibeji: Provided technical assistance on the project. He did part of 
the calculations and writing of the manuscript. 
Sibusiso Maseko: Performed experimental work. 
Thavendran Govender and Gyanu Lamichhane: Provided technical and experimental assistance in the 
overall project. 
Bahareh Honarparvar: Supervisor.  
Hendrik G. Kruger and Glenn E. M. Maguire: Co-supervisors. 
 
4. Gideon F. Tolufashe, Victor T. Sabe, Collins U. Ibeji, Monsurat M. Lawal,  Thavendran Govender,  
Glenn E. M. Maguire,  Gyanu Lamichhane,   Hendrik G. Kruger and  Bahareh Honarparvar. (2018) 
Inhibition Mechanism of L,D-transpeptidase 5 in presence of the β-lactams using ONIOM 
Method. Journal of molecular graphics and modelling, 87, 204-210. DOI: 
10.1016/j.jmgm.2018.11.009 
Contributions:  
Victor T. Sabe: Principal investigator in the contextualisation and design of the project. 
Gideon F. Tolufashe: Responsible for the calculations, writing and preparation of the manuscript. 
Collins U. Ibeji and Monsurat M. Lawal: Provided technical assistance to the project.  
Bahareh Honarparvar: Supervisor.  
Hendrik G. Kruger and Glenn E. M. Maguire: Co-supervisors. 
 
Publication not included in this Thesis 
Ibeji, Collins U., Gideon F. Tolufashe, Thandokuhle Ntombela, Thavendran Govender, Glenn EM 
Maguire, Gyanu Lamichhane, Hendrik G. Kruger, and Bahareh Honarparvar. "The catalytic role of 
water in the binding site of L, D-Transpeptidase 2 within acylation mechanism: A QM/MM (ONIOM) 
modeling." Tuberculosis (2018). 
 
 
 
v 
 
RESEARCH OUTPUTS 
CONFERENCE PRESENTATIONS 
1. Poster presentation “Binding free energy calculations of carbapenem inhibitors against L,D-
transpeptidase 5 using molecular dynamics(MD) simulation”, CHPC National Meeting & 
Conference, East London, 4-9 December 2016. 
2. Oral presentation “Inhibition mechanism of L,D-Transpeptidase 5 from Mycobacterium Tuberculosis 
in presence of Carbapenems: Molecular Dynamics study”, College of Health Sciences Annual 
Research Symposium, Nelson Mandela Medical School, K-RITH Building, 5-6 October 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
DEDICATION 
This thesis is dedicated to God Almighty, my ever-supporting father, loving wife and daughter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
ACKNOWLEDGEMENTS 
To God be the Glory in the highest for His help and making this degree a successful one, I am very 
grateful.  I would like to express my earnest gratitude and appreciation to:  
• My supervisors, Dr Bahareh Honarparvar, Prof. Gert Kruger and Dr Glenn Maguire for accepting to 
supervise, guide, motivate and impart on me out of what they have academically and morally during this 
program.  These virtues inculcated in me are well appreciated.  
• Dr Adebayo Kutu and Dr Adeola Shobo for paving the way into UKZN and CPRU respectively.  The 
opportunity is highly esteemed.  
• My deepest gratitude to my family (Mr & Mrs Michael Tolufashe, Ifeoluwa and Excellence), for the 
continuous support in terms of prayers, finances and unconditional love all through this program. These 
are things that kept me going.  
• The entire computational chemistry group for the assistance and readiness to work as a team; Dr Amit 
Halder, Dr Collins Ibeji, Dr Zaynab Fakhar, Monsurat Lawal, Zainab Sanusi, Thandokuhle Ntombela, 
Siyabonga Maphumulo, Victor Sabe, Chairmane Kahiya and Llyod.  The entire Catalysis Peptide 
Research Unit (CPRU), most especially Prof Thavendran Govender and Dr Tricia Naicker.  
• The pastorate of Redeemed Christian Church of God, Durban (RCCG) for the spiritual oversight and 
teaching is well helpful and more appreciated. The love I received from my friends are immeasurable.  
• Dr Krishna Govender of Centre of High Performance Computing (CHPC) for the assistance in using the 
computational facilities when I encountered errors. 
The University of KwaZulu-Natal (College of Health Sciences), National Research Foundation (NRF, SA) 
for the financial support and CHPC for the resources. 
 
 
  
viii 
 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................................. i 
DECLARATION..................................................................................................................................... ii 
RESEARCH OUTPUTS ........................................................................................................................ v 
DEDICATION........................................................................................................................................ vi 
ACKNOWLEDGEMENTS ................................................................................................................. vii 
LIST OF FIGURES .............................................................................................................................. xii 
LIST OF TABLES ................................................................................................................................ xiv 
ABBREVIATIONS ............................................................................................................................... xvi 
ABSTRACT ......................................................................................................................................... xviii 
CHAPTER ONE ..................................................................................................................................... 1 
INTRODUCTION ................................................................................................................................... 1 
1.1 Tuberculosis ................................................................................................................................. 1 
1.2 Peptidoglycan synthesis in Mycobacterium tuberculosis ........................................................ 2 
1.2.1 L,D-transpeptidases from Mycobacterium tuberculosis ............................................................ 3 
1.2.2 Carbapenem derivatives as inhibitors of L,D-transpeptidases .................................................. 3 
1.2.3 Catalytic mechanism of L,D-transpeptidases .............................................................................. 4 
1.2.4 Structural and functional behaviour of L,D-transpeptidase 5 ................................................... 6 
1.3 Molecular modelling approaches to study drug-enzyme interactions .......................................... 6 
1.3.1 Computational chemistry .............................................................................................................. 6 
1.3.2 Molecular mechanics ..................................................................................................................... 7 
1.3.4 Force fields ...................................................................................................................................... 7 
1.3.3 Molecular dynamics ....................................................................................................................... 8 
1.3.5 Hybrid quantum molecular/molecular mechanics ...................................................................... 9 
1.3.6 Virtual Screening Techniques ..................................................................................................... 10 
1.4 Databases of potential bio-active compounds ............................................................................... 12 
1.5 Novelty and significance of the study ............................................................................................ 12 
1.6 Aims and Objectives ....................................................................................................................... 13 
1.7 Thesis outline ................................................................................................................................... 14 
1.8 References ........................................................................................................................................ 15 
CHAPTER TWO .................................................................................................................................. 23 
LITERATURE REVIEW .................................................................................................................... 23 
ix 
 
2.1  Introduction .................................................................................................................................... 25 
2.2  Structure and function of D,D- and L,D-transpeptidases .......................................................... 26 
2.3  Mechanistic pathway of transpeptidases ..................................................................................... 35 
2.4  Drugs for Mtb transpeptidase inactivation.................................................................................. 37 
2.5  Experimental case studies ............................................................................................................. 38 
2.6  Computational case studies ........................................................................................................... 41 
2.7  Conclusive remarks and perspectives .......................................................................................... 43 
Abbreviations ........................................................................................................................................ 44 
Competing interests .............................................................................................................................. 44 
Acknowledgements ............................................................................................................................... 45 
References .............................................................................................................................................. 45 
CHAPTER THREE .............................................................................................................................. 51 
Abstract .................................................................................................................................................. 51 
3.1  Introduction .................................................................................................................................... 52 
3.2  Materials and methods .................................................................................................................. 57 
3.2.1  Inhibitor/Enzyme structural preparation ................................................................................. 57 
3.2.2  Preparation of the inhibitor-enzyme complex .......................................................................... 57 
3.2.3  Molecular dynamics (MD) simulations ..................................................................................... 58 
3.2.4  Principal component analysis (PCA) ......................................................................................... 59 
3.2.5  Binding free energy calculations ................................................................................................ 59 
3.2.6  Per-residue binding free energy decomposition analysis ........................................................ 60 
3.2.7  QM/MM Mechanistic studies ..................................................................................................... 60 
3.3  Results and discussion ................................................................................................................... 61 
3.3.1  Molecular docking ...................................................................................................................... 62 
3.3.2  Molecular dynamics simulations ............................................................................................... 62 
3.3.3  RMSD analysis ............................................................................................................................ 63 
3.3.4  RMSF analysis ............................................................................................................................. 64 
3.3.5  Binding free energy analysis ...................................................................................................... 65 
3.3.6  Per-residue decomposition energy analysis .............................................................................. 66 
3.3.7  Tip-tip distance analysis of the enzymes’ hairpin/loop ............................................................ 68 
3.3.8  Principal component analysis (PCA) ......................................................................................... 71 
3.3.9  Hydrogen bonding Analysis ....................................................................................................... 72 
x 
 
3.3.10  Thermochemical analysis ......................................................................................................... 73 
3.4  Conclusion ...................................................................................................................................... 77 
Competing interests .............................................................................................................................. 78 
Acknowledgement ................................................................................................................................. 78 
References .............................................................................................................................................. 78 
CHAPTER FOUR ................................................................................................................................. 84 
Abstract .................................................................................................................................................. 84 
4.1  Introduction .................................................................................................................................... 85 
4.2  Materials and methods .................................................................................................................. 88 
4.2.1 System preparation ...................................................................................................................... 88 
4.2.2  Virtual screening using AutoDock Vina ................................................................................... 89 
4.2.3  Virtual screening using Schrödinger Maestro .......................................................................... 89 
4.2.4  Molecular dynamics simulation ................................................................................................. 91 
4.2.5  Binding free energy calculation ................................................................................................. 91 
4.3  Results and discussions .................................................................................................................. 91 
4.3.1 Data set preparation .................................................................................................................... 91 
4.3.3 Binding free energy analysis ....................................................................................................... 96 
4.3.4  Trajectory analyses of β-lactam-LdtMt5 complexes ................................................................ 102 
4.3.4.1  Root mean square deviation (RMSD) analysis .................................................................... 102 
4.3.4.2  Analysis of the radius of gyration (Rg) ................................................................................ 103 
4.3.4.3 Binding free energy (∆Gbind) analysis of β-lactam-LdtMt5 complexes ................................. 103 
4.3.4.4  Residue-inhibitor interaction analysis ................................................................................. 104 
4.4  Conclusion .................................................................................................................................... 106 
Acknowledgements ............................................................................................................................. 107 
Conflict of interest ............................................................................................................................... 107 
References ............................................................................................................................................ 107 
CHAPTER FIVE ................................................................................................................................ 111 
Abstract ................................................................................................................................................ 111 
5.1  Introduction .................................................................................................................................. 112 
5.2  Computational methods .............................................................................................................. 114 
5.2.1  System preparation ................................................................................................................... 114 
5.2.3  Second-order perturbation analysis ........................................................................................ 116 
xi 
 
5.2.4  Frontier molecular (FMO) orbitals ......................................................................................... 116 
5.3  Results and discussion ................................................................................................................. 117 
5.3.2  Frontier molecular orbitals and electrostatic potential mapping ......................................... 119 
5.3.3 Natural bond orbital (NBO) analysis ....................................................................................... 120 
5.4  Conclusion .................................................................................................................................... 122 
Competing interests ............................................................................................................................ 123 
Acknowledgement ............................................................................................................................... 123 
References ............................................................................................................................................ 123 
CHAPTER SIX ................................................................................................................................... 127 
Conclusion ........................................................................................................................................... 127 
References ............................................................................................................................................ 129 
Appendix 1. Supplementary material for Chapter 3 ....................................................................... 130 
Appendix 2. Supplementary material for Chapter 4 ....................................................................... 146 
Appendix 3. Supplementary material for Chapter 5 ....................................................................... 148 
 
  
xii 
 
LIST OF FIGURES 
CHAPTER ONE 
Figure 1.1 Illustration of peptidoglycan synthesis16 ..................................................................................... 3 
Figure 1.2 (a) The acylation step and (b) Deacylation step process in the binding site of LdtMt2. Diagram 
was adapted from Silva et al.18 ...................................................................................................................... 5 
Figure 1.3 A QM/MM model86. The active site, water and inhibitor are in ball and stick (QM region) 
while rest protein-solvent environment (MM region) is in line format. ..................................................... 10 
 
CHAPTER TWO 
Figure 2.1 Structure of Mtb LdtMt114, LdtMt217, and LdtMt539.  Residues of the active sites are represented as 
sticks within the enzyme. On aligning the sequences of LdtMt1, LdtMt2 and LdtMt5, the important regions of 
these enzymes such as the catalytic domains, the BIgA and BIgB interfaces and loop LD, are presented in 
Figure 2. ...................................................................................................................................................... 31 
Figure 2.2 Molecular structure of the Cys354-meropenem adduct formed with LdtMt250 .......................... 32 
Figure 2.3 The description of the Cys354 adduct formation of biapenem with LtdMt2 showing where the 
inner and outer cavities37. ............................................................................................................................ 33 
Figure 2.4 The sequence alignment based on the structural superposition of LdtMt114, LdtMt217 and 
LdtMt539. The observed secondary structures are noted above the amino acid sequences. red: catalytic 
residues; yellow: loop LD). .......................................................................................................................... 34 
Figure 2.5 Diagrammatic illustration of peptidoglycan transpeptidation. D,D-transpeptidases (4-3) while 
L,D-transpeptidases (3-3) linkages, redrawn from literature9. .................................................................... 35 
Figure 2.6. Reaction mechanism for (a) Acylation Step and (b) Deacylation Step in the active site of the 
LdtMt2 enzyme58. .......................................................................................................................................... 37 
 
CHAPTER THREE 
Figure 3.1 The modelled structure of MERO—LdtMt5 with displaying active site residues and loop regions. 
The β-hairpin flap (312-330) and Lc loop (338-358) are highlighted in yellow and active site pocket in CPK 
form [HIS342 (287), THR357 (302), ASN358 (303) and CYS360 (305)] and meropenem (inhibitor) are 
presented in stick form. .............................................................................................................................. 55 
Figure 3.2 Chemical structures of the selected carbapenems; 1: ertapenem, 2: imipenem and 3: 
meropenem. ................................................................................................................................................. 56 
Figure 3.3 3D Structural representation of the meropenem—LdtMt5 pre-complex system used for ONIOM 
(B3LYP/6-31+G(d,p):Amber) calculations with the specified QM and MM regions.  The atoms in tubes 
are treated at the QM level, while the atoms in line display style at the MM layer.  The distance between 
the nucleophilic sulfur atom and the electrophilic carbonyl carbon is approximately 3.27 Å.  The 
minimized 3D structures (PDB format) for all inhibitor—LdtMt5 complexes are provided as supplementary 
information. ................................................................................................................................................. 61 
Figure 3.4 The 3D conformation for meropenem in complex with LdtMt5 enzyme obtained by molecular 
docking. The 3D conformation for other selected carbapenems is provided in the supplementary 
information (Figure S1). The minimized 3D structures for all inhibitor—LdtMt5 complexes are provided 
in the supplementary information. .............................................................................................................. 62 
xiii 
 
Figure 3.5 Time evolution of the RMSD from the initial structures in the production MD simulations of  
Free—LdtMt5 (blue), ERT—LdtMt5 (black), IMI—LdtMt5 (red)  and MERO—LdtMt5 (green) during 60 ns 
MD simulation time The minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are 
provided as supplementary information. ..................................................................................................... 63 
Figure 3.6 RMSF plot of the backbone atoms versus the residue numbers for Free—LdtMt5 (blue), ERT—
LdtMt5 (black), IMI—LdtMt5 (red) and MERO—LdtMt5 (green) during 60 ns MD simulation time.  The 
minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary 
information. ................................................................................................................................................. 64 
Figure 3.7 The plot of per-residue decomposition analysis for ERT—LdtMt5, IMI—LdtMt5 and MERO—
LdtMt5 complex from 1000 snapshots extracted from the last 10 ns MD trajectories. The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information. 67 
Figure 3.8 The three center of mass tip-tip distances of the β-hairpin flap and three facing points at the 
loop LC of ERT—LdtMt5. PRO319-GLY349 D1: 13.32 Å PRO319-ALA350 D2: 13.34 Å PRO319-
GLN351 D3: 12.18 Å ALA320-GLY349 D4: 12.77 Å ALA320-ALA350 D5: 13.24 Å ALA320-GLN351 
D6: 11.30 Å ALA321-GLY349 D7: 9.37 Å ALA321-ALA350 D8: 10.29 Å ALA321-GLN351 D9: 9.20 
Å. The minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as 
supplementary information. ........................................................................................................................ 69 
Figure 3.9 The plot of the center of mass tip-tip distances between ALA321—GLN351 residues for the 
ERT—LdtMt5, IMI—LdtMt5 and  MERO—LdtMt5 over the 60 ns MD simulations.  The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information. 70 
Figure 3.10 Histogram distribution of center of mass tip-tip distance [ALA321-GLN351] distances for 
ERT—LdtMt5, IMI—LdtMt5 and MERO—LdtMt5 over the 60 ns MD trajectories.  The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information. 71 
Figure 3.11 The first principal components (PC1) collective motions for the obtained predominant 
eigenvectors using principal component analysis over the 60 ns MD trajectories for ERT— LdtMt5, IMI—
LdtMt5 and MERO—LdtMt5.  The minimized 3D structures (PDB format) for all inhibitor- LdtMt5 
complexes are provided as supplementary information. ............................................................................. 72 
Figure 3.12 Gibbs free energy pathway of 6-membered ring mechanism of inhibition of L,D-
transpeptidase (LdMt5) by meropenem obtained using the ONIOM [M06/6-311++G(2d,2p):Amber] 
method. ....................................................................................................................................................... 76 
 
CHAPTER FOUR 
Figure 4.1 The rendering of MERO-LdtMt5 crystal X-ray structure.  Shown is a β-hairpin flap (312-330) 
and Lc loop (338-358) and active site pocket in CPK form [HIS287 (342), THR302 (357), ASN303 (358) 
and CYS305 (360)] and meropenem (inhibitor) in stick form 13 ................................................................ 86 
Figure 4.2 2D scaffold structures of (1) β-lactam (2) Diarylquinoline (3) Oxazolidinone (4) Rifamycin (5) 
Quinolone classes of TB antibiotics ............................................................................................................ 87 
Figure 4.3 Virtual screening workflow to the ten final lead compounds and then more elucidation on five 
best β-lactams. ............................................................................................................................................ 93 
Figure 4.4 Time evolution of the root mean square deviation (RMSD) of the β-lactam- LdtMt5 complexes 
of A 02475683-LdtMt5 (black), B 02462884-LdtMt5 (red), C 03808351-LdtMt5 (green), D 03808352-LdtMt5 
(blue) and E 03785001-LdtMt5 (yellow) during 20 ns MD trajectories ...................................................... 102 
xiv 
 
Figure 4.5 The radius of gyration (Rg) of the β-lactam-LdtMt5 complexes of A 02475683-LdtMt5 (black), B 
02462884-LdtMt5 (red), C 03808351-LdtMt5 (green), D 03808352-LdtMt5 (blue) and E 03785001-LdtMt5 
(yellow) during 20 ns MD trajectories ...................................................................................................... 103 
Figure 4.6 2D schematic representations of the hydrogen and hydrophobic interactions between LdtMt5 
residues and the selected β-lactam compounds, ZINC ID (A) 02475683, (B) 02462884, (C) 03808351, 
(D) 03808352, and (E) 03785001.  All structures are average conformations generated from the last 10 ns 
snapshots of each MD system ................................................................................................................... 105 
 
CHAPTER FIVE 
Figure 5.1 2D structures of the selected β-lactam derivatives. ................................................................ 114 
Fig.  2 2D structure of the 6-membered ring transition states starting structures obtained using constraints 
with ONIOM (B3LYP/6-31+G(d):AMBER), where a =1.64 Å, b = 2.14 Å, c =1.60 Å, d = 1.58 Å, e = 1.3 
Å, f = 1.3 Å.  The TS optimized coordinates of all enzyme-inhibitor complexes are provided in the 
supplementary material) ............................................................................................................................ 116 
Figure 5.3 Gibbs free energy pathway for the 6-membered ring mechanism of inhibition of L,D-
transpeptidase (LdtMt5) by the β-lactams compounds obtained at (ONIOM) B3LYP/6-
311++G(2d,2p):AMBER, extrapolated from Table 1.  See Fig. 1 for the structure of the inhibitors. ..... 119 
Figure 5.4 Molecular electrostatic potential surface of the selected β-lactams—LdtMt5 calculated at the 
B3LYP/6-31 + G(d,p), mapped onto electron density (0.004 electrons per Å3) isosurfaces. The red 
regions correspond to the site most susceptible to nucleophilic attack. Blue and red regions represent 
positive and negative potential areas, respectively. .................................................................................. 120 
Figure 5.5 Depiction of electron transfer for β-lactams/LdtMt5 complexes derived from second-order 
perturbation theory of NBO analysis.  The curved arrows (a, b and c) depict the direction of charge 
transfer from lone pair to antibonding (LP→σ*). (The TS optimized coordinates are provided in the 
supplementary material) ............................................................................................................................ 121 
 
LIST OF TABLES 
CHAPTER TWO 
Table 2.1.  Summary of the Mtb transpeptidases whose structures have been determined. ...................... 27 
 
CHAPTER THREE 
Table 3.1. Calculated binding free energies and its components for the inhibitors—LdtMt5 precomplex 
using MM-GBSA method and normal mode analysis.  The energy components are in kcal/mol.  The 
minimized 3D structures (PDB format) for all inhibitors—LdtMt5 complexes are provided as 
supplementary information (Figures S2, S3 and S4). ................................................................................ 65 
Table 3.2. The hydrogen bonds between carbapenems and active site residues for ERT—LdtMt5, IMI—
LdtMt5 and MERO—LdtMt5 complexes over the simulation time. ............................................................... 73 
Table 3.3. The thermochemical parameters of 6-membered ring reaction pathways of LdtMt5 obtained in 
ONIOM (B3LYP/6-31+g(d,p):Amber) using different density functionals.  The ∆E, ∆G, ∆H (kcal/mol) 
and ΔS (cal/mol/K). .................................................................................................................................... 75 
xv 
 
 
CHAPTER FOUR 
Table 4.1 Physiochemical properties set for all screened compounds. ...................................................... 89 
Table 4.2 The selected five categories of antibacterial compounds from the ZINC database ................... 92 
Table 4.3 The top 10 ligands per class based on the highest docked energies were chosen for AutoDock 
Vina against LdtMt5 (The optimal ligands in the active pocket, highlighted in blue, were selected for 
further MD analysis) ................................................................................................................................... 94 
Table 4.4 The Schrödinger Maestro top ligands per class based on the highest Glide docking score 
against LdtMt5 (The optimal ligands in the active pocket, highlighted in blue, were selected for further MD 
analysis) ...................................................................................................................................................... 95 
Table 4.5 Binding free energies method and their corresponding components using MM-GBSA method 
for compounds screened against LdtMt5 in AutoDock Vina program. ........................................................ 97 
Table 4.6 Binding free energies and their corresponding components using MM-GBSA method for 
compounds screened against LdtMt5 in Schrödinger Maestro. .................................................................... 98 
Table 4.7 Identified lead compounds with their antibacterial class, ZINC ID, calculated binding energies 
and the corresponding chemical structure, ten in total ................................................................................ 99 
Table 4.8 Drug-like properties of the 10 potential lead from the ZINC database .................................... 101 
Table 4.9 Comparison of the calculated binding energies for carbapenems on LdtMt5 versus the calculated 
and experimental 55, 56 binding energies for LdtMt2 .................................................................................... 101 
Table 4.10 Calculated binding free energies and their corresponding components using MM-GBSA 
method for the selected β-lactam-LdtMt5 complexes. ................................................................................ 104 
 
CHAPTER FIVE 
Table 5.1 Relative energy, ∆H (kcal mol-1) and ΔS (kcal mol-1) of LdtMt5 for the 6-membered ring 
reaction pathway of the acylation step obtained in ONIOM model using different density functionals at 6-
311++G(2d,2p):AMBER. ......................................................................................................................... 118 
Table 5.2 Second-order perturbation stabilization energies corresponding to the core intermolecular 
charge transfer interaction (Donor to Acceptor) of the LdtMt5 for 6-membered transition states of 
carbapenems obtained at B3LYP/6-311++G(d,p). ................................................................................... 122 
 
  
xvi 
 
ABBREVIATIONS 
Tuberculosis        TB 
Mycobacterium tuberculosis      Mtb   
L,D-transpeptidase 5       LdtMt5 
Transition state        TS 
Molecular dynamics       MD 
Quantum mechanics       QM  
Density functional theory      DFT  
Molecular mechanics       MM 
Hybrid quantum mechanics/molecular mechanics   QM/MM 
Ertapenem        ERT 
Imipenem        IMI  
Meropenem        MERO 
Natural substrate       SUB 
World Health Organization’s      WHO 
Millennium Development Goals     MDGs 
Sustainable Development Goals     SDGs 
Peptidoglycan        PGN 
N-acetylglucosamine       GlcNAc  
N-acetylmuramic acid       MurNAc 
Meso-diaminopimelic acid      mDAP 
Penicillin binding proteins      PBPs  
Food and Drug Administration      FDA 
Protein data bank       PDB 
Monte Carlo        MC 
xvii 
 
Generalized Born       GB  
Polarisable Continuum Models      PCM 
Virtual screening       VS 
High-throughput screening      HTS 
Isothermal titration calorimetry      ITC 
Molecular Mechanics-Generalized Born Surface Area   MM-GBSA 
Principal component analysis      PCA 
L,D-transpeptidases       DDT 
L,D-transpeptidases       LDT 
Root mean square deviation      RMSD  
Root mean square fluctuation      RMSF 
Intrinsic reaction coordinates      IRC 
Glide simple precision       SP  
Glide extra precision       XP  
Glide extra precision       XP 
General AMBER force field      GAFF 
Partial Mesh Ewald       PME 
Highest occupied molecular orbitals     HOMOs  
Lowest unoccupied molecular orbitals     LUMOs 
 
  
xviii 
 
ABSTRACT 
Tuberculosis (TB) is one of the world’s deadliest diseases caused by the bacterium, Mycobacterium 
tuberculosis (Mtb).  Peptidoglycan is the exoskeleton of bacterial cells and is required for their survival and 
growth including Mtb.  For Mtb, a mycobacterium, the final step of peptidoglycan synthesis involves the 
generation of 4→3 and 3→3 transpeptide crosslinks catalyzed by D,D-transpeptidase and L,D-
transpeptidase (Ldt) enzymes, respectively.  Unlike in most other bacteria, for Mtb, the majority of the 
cross-links are generated by L,D-transpeptidases.  Mtb genome encodes five Ldt paralogs, namely LdtMt1 
to LdtMt5.   
Any Mtb strain that lacks a functional copy of an Ldt, namely L,D-transpeptidase 5 (LdtMt5), displays 
aberrant growth phenotype and is more susceptible to killing by cell wall perturbing agents including 
carbapenems which are considered the last resort antibiotics to treat resistant bacterial infections in humans.  
Carbapenems inactivate L,D-transpeptidases by acylation, although differences in antibiotic side chains 
modulate drug binding and acylation rates.  However, it is known that carbapenems do not show any 
reasonable inhibitory activities against LdtMt5 and also an adduct of meropenem exhibited slow acylation.   
The inhibition mechanism of  L,D-transpeptidase 5 against carbapenems were investigated using molecular 
dynamics and transition state (TS) structural models. Virtual screening of new compounds was also carried 
out in this present study.  The investigation was adopted to clarify the acylation process of carbapenems, 
compute their activation energies and propose new β-lactams inhibitors with lower activation energies in 
comparison to the known FDA approved carbapenems.  
Molecular dynamics (MD), Quantum mechanics (QM) methods which include density functional theory 
(DFT) models, molecular mechanics (MM), hybrid QM/MM and virtual screening methods were used 
together to probe and give a better understanding on this topic.  To understand the macromolecular 
structure-to-function relationships, molecular dynamics simulations were proposed.  The complexes 
[ertapenem (ERT), imipenem (IMI) and meropenem (MERO) with LdtMt5] were simulated and trajectory 
analyses were carried out using CPPTRAJ module implemented in Amber 14 package.  To further 
understand the catalytic reaction mechanism of LdtMt5 with the selected carbapenems, the possible reaction 
pathways (thermodynamics and kinetics) were investigated using a two-layered ONIOM [B3LYP/6-
31+g(d,p):Amber] model.  Due to the high activation energies calculated for meropenem and imipenem, 
which correspond to experimental observations, the need for screening of potential inhibitors against LdtMt5 
arises.  
Herein, we have aimed to find new compounds with better binding free energies for LdtMt5.  The automated 
docking process was performed using Autodock Vina and Schrödinger Maestro programs to screen the 
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libraries of compounds.  Subsequently, the molecular dynamics of compounds with best binding affinities 
were simulated to calculate the binding free energies of the drug-enzyme precomplexes.  Thereafter, the 
catalytic mechanism of six β-lactams within the enzyme was studied using hybrid QM/MM; Our own N-
layered Integrated molecular Orbital and Molecular mechanics (ONIOM) method.  Activation energies for 
these drugs were calculated.   
The study on the molecular interactions of carbapenems with LdtMt5 confirms that the computational 
inhibitor-enzyme precomplex model for transpeptidases correctly reflects experimental observations in 
terms of the activity and binding energies.  In addition, the high free energies of activation (∆G#) for 
meropenem and imipenem, explain the reason behind inefficient binding of these carbapenems to LdtMt5 
(Chapter 3).  One of the first aims of this study was to find new β-lactams compounds that will potentially 
inhibit LdtMt5.  This was achieved via virtual screening, molecular dynamics and calculation of activation 
energies of a six-membered cyclic TS in the active pocket of the enzyme.  Out of the 12766 compounds 
tested against LdtMt5, 37 compounds showed favourable docking scores (Chapter 4). These compounds 
were further analysed to determine the activation energies.  It was also observed that several of the 
compounds showed an improved and lower activation free energies when compared to the previously 
calculated for imipenem and meropenem for the acylation step for LdtMt5 (Chapter 5).  Finally, the last 
chapter (Chapter 6) gathers the conclusion of the work. The outcome of this study provides insight into the 
design of a potential novel leads for LdtMt5.   
Keywords: Mycobacterium tuberculosis (Mtb); L,D-transpeptidase 5 (LdtMt5); Carbapenems; Molecular 
dynamics (MD); quantum mechanics/molecular mechanics (QM/MM), Catalytic mechanism; Virtual 
Screening. 
 CHAPTER ONE 
INTRODUCTION 
1.1   Tuberculosis 
Mycobacterium tuberculosis (Mtb) is the causative organism responsible for TB1.  TB is transmitted through 
droplet infection and starts when an infected person coughs or spits, which results in the bacterium going 
into the air and being inhaled by a new host.  If infection occurs the bacteria will later develop in the host.  
TB can occur as latent infection where someone has been infected with the bacteria but does not have any 
symptoms of the active disease. Pulmonary TB can affect the lungs and causes symptoms, or as 
extrapulmonary TB which occur outside the lungs2-4.  
The World Health Organization’s (WHO) target to halt and reverse TB incidence from 2011 to 2015 
supported the UN Millennium Development Goals (MDGs) of stopping and beginning to reverse the 
epidemic by 2015.  In addition, statistics showed that the overall TB death rate in 2015 was 47% less than 
what was reported in 1990 and that the objective of a 50% decrease was not achieved.  The objectives were 
achieved in some regions, excluding African, Europe and in a few high burden countries5, 6.  WHO has gone 
one step further and set a 2035 target of 95% reduction in deaths and a 90% decline in TB incidence – like 
the current levels in low TB incidence countries today7. 
Statistics show that approximately 10 million persons were regarded as being infected with TB in 2017, 
of whom 5.8, 3.2 and 1.0 million were men, women and children respectively, with 9% being HIV-
positive worldwide7.   In order to reduce the growing burden of new TB cases, discovering and treatment 
gaps must be targeted, funding gaps closed, and novel techniques established.    
It has been five decades since the introduction of effective antibiotics to combat TB8.  As a result of the 
endemic and persistent occurrence of TB, the United Nations adopted the Sustainable Development Goals 
(SDGs) in 2015 to be achieved in 2030 to set the pace for a new direction to end the global TB prevalence.  
The targets are a 90% decrease in TB mortality and an 80% decrease in the TB occurrence rate by 2030, 
related to 20159.  The inability to curb TB prevalence is a result of Mtb mutants that have become drug-
resistant toward the age-long traditional anti-mycobacterial drugs. For example, isoniazid and rifampicin, 
among the early therapies are no longer effective against drug resistant TB, therefore there is a need for 
immediate development of new and potent antibacterial drugs10.   
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1.2   Peptidoglycan synthesis in Mycobacterium tuberculosis 
The peptidoglycan (PGN) is one of three major layers linked to the cytoplasmic membrane, the others being 
mycolic acids and arabinogalactan, all of which are inside the Mtb cell wall11, 12.  PGN is accountable for 
major cellular mechanisms of Mtb, for example, cell growth and division, and revitalization from inactivity.  
The bacteria can endure hostile physical and chemical environments or nutrient starvation13, especially in 
its metabolically inactive state.  This microbial inactive state is the cause of the dormant infection affecting 
one-third of the world's population.  Thus, peptidoglycan is a crucial ‘organelle’ that is needed for the 
survival and growth of Mtb 14, 15. 
PGN biosynthesis starts with the addition of 1–4-linked-N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) cross-linked by tiny peptidoglycan stems (Figure 1.1).  PGN in Mtb is 
categorized as meso-diaminopimelic acid (mDAP)-type, as it contains a DAP residue at the third position 
of the peptidoglycan stem.  The UDP-MurNAc-pentapeptide is produced by adding L-alanine to the lactate 
moiety of the UDP-MurNAc, and the following chronological addition of D-glutamic acid, DAP and D-
alanyl-D-alanine dipeptide to form UDP-MurNAc pentapeptide11.  The transmission of the phospho-
MurNAc-pentapeptide moiety of the nucleotide to the lipid carrier and the addition of GlcNAc occurs at 
the membrane step of peptidoglycan synthesis.  The whole antecedent related to the lipid carrier is 
translocated via the membrane and is polymerized by glycosyltransferases and D,D-transpeptidase activity.  
The cleavage of the D-Ala4-D-Ala5 bond belonging to the pentapeptide donor is achieved by these enzymes, 
therefore linking the carbonyl atom of D-Ala4 to the side chain amine of mDap at the third location of an 
acceptor stem (4→3 cross-linkage).  β-Lactam antibiotics are structural equivalents of the D-Ala4-D-Ala5 
extreme of the antecedents and act as suicide substrates of the penicillin binding proteins (PBPs).  The 
mDap3-D-Ala4 bond of a tetrapeptide donor is cleaved by L,D-transpeptidases and links the carbonyl of 
mDap3 to the acceptor stem (3→3 cross linkages)16. 
The peptidoglycan of Mtb exhibits 80% occurrence of 3→3 cross linkages made by L,D-transpeptidation16, 
whereas the 4→3 peptidoglycan cross linkages are predominantly generated by PBPs throughout the 
exponential period of growth17. 
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Figure 1.1 Illustration of peptidoglycan synthesis16 
Both L,D and D,D transpeptidase enzymes should be inhibited simultaneously to inhibit biosynthesis of the 
peptidoglycan layer and, consequently, kill the bacteria18. 
1.2.1 L,D-transpeptidases from Mycobacterium tuberculosis 
L,D-transpeptidation was first reported in wild-type strains of Enterococcus faecium and linked with a side 
catalytic process of D,D-transpeptidases needed in PGN production19.  It was reported that Enterococcus 
faecium was 3% 3→4 cross-linked, making it insignificant, while Mtb showed 80% 3→3 cross-linkages, 
making L,D-transpeptidase an attractive target20.  This family of enzymes utilize cysteine in its active site, 
while serine fulfils the same role for D,D-transpeptidases21, 22. 
The genome of Mtb contains five mutants of L,D-transpeptidases (LdtMt1, LdtMt2, LdtMt3, LdtMt4 and LdtMt5), 
with 1 and 2 being reported to be responsible for in vitro peptidoglycan cross-linkage assay17, 23.  LdtMt1 is 
believed to show a distinct function in peptidoglycan adaptation to the non-replicative form of the bacillus16.  
LdtMt2 is known to be essential for virulence in a mouse model of acute infection
23, while LdtMt5 performs 
a major and distinct role in the good maintenance of Mtb cell wall integrity21.   
1.2.2 Carbapenem derivatives as inhibitors of L,D-transpeptidases 
Carbapenem antibiotics were initially developed from thienamycin24, 25, a naturally occurring product 
discovered in culture filtrates of Streptomyces cattleya26.  The β-lactams were discovered in the 1920s27 and 
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first used as therapeutic agents in the 1940s28 against an enzyme from the bacteria.  Since then, this family 
of drugs has played a major role in antibiotherapies29.  These compounds are thus one of the most important 
antibiotic groups, which include cephalosporins monobactams, penicillin derivatives, β-lactamase, and 
carbapenems inhibitors.  Among the aforementioned categories, carbapenems have proven to exhibit the 
widest range of bioactivities and they provide safe and effectual treatments in dealing with dangerous 
infections triggered by Gram-positive, Gram-negative and anaerobic microbial pathogens30, 31. 
In 1985, the USA Food and Drug Administration (FDA) organization approved imipenem, the first 
commonly used carbapenem drug for the treatment of serious bacterial infections.  Application of 
meropenem for human use was endorsed in 1995, thereafter ertapenem in 2001, while doripenem became 
available in 2007.  Apart from imipenem, all carbapenems are stable against the mammalian kidney 
dehydropeptidase32.  The weight-dosage adjustment of imipenem is required to minimize the chance of 
seizures33.  Ertapenem and doripenem can be given once per day due to their high target affinity and 
circulating stability31, 34.  Possible side effects can be reduced if smaller effective doses of the latter drugs 
are used, as well as the development of resistance35.  Presently, complex intra-abdominal and urinary tract 
infections are treated with ertapenem and doripenem 36,37.  
The first study to explore the kinetics and processes of inactivation of some selected carbapenems and 
cephalosporins against L,D-transpeptidase LdtMt1 in Mtb was conducted by Dubee et al
17.  The study 
revealed that the families of drugs form covalent adducts with LdtMt1, while the acylation with 
cephalosporins is not fast, and resulted in the removal of one of their side chains. The evaluation of the 
kinetic rate constants for drug binding, acylation and acyl enzyme hydrolysis indicated that carbapenems 
and cephems can be employed together to inhibit peptidoglycan biosynthesis in Mtb17. 
In another study, the structure of LdtMt2, an L,D-transpeptidase inherent in Mtb, was crystallized by Bӧth 
and co-workers.  They used mass-spectrometric analysis to demonstrate that LdtMt2(Cys354) forms covalent 
adducts with the β-lactam antibiotics imipenem and ampicillin22.  In addition to the previously reported 
binding of imipenem and meropenem to LdtMt2 using ITC
38, they suggested that LdtMt2 can identify and 
bind a variety of β-lactam antibiotics.   
1.2.3 Catalytic mechanism of L,D-transpeptidases 
The catalytic mechanism of  L,D-transpeptidases from Mtb, and the atomistic details of their transition 
states provide useful information for the design of new antituberculosis drugs39.  So far, two catalytic 
mechanism proposals have been reported for these enzymes in Mtb.  Biarrote-Sorin and co-workers40 
reported on two reaction pathways to the catalytic cysteine,  one for the acyl donor and the other for the 
acyl-acceptor substrates.  Erdemli et al.38 gave the most recent proposal for the catalytic process, which was 
also based on cysteine proteases process.  Erdemli’s approach provides an easier pathway for the catalytic 
process in comparison to the Biarrotte-Sorin approach18. Here, the L,D-transpeptidase will undergo various 
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configurational variations within the flap region in order to enable the natural substrates to enter and to 
discharge the adducts with the binding site channel40.  The catalytic mechanism proposed for LdtMt2
38 
(Figure 2) happens in two steps.  In the first step (acylation), the formation of the catalytic Cys354 thiolate 
by hydrogen removal is followed by an attack on the carbonyl carbon of the natural substrate, resulting in 
a tetrahedral intermediary. The addition of hydrogen to His336 imidazolium group results in the D-Ala 
being given away after the intermediary thioester is formed.  In the second step (deacylation), an additional 
peptidoglycan stem goes in the binding site and binds to active site residues using the side chain amide of 
the m-A2pm3′ residue.  His336 serves as a catalytic base by removing a hydrogen atom from the amine 
group of the mA2pm3′ residue, although the same amine group does a nucleophilic attack on the carbonyl 
carbon of acyl-enzyme18, 38.   
A computational approach was carried out using QM/MM MD simulations on LdtMt2 with substrate
18 on 
the aforementioned described catalytic mechanism as presented in Figure 1.2. 
 
 
 
Figure 1.2 (a) The acylation step and (b) Deacylation step process in the binding site of LdtMt2. Diagram 
was adapted from Silva et al.18 
The free energy results derived from the PMF data revealed that in the entire binding process of a four-
membered ring transition state, the rate-limiting stage occurs at the acylation stage. This supports the 
experimental observation18 of the acylation step proposed by Erdemli38.  In a more recent study in our group, 
the process of nucleophilic attack by Cys354 thiol in LdtMt2 to the acyl carbon of the β-lactam, followed by 
concerted proton transmission to the β-lactam nitrogen atom via a four (without the involvement of water) 
and water aided six-membered ring transition state models41 was investigated. 
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Papain42, 43, another cysteine protease family, also revealed a similar acylation stage in which the first step 
is proposed to be a proton transfer to form a zwitterionic form (i.e. Cys-S−/His-H+ ion-pair), and the second 
step is the nucleophilic attack on the carboxyl carbon of the substrate accompanied by the dissociation of 
4-nitroanilide42.   
1.2.4 Structural and functional behaviour of L,D-transpeptidase 5 
L,D-transpeptidase 5 creates 3→3 cross-links in the peptidoglycan, catalysing the joining of the mDap(3)-
D-Ala(4) bond of a tetrapeptide donor stem, and the formation of a bond between the carbonyl of mDap(3) 
of the donor stem and the side chain of mDap(3) of the acceptor stem21.  L,D-transpeptidase 5 is peculiar 
for donor substrates containing a tetrapeptide stem, as it cannot use pentapeptide stems.  The free and 
meropenem bound crystal structures of an N-terminally shortened LdtMt5 protein lacking the hydrophobic 
domain was predicted to be a membrane anchor for this protein.  The structures were determined using X-
ray crystallography with resolution solved to 2.8 Å. RMSD21.  The shortened enzyme showed a large degree 
of sequence similarity to LdtMt2 (31%) when compared to the full-length enzyme of LdtMt5 (28%).  LdtMt5 
comprises of a proline-rich extension of the C-terminal subdomain (amino acids 417-451) that are not 
present in all other Mtb L,D-transpeptidases21.  The free enzyme and meropenem bound crystals to have a 
P6222 space group with comparable cell dimensions and one molecule in the asymmetric unit
21.  The 
structures are available in the protein data bank (PDB) with the accession codes 4Z7A (Free LdtMt5) and 
4ZFQ (Meropenem-LdtMt5)
21. 
1.3 Molecular modelling approaches to study drug-enzyme interactions  
An overview of computer modelling and simulation methods that play an increasing role in drug design44 
will be presented in this section: computational chemistry, molecular mechanics, molecular dynamics, force 
fields, hybrid quantum molecular/molecular mechanics and virtual screening.  
1.3.1 Computational chemistry 
Computational chemistry is, in its widest sense, the use of computers to elucidate and understand chemical 
and biological phenomena, that is, the behaviour and properties of atoms, molecules, protein-ligand and 
solids45.  Vast progress in computational chemistry has been accomplished, our review demonstrates that 
the field of rational drug design with the aid of molecular modelling has matured in the past decade, and it 
is now realized that an integrated experimental and theoretical approach is essential for optimum impact48,46. 
Theoretical methods, which include quantum mechanics, molecular dynamics, and statistical mechanics, 
have been effectively used to describe chemical systems and build new materials, drugs and chemicals47. 
Comprehensive reviews on the combined method to structure-based enzymatic drug design is readily 
available in the literature48-50, on which this study is based. 
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1.3.2 Molecular mechanics 
Molecular Mechanics (MM) is one of the best computational chemistry approaches for protein and also 
biological molecules simulations, and useful in studying their conformational flexibility51, 52.  The 
underlying model for a molecular mechanics calculation, as well as classical atomistic Molecular dynamics 
(MD) or Monte Carlo (MC) simulations, is that the energy of a molecule can be described in terms of a 
function called the force field that depends only on the atomic positions, a highly simplifying assumption.  
This function must provide a good description of the forces acting within the molecule53, 54.  MM is vital in 
most of the computational structure-based drug discovery projects, due to the significance of protein 
flexibility in drug binding51.  The use of semiempirical approaches has received much attention55, although 
has severe constraints on the simulation time.  MM force fields, approximate the quantum mechanical 
energy surface with a classical mechanical model, thereby reducing the computational cost of simulations 
on the large system by orders of magnitude51.   
1.3.4 Force fields   
Force fields are the combination of mathematical functions that describe parameters used in molecular 
mechanics or dynamics calculations in order to evaluate the conformations, flexibility and interactions of 
molecules56.  These various force fields are created for application to biologically fascinating molecules.  
These could be due to the greater difficulty of the interactions, which include the ionic and polar groups in 
aqueous solution, and the struggle to obtain a clear test set to appraise such force fields.  Many of these 
force fields were established prior to 1987, which were defined temporarily by McCammon and Harvey57.  
The conformations of the molecule are stable at low energy regions of the potential energy function, and 
the forces on the individual atoms are related to the gradient of this potential energy function. So, such 
functions are commonly known as “force fields”58.  In addition, the force field is a collection of equations 
and associated constants designed to reproduce molecular geometry and selected properties of the tested 
structures.  For an atomistic force field, one needs parameters for every type of atom.  The parameters are 
usually derived from experimental data or quantum mechanical calculations.  The potential energy function 
can be divided into bonded and non-bonded interaction energies, and these can be split up again: 
 
𝐸𝑡𝑜𝑡𝑎𝑙=  𝐸𝑏𝑜𝑛𝑑𝑠 + 𝐸𝑎𝑛𝑔𝑙𝑒 + 𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 + 𝐸𝑣𝑑𝑊 + 𝐸𝑐𝑜𝑢𝑙𝑜𝑚𝑏 
 
 
With such a potential energy function we can calculate the force on each atom (via F~ = −Δ𝐸𝑡𝑜𝑡𝑎𝑙) and with 
that the position and velocity for each time step59.   
bonded interactions non-bonded interactions 
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Force fields, including AMBER60, 61, are commonly used for proteins and DNA. CHARMM62 is mostly 
applicable for both molecules and macromolecules.  CHARMM is used for various systems ranging from 
isolated molecules to solvated complexes of large biological macromolecules63  CVFF64 is used for 
molecules and macromolecules.  GROMOS65 can be applied to aqueous or apolar solutions of proteins, 
nucleotides, sugars, and lipids simulation.  For a gas phase system, simulation of isolated molecules is 
available as OPLS66 and ECEPP/267, 68 as a free energy force field.  However, the use of OPLS is not 
limited to simulation in the gas phase.  The advent of these force fields has gained increasing success in 
studying compounds of biochemical and organic chemical significance, with the aid of computer-based 
models.  As a result of their significance, ample effort has been invested in considering both the functional 
form and the parameters that must be developed to use such force fields69.  
1.3.3 Molecular dynamics  
MD has been a useful tool in areas of physics and chemistry due to advances in algorithms and computer 
technology.  The basic idea behind MD simulations is the representation of the energy of the molecule as a 
function of its atomic coordinates.  The first molecular dynamics simulation methods were introduced by 
Alder, Wainwright, and Rahman between 1950s and 1960s, which were applied to the dynamics of liquids.  
Later, in the 1970s, MD was broadly applied to determine the structure and dynamics of proteins and protein 
in complex with ligands.  In addition, MD is largely used to simulate complex structures that are designed 
at the atomic level.  MD obeys the equations of motion, which are explained numerically to mirror the time 
evolution of the system, permitting the solving of the kinetic and thermodynamic properties of interest by 
means of computer testing.  Temperature control algorithms (Constant total energy classical dynamics, 
Constant temperature, using the weak-coupling algorithm, Andersen temperature coupling scheme, 
Langevin dynamics, Optimized Isokinetic Nose-Hoover chain ensemble (OIN), and Stochastic Isokinetic 
Nose-Hoover RESPA integrator)71 are an important component of many molecular dynamics simulations.  
Using a method to enforce constant temperature is necessary to compare simulation results with laboratory 
experiments conducted at a constant temperature and either constant pressure or volume70, 71.  A molecular 
dynamics thermostat couples a fictitious heat bath to the system or some portion of the system, such that 
the time-averaged instantaneous kinetic energy of the coupled degrees of freedom corresponds to a target 
temperature72.  The result is that conformational constraints are overcome at a high enough simulation 
temperature.  The properties of biologically active large molecules (structure and dynamics), and their 
surroundings are normally calculated using MD simulation approaches.  While quantum MD was reported 
by Car and Parrinello,73 this approach explicitly considers the significant nature of the chemical bond 
required in the activity.  The valence electrons that take part in the bonding of the system is calculated using 
quantum equations, while the dynamics of ions are measured classically.  While important information on 
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some biological problems is best derived using Quantum MD simulations, as it was designed to consider 
the important system alone over the classical approach, they have high computational cost62, 74.  
1.3.5 Hybrid quantum molecular/molecular mechanics 
The use of hybrid potentials in a system is sectioned in different regions, which are then modelled by 
different levels of approximation75.  The concept is to apply a QM method to the region, where the chemical 
reaction occurs and treat the rest of the system using the MM method.  The QM and MM generally interact, 
so it is not possible to write the total energy of the entire system simply as the sum of the energies of the 
subsystems76.  As computational methods improve, the need for accuracy must still be tempered with 
practicality.  When calculating how molecules interact in solution, treating solute molecules quantum 
mechanically and the surrounding solvent molecules classically combine accuracy with computational 
efficiency77.  Quantitative prediction of thermodynamic properties of solute molecules requires an accurate 
description of the solvent78.  Distinct solvent models may refer to either explicit (TIP3P, TIP4P, TIP5P, and 
SPC/E) solvent molecules or an implicit (Generalized Born (GB)79 and Polarisable Continuum Models 
(PCM)) description of the solvent environment78.  Explicit-solvent methods, without further 
approximations, treat solvent molecules explicitly, i.e., interactions between all pairs of solute and solvent 
atoms are explicitly computed80, 81.  Implicit-solvent methods, on the other hand, speed up atomistic 
simulations by approximating the discrete solvent as a continuum, thus drastically reducing the number of 
particles to keep track of in the system79, 81.   
Warshel and Levitt in 1976 presented the concept of QM/MM to the study of chemical reactions in 
lysozyme82 treated semi-empirically.  The method has spread over the last 20 years, and many review 
articles have dealt with both the advance of the QM/MM methods and their application in the biomolecular 
field.   
Essential to the QM/MM idea is the partition (Figure 1.3) of the system into QM (inner) and MM (outer) 
regions that are defined by a force field.  Morokuma et al.83, 84 developed Our own N-layered Integrated 
molecular Orbital and Molecular mechanics (ONIOM) Hybrid Method. ONIOM is one of the approaches 
used to understand the mechanisms of enzymatic reactions85 in proteins, DNA/RNA, carbohydrates, and 
artificial enzymes.  
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Figure 1.3 A QM/MM model86. The active site, water and inhibitor are in ball and stick (QM region) while 
rest protein-solvent environment (MM region) is in line format. 
ONIOM has been widely used to describe the bond formation and breaking processes, which cannot be 
treated by MM methods, and involve systems that are too large and computationally demanding for the QM 
methods85, 87.   In a two partition ONIOM calculation, the total energy of the system is derived from three 
independent calculations:  
𝐸𝑂𝑁𝐼𝑂𝑀(𝑄𝑀:𝑀𝑀) =  𝐸𝑚𝑜𝑑𝑒𝑙
𝑄𝑀
 +  𝐸𝑟𝑒𝑎𝑙
𝑀𝑀
  - 𝐸𝑚𝑜𝑑𝑒𝑙
𝑀𝑀  = 𝐸𝑚𝑜𝑑𝑒𝑙
ℎ𝑖𝑔ℎ
 + 𝐸𝑟𝑒𝑎𝑙
ℎ𝑖𝑔ℎ
 - 𝐸𝑚𝑜𝑑𝑒𝑙
𝑙𝑜𝑤  
Where, 𝐸𝑚𝑜𝑑𝑒𝑙
𝑄𝑀
 is energy othe f the QM model region, 𝐸𝑟𝑒𝑎𝑙
𝑀𝑀  is the energy of the MM real region, 𝐸𝑚𝑜𝑑𝑒𝑙
𝑀𝑀  is 
the energy of the MM model region, 𝐸𝑚𝑜𝑑𝑒𝑙
ℎ𝑖𝑔ℎ
 is energy of the high layer model the the region, 𝐸𝑟𝑒𝑎𝑙
ℎ𝑖𝑔ℎ
 is 
energy of the high layer for the modelthe   region, and  𝐸𝑚𝑜𝑑𝑒𝑙
𝑙𝑜𝑤  is energy of the low layer model region. The 
entire system encompasses all the atoms and is derived only at the MM level88, 89.  The model system 
comprises the part of the system treated at the QM level, along with the linked atoms between the QM and 
the MM regions88, 89. 
1.3.6 Virtual Screening Techniques 
The journey of drug discovery starts from virtual screening (VS) of libraries of compounds against the 
target before conducting wet-lab experiments90.  VS is an approach used in automated docking for a larger 
set of drug-like compounds, small molecules, or fragments/scaffolds of known biologically active 
compounds inside the binding site of a protein, and ranking their binding affinities48, 91.  Methods applied 
in VS are divided into two categories: structure- or ligand-based approaches92.  Structure- or receptor-based 
approaches have been reported to be more efficient than the old-style way of drug discovery.  This is aimed 
 
Active site 
QM 
MM 
11 
 
at understanding the molecular origin of a disease, thereby applying the knowledge of the three-dimensional 
(3D) structure of the biological target-derived.  The 3D structure can be retrieved from experimental data 
(X-ray, NMR or neutron scattering spectroscopy), by homology modelling, or from molecular dynamics 
(MD) simulations93.  Information derived from the 3D structure is used to dock each library of compounds 
into the binding pocket of the relevant enzyme associated with the disease using a docking program93.  
Thereafter, important underlying molecular interactions utilized in ligand-protein binding can be deduced 
to provide explanations to experimental results at an atomic-level93.  In the same manner, identifying and 
developing potential ligands to a particular protein target form the basis in the drug discovery process94, 95.  
Compounds/drugs with known activities are used as a reference in ligand-based virtual screening in order 
to find filters that are closely related experimental data or possess a pharmacophore or substructure similar 
to the potent drug/compound96.  Ligand-based approaches are built on the concept of likeness, that is, 
compounds that are alike are assumed to yield comparable bioactivity.  Using this approach, if one or more 
potent compounds are identified, we can search the databases for comparable and more active molecules97.   
Generally, structure- and ligand-based virtual screening procedures are combined in a serial in order to 
meet the demanding search algorithms98.  At the moment, numerous software tools are available for 
enzyme-ligand docking, for example, AutoDock Vina99, Glide100, FlexX101, GOLD102 and DOCK103.  
Equally, several methods have been developed to enhance the speed of executing the job104.  The use of 
virtual screening has advanced the field forward, although with the shortcomings of scoring functions and 
the magnitude of having to dock millions of ligands into any given target or several possible targets.  
Accurately calculated binding energies and scores are not qualitative for meaningful compound selection.  
Finding active compounds in the shortlist is, however, critically important.  Appropriate selection strategies, 
therefore, compensate for methodological shortcomings, while deselection of inappropriate compounds 
reduces the risk of taking a non-promising candidate through a drug-discovery campaign105. Albeit docking 
methods have contributed enormously to rational drug design, it should be noted that there are still some 
major challenges to be addressed.  These include docking into flexible receptors. In this case, the same 
protein adopts different conformations depending on which ligand it binds to106-108.  Water molecules often 
play a key role in protein-ligand recognition109, in most cases, solvent effects are neglected, and real 
dynamic movement of the inhibitor-enzyme complex is not possible48.  Also, docking techniques were 
designed to provide an estimation of the binding affinity of the inhibitor upon finding the best fit inside the 
active enzymatic pocket.  Scoring failures in docking indicate the inaccuracy of the energy function to fit 
in the most compatible score to a correct sampled conformation out of the generated ensemble.  Now the 
choice of a more accurate energy function implemented in the software may improve the overall results.  
The effectiveness of the docking algorithm decreases as a function of the number of rotatable bonds110.  
Another challenge in docking is accounting for the various tautomeric and protomeric states the molecules 
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can adopt.  In many databases, molecules such as acids or amines are deposited in their neutral forms.  
Seeing that they are ionized under physiological conditions it is necessary to ionize them prior to docking. 
One approach to this would be to generate all possible forms, subsequently to dock all of them and to choose 
the relevant form based on the scores109.  In addition, since most docking software (for example AutoDock) 
remove the protons of the enzyme and inhibitors, more useful information can be obtained from MD studies 
where the protons (and water molecules as the solvent) are considered48.   
1.4 Databases of potential bio-active compounds 
Free databases of commercially available compounds for virtual screening are crucial in the journey to drug 
discovery111-113.  The compounds deposited in the databases have been assigned their biologically relevant 
information.  These include the appropriate protonation states, and characteristics that include molecular 
weight, calculated LogP, and a number of rotatable bonds111, 114.  Each molecule in the database has 
merchant and procuring information, and is available for docking using a number of common docking 
programs111.  The concept of a drug-like molecules115, 116 has existed for many years117, and include 
optimized parameters for physicochemical properties as well as the functional groups to be avoided.  This 
concept starts with finding a lead-like115 instead of a drug-like117, and then to hit-like118 molecules, which 
are tailored toward providing true positive results in high-throughput screening (HTS) assays and thereby 
yielding a basis for lead generation117.  The structures of the receptors/enzymes are generated through X-
ray crystallography, NMR or homology modelling, which are then deposited in the Protein data bank 
(PDB)48, 119.  Similarly, the structures of compounds with different biological properties have been deposited 
into databases, where they can be retrieved for virtual screening purpose.  These include PubChem120, 
ZINC121, ChEMBL122, NCI123, ChemDB124, ChemSpider125, BindingDB126, PDB-Bind127, PDBeChem128, 
KEGG129, HMDB130, SMPDB131, BIAdb132, DrugBank133, HIT134, SuperNatural135, NPACT136, TTD137, 
PharmaGKB138 and SuperDrug139 among others. For this study, we have selected ZINC database, which is 
a commercially free database with 21 million compounds available for virtual screening111.  
1.5 Novelty and significance of the study 
Tuberculosis remains a general health threat affecting people in all nations of the world. The drug resistance 
strains of Mtb have weakened the capability to respond effectually to this threat23.  Five Ldt paralogues 
have been identified in Mtb, LdtMt1 to LdtMt5, four of these, with the exception of LdtMt3, being active in 
vitro peptidoglycan cross-linking assays, whereas all but LdtMt5 are inhibited by carbapenems
140. 
Recently, Brammer and co-workers21 reported the crystal structures of apo- and meropenem-bound LdtMt5 
for the first time.  An experimental study using isothermal titration calorimetry (ITC) demonstrated that the 
interaction of meropenem with LdtMt5 is not associated with significant heat exchange
21.  Similar results46 
were observed for other tested carbapenems, with no adduct being detected by mass spectrometry after five 
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hours incubation of meropenem and LdtMt5.  It was concluded that meropenem will acylate LdtMt5 over an 
extended incubation period that is required for co-crystallization due to the meropenem—adduct crystal 
formation, which suggests the very slow acylation of LdtMt5 over many days
21.  They did not rule out the 
possibility that LdtMt5 is more rapidly inactivated by this class of β-lactams in vivo, particularly in the event 
of LdtMt5 requiring a protein-protein interaction for productive catalysis
21.  In conclusion, since 
carbapenems do not show any reasonable inhibitory activities against LdtMt5 and also an adduct of 
meropenem exhibited slow acylation requires more investigation theoretically, which would serve as a lead 
for experimental findings.  
1.6 Aims and Objectives   
1. Literature review on structure and function of L,D- and D,D-transpeptidase family enzymes from 
Mycobacterium tuberculosis. To accomplish this, the following objectives were outlined: (Chapter 
two) 
1.1  To summarize recent findings and observations regarding the structure and function of the LDTs 
and DDTs of Mtb. 
1.2 To provide bioactivities of known Mtb drugs against these targets both experimentally and 
computationally. 
2. To theoretically study carbapenems inactivation against L,D-transpeptidase 5 from Mycobacterium 
tuberculosis using  MD and QM/MM Mechanistic methods. To accomplish this, the following 
objectives were outlined: (Chapter three) 
2.1 To study the conformation of carbapenems in the binding site of LdtMt5 by docking.  
2.2 To explore the inactivation of LdtMt5 in complexation with the selected carbapenems upon ligand 
binding using 60 ns MD simulations in explicit solvent. 
2.3 To identify the conformational changes in terms of opening and closing of the β-hairpin flap and 
the Lc loop upon binding, using distance metrics. 
2.4 To qualitatively understand the divergent effects of different inhibitors on the dominant motion of 
each enzyme residue using Principal component analysis (PCA). 
2.5 To assess the binding free energies of the considered complexes and to characterize the 
participation of the key residues to the total binding free energies using Molecular Mechanics-
Generalized Born Surface Area (MM-GBSA). 
3. To identify new potent inhibitor against LdtMt5 from Mycobacterium tuberculosis with the known 
classes of antituberculosis drugs using virtual screening. To accomplish this, the following objectives 
were outlined: (Chapter Four) 
3.1 To retrieve libraries of compounds with similar scaffolds with β-lactam, Diarylquinoline, 
Oxazolidinone, Rifamycin, and Quinolone classes of TB antibiotics from the ZINC database. 
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3.2 To select compounds from the ZINC database with drug-like properties using Lipinski and Weber's 
rules. 
3.3 To study the conformation of the refined libraries of compounds into the active pocket of LdtMt5 
using virtual screening techniques implemented in the Glide and AutoDock Vina. 
3.4 To rank the scoring functions of the docked poses based on compounds with more negative binding 
affinity and by visual inspection. 
3.5 To study the dynamics of the complexes using molecular dynamics. 
4. To determine the mechanistic acylation step of β-lactam derivatives from virtual screening study 
against LdtMt5 from Mycobacterium tuberculosis. To accomplish this, the following objectives were 
outlined: (Chapter Five) 
4.1 To obtain a favourable and lowest energy conformation of the β-lactam-LdtMt5 complexes by full 
geometry optimization of the system using the ONIOM method. 
4.2 To determine the thermodynamics and energetics of the reaction path, a geometry optimization to 
transition state model using a two multilayer ONIOM model. 
4.3 To determine the relative energies of the stationary points (reactant, transition and product) using a 
single-point calculation and employing electronic embedding scheme. 
1.7 Thesis outline 
The thesis is presented in a paper format in which each chapter is dedicated to addressing one or two 
research questions.  In the first and last chapters, a general introduction and an overall conclusion are 
provided, respectively, for the entire study.  The outline is therefore highlighted. 
Chapter one: General introduction to the disease and applications used in the study was first highlighted in 
the dissertation. 
Chapter Two: Literature review on structure and function of D,D and L,D-transpeptidase receptors from 
Mycobacterium tuberculosis. 
Chapter Three: Inhibition of Mycobacterium tuberculosis L,D-transpeptidase 5 by carbapenems: MD and 
QM/MM mechanistic studies. 
Chapter Four: Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as 
potential anti-TB leads: Virtual Screening and Molecular Dynamics Simulations. 
Chapter Five: Investigating the reaction mechanism of L,D-transpeptidase 5 by β-lactams using ONIOM 
Method. 
Chapter Six 
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The overall conclusion of the research outcome. 
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Abstract 
Peptidoglycan, the exoskeleton of the bacterial cell and an essential barrier that protects the cell, is 
synthesized by a pathway whose final steps are catalysed by transpeptidases, including M.tuberculosis.  
Knowledge of the structure and function of these vital enzymes that generate this macromolecule in M. 
tuberculosis could facilitate the development of potent lead compounds against tuberculosis.  This review 
summarizes the experimental and computational studies to date on these aspects of transpeptidases in M. 
tuberculosis that have been identified and validated.  The reported structures of L,D- and D,D-
transpeptidases, as well as their functionalities, are reviewed and the proposed enzymatic mechanisms for 
L,D-transpeptidases are summarized.  In addition, we provide bioactivities of known M. tuberculosis drugs 
against these enzymes based on both experimental and computational approaches.  Advancing knowledge 
about these prominent targets in M. tuberculosis supports the development of new drugs with novel 
inhibition mechanisms overcoming to address the current need for new drugs against tuberculosis. 
Keywords: Mycobacterium tuberculosis (Mtb); Peptidoglycan, L,D-transpeptidase, D,D-transpeptidase.  
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2.1  Introduction 
The first genome sequence of the H37Rv strain of Mycobacterium tuberculosis (Mtb) was completed in 
19981.  This major breakthrough greatly facilitated molecular studies of the biology, metabolism, and 
evolution of this dangerous pathogen, and thereby ushering tuberculosis research into a new era.  TB 
occurrence has the highest incidence in Africa, while a large fraction of recent cases has been reported in 
six Asian countries, namely, Bangladesh, China, India, Indonesia, Pakistan and the Philippines2, 3.  The 
ability of a sub-population of Mtb to persist, or survive for long durations even in the presence of otherwise 
lethal actions of antibiotics, requires several months of therapy with multiple drugs or drug regimes and 
therefore contributes to the overall burden of treating TB 4, 5.  This long duration of treatment has been 
associated with poor compliance and the selection of multidrug-resistant strains, which characterize a 
growing segment of TB cases in much of the world6.  Although various antibiotics are effective in treating 
Mtb infections, they only target a small number of essential functions in the cell7.  Identifying the pathways 
required for Mtb’s survival and growth would provide many new targets for designing more effective agents 
that could be active against drug-resistant strains8.  Peptidoglycan (PG) is required for its vital cellular 
stages, which include cell growth and division, and recovery from latency.  Mtb often remains in a 
metabolically non-replicating condition that favours its survival during adverse physio-chemical 
circumstances or nutrient starvation9.  Bacilli in a metabolically non-replicating state have been proposed 
to the sub-population that produce clinically latent infection.  It is estimated that one-third of the world’s 
population harbours latent Mtb infection10  Polymerization and regrowth of the PG is a prerequisite for Mtb 
to resuscitate from non-replicating persistence, to elongate its cell, divide and proliferate and to cause the 
active disease.    
The PG of Mtb is unique: two distinct families of transpeptidases catalyse the polymerization of PG 
subunits, the classical D,D-transpeptidases (DDT), also known as penicillin binding proteins (PBP), 11, 12 13 
and the recently discovered L,D-transpeptidases (LDT) 14, 15 16 17.  These enzyme families are evolutionarily 
unrelated as their amino acid sequences share no similarity and their structures are different. While DDTs 
use serine as the catalytic residue, a conserved cysteine serves this role in the LDTs9, 18. The LDTs and 
DDTs also differ in their substrate with the former using tetrapeptide19 in contrast to the pentapeptide20 
substrate that is a requirement for the latter19.  Emerging evidence shows that the PG of Mtb is distinct from 
that in Gram-positives and negatives, and is not represented by the historical model of PG21, 22.  According 
to the model, which was developed largely from studies using E. coli, the final step of PG synthesis is 
catalysed by one enzyme, DDTs19, which generate transpeptide linkages between the 4th amino acid of one 
step peptide and 3rd amino acid of another (4→3 linkages).  It was documented in 1974 that PG of Mtb 
consists predominantly of cross-links between the 3rd amino acid of one step peptide and the 3rd amino acid 
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of another (3→3 linkages)23, 24.  These unusual 3→3 linkages, which are not included in the historical model 
of the PG, not only distinguish Mtb PG from others, it also has direct relevance to the antibiotics whose 
mechanism is based on inhibiting PG synthesis. Emerging evidence shows that Mtb LDTs that generate 
these linkages are uniquely susceptible to the carbapenem subclass of β-lactams17, 25-29.  In this review, we 
summarize recent findings and observations regarding the structure and function of the LDTs and DDTs of 
Mtb.  Knowledge of these enzymes and their bioactivities could serve to facilitate the discovery of 
antibiotics in targeting this key component of Mtb. 
2.2  Structure and function of D,D- and L,D-transpeptidases   
The Mtb genome encodes two classes of DDTs,  two class A (ponA1 and ponA2), two class B (PBPA and 
PBPB) and a lipoprotein (PBP-lipo) with common motifs as class B PBPs30.  There are additional six class 
C proteins, one categorized as type-4 (PBP4), one type-5 (PBP5), one type-7 (PBP7) and three putative 
type AmpH; PBP (Rv0907), PBP and PBP (Rv1367c)31, 32.  Among these PBPs, only PBPA, PonA1 and 
PonA2 have reported crystal structures11, 12.  There are five LDT paralogs in Mtb, namely: LdtMt1, LdtMt2, 
LdtMt3, LdtMt4 and LdtMt5
33
 and have been outlined in Table 2.1.  No crystal structures for LdtMt3 and LdtMt4 
have been reported yet. 
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Table 2.1.  Summary of the Mtb transpeptidases whose structures have been determined. 
Target Target 
protein 
Type of 
transpeptidases 
in PG synthesis 
Reported structure (PDB Code) 
Cell wall PBPA D,D-transpeptidase   3LO7 (wild-type)11, 3UN7 (mutant)12, 3UPN (PBPA-imipenem)12, 
3UP0 (PBPA-penicillin G)12 and 3UPP (PBPA-ceftriazone)12 
 PonA1 D,D-transpeptidase   5CRF (mutant)34 and 5CXW (PonA1-penicillin V)34 
 PonA2 D,D-transpeptidase   1QMF (PBP2x-cefuroxime), 1QME (wild-type) 35,2KUI (mutant)35 , 
2MQV (mutant)35  
L,D-
transpeptidase 
(LdtMt1) 
L,D-transpeptidase   4JMN (mutant)14 and 4JMX (imipenem)14 
 
L,D-
transpeptidase 
(LdtMt2) 
L,D-transpeptidase   3VYP (LdtMt2-meropenem)
15, 3VYN (mutant)15, 3VYO (mutant)15, 
4HU2 (wild-type) 16, 4HUC (wild-type) 16, 3U1Q (LdtMt2-2-
mercaptoethanol), 3TX4 (mutant)17, 3U1P (LdtMt2-β-
mercaptoethanol)17, 3VAE (mutant)17, 3TUR(mutant)17, 
4GSQ(mutant)36, 4GSR(mutant)36, 4GSU(LdtMt2-meropenem)
36, 5DU7 
(mutant)29, 5DUJ (LdtMt2-faropenem) 
29, 5DVP (LdtMt2-doripenem)
29, 
5E5L (mutant)29, 5E51 (LdtMt1-faropenem)
29, 5DZJ (mutant)29 5DZP 
(mutant)29, 5E1G (mutant) 29, (mutant) 5E1I  (mutant)  29, 5K69  
(mutant) 29, 5D7H (mutant) 37, 5DCC  (LdtMt2-biapenem) 
37, 5DC2  
(LdtMt2-tebipenem)26, 5LB1(mutant) 26, 5LBG (mutant)26, 4QR7 
(LdtMt2-Se-meropenem)
38, 4QTF (LdtMt2-imipenem)
38, 4QRA (wild-
type)38, 4QRB (mutant)38  
L,D-
transpeptidase 
(LdtMt5) 
L,D-transpeptidase   4ZFQ (LdtMt5-meropenem)
39, 4Z7A (mutant)39 
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The first structure of a DDT of Mtb was reported by Fedarovich et al. in 2010 11.  PBPA from 
Mycobacterium tuberculosis is a class B penicillin-binding protein which is important for cell division11.  
The crystal structure of PBPA from H37Rv was resolved at 2.05 Ǻ resolution and refined to an R-factor of 
21.7% with excellent stereochemistry.  The alignment with the class B PBPs shows that the SxN motif of 
PBPA occupies a position that is farther from the core of the binding site than that observed in other PBPs, 
which places Ser281 beyond hydrogen-bonding distance with residues of the SxxK and KTG motifs11.  
Later, this same group determined the second crystal structure of PBPA, also in the apo form, and compared 
it with their earlier structure11.  Significant structural differences in the active site region were apparent, 
including increased ordering of a β-hairpin loop and a shift of the SxN active site motif such that it occupied 
a position that appears catalytically competent.   
The second-order acylation rate constants for some selected antibiotics, imipenem, penicillin G and 
ceftriaxone were assayed against PBPA.  Among these antibiotics, only imipenem demonstrated anti-
tubercular activity with maximum acylation efficiency.  Different conformational behaviour was observed 
in the complexation of PBPA with the same antibiotics in the β5-α11 loop near the active site, but these 
varied for each β-lactam and the two molecules in the crystallographic asymmetric unit.  In general, it was 
revealed that the β5-α11 loop of PBPA has a flexible region that appears important for acylation and 
provides further indication that the PBPs in the apo form can occupy different conformational forms12. 
In another study, the crystal structure of the PonA1 transpeptidase domain from the Mtb strain H37Rv in 
the apo form and bound to penicillin V was reported.  PonA1 is a class A penicillin-binding protein, that is 
required for maintaining physiological cell wall synthesis and cell shape during growth in the 
mycobacteria34.  The general structural detail and the penicillin-binding site were characterized.  The 
crystallized PonA1 structure (residues 249–643) contains the transpeptidase domain and one small adjacent 
domain at the N terminus of the transpeptidase enzyme.  The first 156 residues that form part of the N-
terminal glycosyltransferase domain and 33 residues at the C terminus of the PonA1 were not observed in 
the protein structure.  These modifications could be due to protein degradation and/or structural disorder.  
The PonA1 X-ray structure has a unique unstructured C terminus that contains a proline-rich region.  This 
region forms an exposed long hydrophobic tail, suggesting that it may be involved in the protein-protein 
interactions that have been suggested by previous studies40.  It was concluded from their study that the 
structural comparison of inhibitor-free and inhibitor-bound states of PonA1 indicates that binding of 
penicillin V induces conformational changes of the loop β4-α3 leading to a widening of the penicillin-
binding pocket.34.   
PonA2 is the second enzyme of the class A PBP in Mtb35, which is involved in the adaptation of Mtb to 
non-replicating persistency, an ability that has been attributed to the presence of a C-terminal PBP and 
Serine/Threonine kinase Associated (PASTA) domain.  The PASTA domains are typically considered as 
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β-lactam antibiotic binding domains and were previously proposed to act as sensors of muropeptides and 
mediate complex mechanisms bacterial revival from the non-replicating state41, 42.  Calvanase and co-
workers35 determined the solution structure of the PASTA domain from the PonA235 and analyzed the 
binding characteristics against a plethora of possible binders, as well as β-lactam antibiotics, two distinctive 
muropeptide mimics, and polymeric peptidoglycan.  Their study showed that, despite a high structural 
similarity with other PASTA domains, the corresponding domain of PonA2 displays varying binding 
characteristics, as it is not able to bind any of the ligands tested.  The findings revealed that the role of the 
PASTA domains cannot be generalized, as their specific binding characteristics largely depend on surface 
residues, which are usually variable35.  The DDT activity of PBPs is catalysed by a common PB domain, 
which binds β-lactam antibiotics.  The latter inhibits the enzymatic DDT activity of the PB domain, based 
on the structural similarity between penicillin and the D-ala-D-ala dipeptide that forms the terminus of the 
natural substrate of PBPs [L-ala D-glu L-lys D-ala D-ala (UDP-MurNAc-pentapeptide43)], the penta-
peptide precursors of the PG31.   
Nuclear Magnetic Resonance (NMR) was used to solve the structure of the PonA2-PASTA domain and 
explored its binding properties toward the β-lactam antibiotics cefuroxime and cefotaxime, the 
muropeptides L-Ala-gamma-D-Glu-mDAP and MurNAc-L-Ala-gamma-D-Glu-mDAP, and polymeric 
peptidoglycan (PGN).  The 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of the 15N-
labeled PonA2-PASTA domain shows a good dispersion of signals, indicative of a well-folded structure 
and consistent with UV circular dichroism (CD) data35.  Triboulet et al.28, performed NMR chemical shift 
perturbation experiments to explore the structural and thermodynamics basis for this specificity, and 
identify β-lactam features that are critical for efficient L,D-transpeptidase inactivation.  In a study where 
LDT (LdtfmC442A) was incubated with increasing β-lactam concentrations up to the drug solubility limit 
in order to observe the formation of noncovalent complexes, it was observed that a fast exchange occurred 
between free enzymes and the protein-beta-lactam complex.  The residues that were affected by drug 
binding were mostly located at the surface of the protein in the vicinity of the LdtfmC442A catalytic cavity 
indicating specific binding of the drugs28. In 2010, Kastrinsky et al.44 performed the synthesis of labeled 
meropenem to identify the protein targets of the carbapenems in whole cells of Mtb, using two labeled 
forms of meropenem to use as probes for transpeptidases.  The use of radiolabeled meropenem synthesis 
that relied on the introduction of a labeled amine, served as an advantage to introduce an alternative label 
in a similar fashion with the only constraints that the label is compatible with the carbapenem nucleus and 
not impart any significant steric demand.  The synthesized 14C labeled meropenems offer useful tools to 
identify and characterize the targets of the carbapenems in other organisms.   
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The overexpression, purification and biochemical characterization of a class A high-molecular-mass 
penicillin-binding protein, PBP1* and its soluble derivative from Mtb were earlier studied by Sanjib Bhakta 
and Joyoti Basu13.  The study was the first report of the complete genome sequence of Mtb1 with the 
presence of two open reading frames (ORFs), Rv3682 and Rv0050, which encodes the two putative class 
A high-molecular-mass PBPs.  They found that Mtb PBP1* has a similar sequence to M.leprae PBP1*.  
The sequence similarity and sensitivity of Mtb PBP1* to β-lactam antibiotics suggests that it is the 
counterpart of M.leprae PBP1*13.  No crystal data was reported for this study.   
Lavollay and co-workers20 reported a new structure of Mtb PG from a stationary-phase culture that showed 
an unusually high content (80%) of 3-3 cross-linkage created by L,D-transpeptidation.  The X-ray 
crystallographic study of one of the LDTs (LdtMt1) (Figure 2.1) from Mtb was performed by Correale et al. 
in 201214.  Analysis of the protein families (PFAM) database45 showed that LdtMt1 comprises of two 
domains, the N-terminal domain, the structure of which cannot clearly be predicted, and the C-terminal 
LDT catalytic domain.  The catalytic domain of LdtMt1 shares 29% sequence identity with that of the LDT 
from Enterococcus faecium46.  The catalytic residues of LdtMt1 are Cys226, His208, and Ser209.  In a further 
study by Correale et al. in 20139, the crystal structures of LDT LdtMt1 from Mtb in the apo form and 
imipenem-bound were reported.  They used X-ray crystallography, spectroscopic and calorimetric assays 
to investigate the structural features of Mtb LdtMt1 in both a ligand-free form and in complex with the 
carbapenem imipenem.  The crystal structure of LdtMt1 showed that the catalytic site is located in a tiny 
tunnel, the results suggesting a high specificity of LdtMt1 for its substrates, as was observed for the LDT 
from Enterococcus faecium47.  Additionally, the structure of the imipenem inactivated LdtMt1 gives a 
detailed molecular view of the interactions between the carbapenem drug and LdtMt1.   
LdtMt1 is upregulated 17-fold during the stationary phase and is believed to perform a role in bacterial 
adaptation to the non-replicating state48.  Furthermore, LdtMt1 is believed to perform an important role in 
PG metabolism to the non-replicative state of the bacilli20.   
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Figure 2.1 Structure of Mtb LdtMt1
14, LdtMt2
17, and LdtMt5
39.  Residues of the active sites are represented as 
sticks within the enzyme. On aligning the sequences of LdtMt1, LdtMt2 and LdtMt5, the important regions of 
these enzymes such as the catalytic domains, the BIgA and BIgB interfaces and loop LD, are presented in 
Figure 2. 
In 2012, Erdemli et al. reported the first crystal structure of Mtb LDT (LdtMt2) containing a bound PG 
fragment. The holo-enzyme structure information provides the catalytic site organization as well as the 
substrate identification by the enzyme.  Added to the description of the structure of LdtMt2 is the 
characterization of the extracellular portion of the enzyme as comprising of two domains.  The N-terminus 
possesses immunoglobulin-like domains and the C-terminus harbours the catalytic ErfK/YbiS/YhnG 
domain.  The catalytic residues of LdtMt2 are Cys354, His336, His352 and Ser337
16, 17, 36  In comparison to 
LtdMt1, the catalytic domain is located at the C-terminus.  On the basis of this structure, comparative 
modelling of the identified Mtb homologs suggested49 that the20 N-terminal domain fold, and that the 
enzyme’s overall conformation differentiate this category from other structurally characterized 
ErfK/YbiS/YhnG domain-containing proteins such as Bacillus subtilis ykuD49 and E. faecium LDT Ldtfm
46.  
An Mtb strain deficient of LdtMt2 loses virulence and has weakened growth during the chronic phase of the 
disease33.  Also, this strain lacking LdtMt2 is more susceptible to the therapeutic combination of amoxicillin 
 
      
 
 
 
LdtMt1 LdtMt2 
LdtMt5 
32 
 
and clavulanic acid33, suggesting that the 3-3 transpeptidation activity is a major contributor to β-lactam 
resistance.   
Also in 2012, Bӧth et al. 16, investigated the structure of LdtMt2 from Mtb and reported its three-dimensional 
structure of LdtMt2 based on the X-ray crystal structures of two fragments of LdtMt2 representing the 
extracellular part of the protein.  Their structural analysis disclosed that LdtMt2 folds into three domains, 
i.e., two domains in the N-terminal portion, both of which display an immunoglobulin-related fold, and the 
C-terminal transpeptidase domain.  This domain composition is different from the two-domain structure of 
the extramembrane part of the LdtMt2 proposed recently
17.  The crystal structures of the LdtMt2
16 constructs 
allow for modelling of the full-length extramembrane part of the enzyme (residues 55–408), providing an 
estimate of the maximal distance of the catalytic site from the membrane and thereby the approximate 
distance at which 3–3 cross-links that are formed in the PG layer.  Additionally, they used mass-
spectrometric analysis to demonstrate that LdtMt2 (Cys354) forms covalent adducts with the β-lactam 
antibiotics imipenem and ampicillin. 
Several X-ray crystal structures of an N-terminal-truncated LdtMt2 (Figure 2.1) were reported by Li et al. in 
201350.  Apart from the free enzyme (apo), these included a trypsin-degraded fragment of LdtMt2 and the 
complex of LdtMt2 with meropenem, at 2.5, 1.8 and 1.4 Å resolutions, respectively.  The authors indicated 
that these structures disclose the inhibition mechanism of meropenem against LdtMt2 (Figure 2.2).  The apo 
LdtMt2 structure
50 showed a linear arrangement of the two N-terminal β-barrel domains (residues 60-148 and 
149-250) and the C-terminal YkuD domain (residues 251-408).  The two N-terminal β-barrel domains, both 
of which adopt an IgG-like fold, contain one three-stranded and one four-stranded sheet, respectively.  It 
was concluded that these two IgG-like domains act as a spacer arm for the YkuD catalytic domain50.  
 
Figure 2.2 Molecular structure of the Cys354-meropenem adduct formed with LdtMt2
50 
The most recent study37 on the X-ray crystal structures of LdtMt2 bound with either biapenem or tebipenem, 
showed that even with significant variations of the carbapenem sulfur side chains, biapenem (Figure 2.3) 
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and tebipenem eventually form similar adducts that bind to the outer cavity of LdtMt2.  The sulfur atom of 
Cys354 forms a covalent bond with the carbonyl group of the β-lactam ring in carbapenems.  This study 
differs from other LdtMt2 studies described previously
17, where binding occurs within the inner cavity.  The 
study proposed that this common adduct is an enzyme catalysed the decomposition of the carbapenem 
adduct by a mechanism similar to the S-conjugate elimination by β-lyases37.  The apo-LdtMt2 structure and 
the previously solved apo-LdtMt2 structure (3VYN
50) have an RMSD of 0.7 Å among 347 Cα atoms 
superimposed on each other.  Therefore, the catalytic residues of LdtMt1 and LdtMt2 behave similarly while 
that of LdtMt5 is different as represented in Figure 2.2.  The earlier study by Correale et al.
9 gave clarification 
on the structural features of LdtMt1 and disclosed analogies and differences between the two key 
transpeptidases of Mtb, the LdtMt1 and LdtMt2.   
 
Figure 2.3 The description of the Cys354 adduct formation of biapenem with LtdMt2 showing where the 
inner and outer cavities37. 
Brammer et al 39 reported the first crystal structures of LdtMt5 (Figure 2.1) in apo form and as a  meropenem 
complex.  It was observed that Mtb with deletion of LdtMt5, exhibits abnormal growth, and is more 
vulnerable to killing by crystal violet, osmotic shock, and select carbapenem antibiotics.  Consequently, 
they concluded that LdtMt5 is not a functionally redundant LDT, but that it serves a unique role in 
maintaining the integrity of the Mtb cell wall.  The catalytic residues of LdtMt5 are Cys360, His342, Thr357 
and Asn358.  The LdtMt5 has two variations in the conserved motif; a motif alternative Thr357 of LdtMt5 
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replaces the LdtMt2 serine (Ser351) and Asn358 replaces the characteristic motif histidine (His352 in 
LdtMt2)
39.   
 
Figure 2.4 The sequence alignment based on the structural superposition of LdtMt1
14, LdtMt2
17
 and LdtMt5
39. 
The observed secondary structures are noted above the amino acid sequences. red: catalytic residues; 
yellow: loop LD).  
 
Recently, Gokulan et al.38 reported the full length crystal structures of the periplasmic region of LdtMt2 apo 
form, in complex with meropenem and imipenem and a calcium bound dimeric structure.  In their 
observations, it was revealed that the periplasmic region of the LDT folds into three domains and that the 
catalytic residues are situated in the C-terminal domain.  The acylation reaction occurs, as before, between 
carbapenem antibiotics and the catalytic Cys-354, forming a covalent complex.  The adduct formed mimics 
the acylation of LDT with the donor PG-stem.  It is interesting to note that in both the apo form and the 
carbapenem complexes, the N-terminal domain has a muropeptide unit non-covalently bound to it.  Another 
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interesting observation is that the calcium complex crystallized as a dimer through head and tail interactions 
between the monomers.  It was concluded that a fragment of the PG-stem binds with the N-terminal domain 
of LDT, which was not observed in the earlier reported structures9, 14, 16, 17, 28, 51. 
2.3 Mechanistic pathway of transpeptidases  
The benefit of understanding the possible reaction mechanisms of the transpeptidases (Figure 2.5) required 
for the growth and metabolism of Mtb PG is more in the context of developing new drugs against TB52-54.  
The β-lactam antibiotics act as a suicide substrate of the DDTs, as the active-site serine residue attacks the 
carbonyl of the β-lactam ring31.  However, the resulting ester bond is hydrolysed at a very slow rate, 
typically 2–10 h-1, with the formation of the acyl enzyme is, therefore, being considered to lead to 
irreversible inactivation of the enzyme at a physiologically relevant time scale.  The active-site cysteine 
residues of LDTs similarly form thioester bonds with the β-lactam ring55.  The enzymes display narrow 
substrate specificity as this reaction occurs preferentially with β-lactams of the carbapenem and penem 
subclasses.   
 
Figure 2.5 Diagrammatic illustration of peptidoglycan transpeptidation. D,D-transpeptidases (4-3) while 
L,D-transpeptidases (3-3) linkages, redrawn from literature9. 
36 
 
Two different catalytic reaction mechanisms were proposed for the LDTs.  The first one was offered by 
Biarrote-Sorin and colleagues46, who proposed that in LDT, the two pathways to the catalytic cysteine 
(Cys442) are used: one for the acyl donor and the other for the acyl-acceptor substrates.  The buried pocket 
also contains Asp422, Ser439, His440 and a conserved His421.  By comparison of the cysteine and serine 
proteases56, the Nε2 of His421 will capture the Sγ hydrogen released by Cys442 to assist nucleophilic attack 
of the carbonyl of the L-Lys3-D-Ala4 peptide bond.  The position of the imidazole ring of His421 is 
stabilized by a hydrogen bond involving Nδ1 and the main-chain carbonyl oxygen of Asp422. The hydrogen 
bond interaction56 is expected to increase the pKa of His421 to a lesser extent than the Nδ1-carboxylate 
interaction in the classical Ser-His-Asp triad found in serine proteases.  The latest and more simplified 
proposal was suggested by Erdemli and colleagues17 for LDT which is based on a cysteine proteases 
mechanism.  In the cysteine protease proposal for LdtMt2 (Figure 2.6), the catalytic mechanism occurs in 
two stages.  First, (acylation step), the catalytic Cys352 thiolate (upon proton abstraction) attacks the acyl 
carbon of the substrate to form a tetrahedral intermediate (EIox).  After the intermediate thioester formation 
and protonation by the His336 imidazolium group, D-Ala is released.  In the second stage (deacylation 
step), another peptide stem enters the catalytic site, also through the external vestibule and binds to the 
catalytic site residues with the side chain amide of the m-A2pm3′ residue (which is isomorphic to D-Ala 
and also has a D chiral centre).  In this step, the His336 acts as a catalytic base by abstracting a proton from 
the amine group of the mA2pm3′ residue, while the same amine group performs a nucleophilic attack into 
the carbonyl carbon of acyl-enzyme17.  Subsequent theoretical studies by Silva et al.57, 58 investigated the 
inhibition reaction of Mtb LdtMt2 in the presence of carbapenems.  The activation energies (𝛥𝐺𝑐𝑎𝑙
‡
) values 
obtained for the whole reaction (acylation and deacylation steps, Figure 2.4) at M06-2X-D3/MM level are 
17.41 and 20.00 kcal mol-1 for the first and second steps (Figure 4), respectively, which is in agreement 
with experimental data15. 
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Figure 2.6. Reaction mechanism for (a) Acylation Step and (b) Deacylation Step in the active site of the 
LdtMt2 enzyme
58.   
2.4 Drugs for Mtb transpeptidase inactivation  
The development of TB drugs started with streptomycin with the isolation of the antibiotic reported in a 
paper in January 1944.  The first human clinical trials of streptomycin were administered on November 
20th, 1944 59.  The treatment occurred a few weeks after the first patient received an oral dose of Para-
Aminosalicylic Acid (PAS) as the derivatives of aspirin in October 194460.  Later, in 1951, isoniazid was 
discovered and found to be ten times more potent than either streptomycin or PAS and it appeared to be 
nontoxic61, 62.  Combined therapy with isoniazid (INH), streptomycin, and PAS turned out to be the typical 
triplicate drugs used for more than a decade.  The usage of the first line antimycobacterial drugs began with 
the inclusion of pyrazinamide (PZA), rifampicin (RIF) and ethambutol (EMB) in 1952, 1957 and 1962 
respectively63.   
The combination of INH, PZA, RIF, and EMB form the four regimens for treating TB at the intensive phase 
of treatment, which is for two months.  Thereafter, at the continuation phase, only INH and RIF are used 
for either four or seven months of the therapy period64, 65.  Drug-resistance to frontline anti-TB drugs has 
become a major public health problem.  The treatment of MDR and XDR tuberculosis according to the 
results of drug vulnerability testing is achieved using both first and second-line drugs together.  Second-
line drugs comprise of aminoglycosides (kanamycin and amikacin), cycloserine, terizidone, ethionamide, 
protionamide, capreomycin, aminosalicylic acid, and fluoroquinolones (together with ofloxacin, 
levofloxacin, gatifloxacin, and moxifloxacin)66.  
Carbapenems were recently introduced to treat TB67, 68.  These antibiotics were initially created from 
thienamycin, a natural product found in the culture filtrates of Streptomyces cattleya69.  Four carbapenems 
have been approved thus far for human use, these being imipenem, meropenem, ertapenem, and 
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doripenem70.  Imipenem was the first carbapenem endorsed by the FDA in 1985 and is the most extensively 
used one of this family.  The use of meropenem was endorsed in 1995, with ertapenem and doripenem 
being approved in 2001 and 2007, respectively71.  Carbapenems kill Mtb, at least in the active phase72, and 
the addition of a β-lactamase inhibitor is recommended72, 73 as it inhibits 3,3-transpeptidases.  Despite the 
general success of β-lactam antibiotics74, faropenem has been approved in Japan and is currently available 
as an orally administered sodium salt, Farom®: while in the USA, faropenem is in Phase III clinical trials 
as the ester prodrug, faropenem medoxomil.  Faropenem is a penem and is structurally similar to the 
carbapenems, which include the clinically available drugs imipenem, meropenem, doripenem and 
ertapenem, it differed by a sulfur atom75.     
2.5 Experimental case studies 
In this section, we highlight the bioactivities of known and approved TB drugs that function by targeting 
LDTs and DDTs.  
The first bioactivity assay of the  PonA134 against penicillin V and meropenem was elucidated by Filippova 
et al. in 201634.  They applied site-directed mutagenesis, antibiotic profiling experiments, and fluorescence 
thermal shift assays to quantify PonA1’s sensitivity to different classes of β-lactams.  Their results showed 
that the structural comparison of the PonA1 apo-form and the antibiotic-bound form indicated that the 
binding of penicillin V induces conformational changes in the position of the loop β40-α3 that surrounds 
the penicillin-binding site.  In addition, their antibiotic profiling experiments indicated that the 
transpeptidase activity of PonA1 in both Mtb mediates tolerance to specific cell wall-targeting antibiotics, 
particularly to penicillin V and meropenem.  Fluorescence thermal shift (FTS) data revealed that formation 
of the acyl-enzyme by compounds such as carbenicillin or penicillin V result in positive thermal (Tm) shifts, 
while others such as clavulanate or meropenem give negative Tm shifts, indicating that they induce a more 
destabilized conformation of PonA1. The conformational changes showed that both antibiotics bind to the 
enzyme.  Meanwhile, the binding of clavulanate or meropenem induced a more destabilized conformation 
of PonA1.  It was concluded that as Mtb is an important human pathogen, the structural data provided could 
serve as a template for designing novel transpeptidase inhibitors to treat tuberculosis infections. 
In 2010, Gupta et al.33 reported that LdtMt2 from Mtb is a non-classical transpeptidase that is essential for 
virulence and resistance to amoxicillin.  They isolated a Mtb mutant lacking LdtMt2 resulting from the 
inactivation of gene encoding it, by screening a group of 5,100 unique transposon insertion mutants for 
growth attenuation.  It was hypothesized that the deletion of LdtMt2 may compromise the mutant’s ability 
to adapt during the chronic phase of infection, a crucial stage in the pathogenesis of tuberculosis.  They 
tested this hypothesis by assessing the susceptibility of the LdtMt2 mutant to amoxicillin.  The deletion of 
LdtMt2 showed increased susceptibility to amoxicillin/clavulanate combination.  Their result showed that 
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deletion of this protein leads to the altered cell surface and colony morphology, loss of virulence and 
increased vulnerability to amoxicillin-clavulanate during the chronic phase of infection.  It was concluded 
that inhibiting LDTs aids in targeting persisting bacilli during the chronic phase of Mtb infection. 
Dubee and colleagues in 201276 investigated the inactivation of LdtMt1 with carbapenems and 
cephalosporins.  Using mass spectrometry and stopped-flow fluorimetry they explored the kinetics and 
mechanisms of inactivation of the prototypic LdtMt1 with some selected carbapenems, while cephalosporins 
were explored using mass spectrometry and stopped-flow fluorimetry.  Inactivation happened through 
noncovalent drug binding and acylation of the catalytic cysteine of LdtMt1, which was eventually followed 
by hydrolysis of the resulting acyl enzyme.  Meropenem quickly inhibited LdtMt1, with a binding rate 
constant of 0.08 µM-1 min-1.  By comparing the kinetic constants for drug binding, it was concluded that 
acylation and acyl enzyme hydrolysis indicated that carbapenems and cephems can both be tailored to 
optimize PG synthesis inhibition in Mtb. 
The in vitro cross-linking of Mtb PG by LDTs, and the inactivation of these enzymes using carbapenems 
was studied by Cordillot and co-workers15 in 2013.  They purified five LDT paralogues of Mtb (LdtMt1 to 5) 
and compared their activities with those of peptidoglycan fragments and carbapenems.  The five LDTs were 
functional in vitro as they were active in assays of PG cross-linking(LdtMt5), β-lactam acylation(LdtMt3), or 
both (LdtMt1, LdtMt2 and LdtMt4).  LdtMt3 was the only LDTs that was inactive in the crosslinking assay, 
suggesting that this enzyme might be involved in other cellular functions, such as anchoring proteins to 
peptidoglycan, as shown in Escherichia coli.  Inactivation of LDTs by carbapenems is a two-step reaction 
consisting of a reversible formation of a tetrahedral intermediate, the oxyanion, followed by irreversible 
rupture of the β-lactam ring, which leads to the formation of a stable acyl enzyme.  It was concluded that 
imipenem could inactivate LDTs more rapidly than ertapenem and that both drugs were more efficient than 
meropenem and doripenem, signifying that modification of the carbapenem side chain could be used to 
optimize their antimycobacterial activity15. 
In 201477, Schoonmaker et al., generated and studied Mtb strains deleted for LdtMt1 or both LdtMt1 and 
LdtMt2.  The study defined the cellular phenotypes linked with deletion of these LDTs.  They used an Mtb 
mutant of CDC1551 without a functional replica of LdtMt2 (strain M2)
33 which represents the parent strain 
for producing a double knockout strain missing in both LdtMt2 and LdtMt1.  The cell surface morphologies 
of Mtb strains at exponential and stationary phases of growth was processed for field emission scanning 
electron microscopy(FESEM) analysis.  Strains lacking LdtMt1, LdtMt2, or both LdtMt1 and LdtMt2 (M12), 
were studied.  Unlike the parent wild-type Mtb strain, whose cell length was 1.8 µm, mutants lacking both 
LdtMt1 and LdtMt2 were consistently shorter, with an average cell length of 1.0 µm.  Complementation of 
this double mutant with wild-type copies of LdtMt1 and LdtMt2 restored the cell length phenotype. However, 
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the minimum inhibitory concentrations (MICs) of imipenem, meropenem and ertapenem tested against the 
strains of LdtMt1, LdtMt2 and M12 showed a trend similar to the burden in mice infected with wild-type Mtb.  
They concluded that the Mtb strain without both LdtMt1 and LdtMt2 shows changed cellular morphology, 
size, physiology, and in vitro and in vivo growth, as well as enhanced vulnerability to amoxicillin-
clavulanate and a glycopeptide drug, vancomycin. 
In 2015, Kaushik and co-workers78 investigated the synergy of carbapenems and rifampin against Mtb.  
They determined the potencies of a number of carbapenems; ertapenem, meropenem, imipenem, 
doripenem, biapenem, tebipenem, panipenem and faropenem against Mtb by determining the minimum 
bactericidal concentration (MIC) and minimum bactericidal concentrations (MBC).  They also examined if 
carbapenems and isoniazid or rifampin, the two drugs that form the pillars of TB treatment, show any 
synergy, indifference, or antagonism in activity.  In addition, they compared the rates of spontaneous 
resistant mutants when Mtb is exposed to either rifampin or faropenem or a combination of these two drugs.  
Finally, they studied antimicrobial activities of combinations containing rifampin and carbapenems against 
drug-resistant clinical Mtb isolates.  They concluded that faropenem or biapenem, doripenem, meropenem 
(carbapenems), and rifampin, act with synergy when combined. 
In 2015, Dhar et al.79 performed in vitro analysis to compare the potency of faropenem and meropenem to 
inhibit the LDTs, which is involved in the last cross-linking step of PG synthesis.  In this study, a kinetic 
analysis of LDT inactivation through faropenem and β-lactams hydrolysis was made using 
spectrophotometry. The results showed that faropenem inactivated LdtMt1 14-fold more efficiently than 
meropenem, as deduced from the kinact/Kapp ratio.  The comparison of inactivation of the other LDTs by 
meropenem and faropenem revealed that the latter drug was also more efficient for inactivation of LdtMt2 
(22-fold), LdtMt3 (6-fold), and LdtMt4 (9-fold).  The acylated adducts of LdtMt1 were identified by mass 
spectrometry.  All acyl enzymes were stable, while the rate constants were slightly higher for faropenem, 
except for LdtMt4.  LdtMt5 was not acylated by meropenem or faropenem.  It was also concluded that the 
target LDT enzymes are inactivated more efficiently by faropenem than by meropenem, mainly due to a 
more favourable catalytic constant for the chemical step of the acylation reaction79.  
In 2015, Brammer et al39., performed the MIC studies to evaluate whether or not the loss of LdtMt5 would 
affect the susceptibility of Mtb to carbapenems.  The MICs were determined using the standard broth 
dilution method80  The LdtMt5 strain reproducibly showed modestly enhanced susceptibility to doripenem 
and faropenem (a penem) compared to wild-type, but neither strain is susceptible to ertapenem or 
meropenem under the conditions that were tested.  
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The study by Kumar et al. in 201729 characterized the inhibitory interactions of faropenem and carbapenems 
with LdtMt1 and LdtMt2 using biochemical and biophysical approaches.  Multiple crystal structures of 
faropenem and carbapenems with the LdtMt1 and LdtMt2) were resolved.  The penem and carbapenems were 
tested against these enzymes in a preclinical mouse model of TB treatment.  Their result showed that while 
each carbapenem gave a unique adduct when reacting separately with the LDTs, acylation by faropenem 
was the only adduct detected in the competition assays with the carbapenem mixture.  This suggests that 
LdtMt1 and LdtMt2 enzymes preferentially bind to faropenem.  In addition, the MIC values of meropenem, 
doripenem, tebipenem and faropenem varied by only 2- to 8-fold between the two strains.  They concluded 
that carbapenems are particularly effective not only because they inhibit DDTs and are not regularly 
inactivated by β-lactamases, but mainly because they also inhibit the LDTs which create most of the 
linkages in the PG of Mtb.   
2.6 Computational case studies  
The first computational report of a transpeptidase enzyme from Mtb was unveiled in 2014 by Silva and co-
workers58, who investigated the catalytic mechanism of L,D-transpeptidase 2.  This group employed an 
umbrella sampling technique to produce the free energy profile connected with the catalytic mechanism of 
LdtMt2.  The Cys354-thiolate/His336-imidazolium pair of LdtMt2 formed the starting point to drive the 
acylation step.  Thereafter, the attack of Cys354 on the carbonyl carbon of the substrate happened in a single 
step to form a covalent intermediate.  This step was found to be rate-limiting, which agrees with 
experimental data17 for cysteine proteases.  In the de-acylation step to complete the mechanism processes, 
the amine group of the second substrate attacks the acyl-enzyme complex, after which the 3→3 peptide 
bond is formed.  In 2015, Silva and co-workers57 explored the inhibition reaction of the LdtMt2 with 
carbapenems and calculated the binding free energy that was used to describe the inactivation of LdtMt2.  
They used QM/MM81 and PMF approaches to determine a new reaction mechanism for the two 
carbapenems, and their theoretical findings agree in principle with experimental data.  Silva et al.82, in 
another study, investigated the non-covalent interaction of imipenem and meropenem with LdtMt2 that 
targeted the cell wall of Mtb using the MM/GBSA83 and SIE84 approaches.  These methods reproduced the 
same order of binding energies as experimentally observed for imipenem and meropenem. 
Our research group has investigated the mechanistic study of the acylation step of the β-lactam ring with 
LDTMt2 was performed by Fakhar et al.
85 using DFT methods.  Four possible reaction pathways with 
different transition states (TS) models were proposed as four membered-ring (TS-4, TS-4-His and TS-4-
water) and a six-membered ring (TS-6-water).  The obtained thermochemical quantities for the proposed 
models indicated that the activation barrier of TS-6-water model was considerably lower and therefore more 
favourable than the other models.  Fakhar et al. recently studied the flap dynamics of LdtMt2
86, and the 
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impact of the induced conformational changes of the flap region to the binding process was studied using 
molecular dynamics simulations in explicit solvent.  Dynamic cross-correlation matrix (DCCM) analysis 
demonstrated significant anti-correlated motions in the imipenem/LDTMt2 flap, whereas ertapenem and 
meropenem binding induced a shift to correlation movement within the flap units.  The MM-GBSA method 
revealed a lower value of ∆Gbind for MERO-LdtMt2 and ERT-LdtMt2 than IMI-LdtMt2. 
The in silico screening of synthetic compounds against Mtb LDTs was carried out by Billones et al., is 
aimed at finding potent anti-tuberculosis drugs.  In their study, they used structure-based pharmacophore 
screening, molecular docking, and in silico toxicity assays to screen compounds from a database of 
synthetic compounds87.  Out of the 4.5 million compounds they screened, 18 were found to have better 
binding energies than meropenem and satisfactory in silico ADMET properties87, 88.  Two of the 18 
compounds that were tested in vitro, with one compound being found to have an excellent bioactivity 
against Mtb H37Ra.  In 2017, Baldin et al. built a full-atom model of LdtMt2 for screening new inhibitors
89.  
They performed molecular modelling of the enzyme binding with the tetrapeptide fragment of 
peptidoglycan, as well as with β-lactam compounds, and built a full-atom model of LdtMt2 for screening and 
optimizing the inhibitor structures.  They observed that binding of the N- and C-terminal fragments of the 
growing PG chain in various tunnels is responsible for the different steps of the catalytic mechanism at the 
formation of non-classical 3-3 cross-linkages in peptidoglycan.  They concluded that to simulate LdtMt2 
interaction with β-lactam inhibitors to inactivate the enzyme through the formation of stable acyl enzymes, 
it is necessary to consider the binding of potential inhibitors in tunnel C of the active site. 
Recently, the non-covalent interactions between carbapenems and LdtMt2 were investigated by Ntombela et 
al.90 using the ONIOM approach.  The binding interactions of LdtMt2 in complexed with four carbapenems 
(biapenem, imipenem, meropenem, and tebipenem) was elucidated, where the carbapenems, together with 
catalytic triad active site residues of LdtMt2 (His187, Ser188 and Cys205), were treated with QM [B3LYP/6-
31+G(d)]. The remaining part of the complexes was treated at the MM level (AMBER force field), for the 
first time, an explicit water molecule was placed in the enzymatic pocket (as suggested by X-ray structures).  
The Gibbs free energy (ΔG), enthalpy (ΔH) and entropy (ΔS) for all complexes showed that the 
carbapenems exhibit reasonable binding interactions towards LdtMt2.  The water molecule increased the 
number of hydrogen bond interactions in the QM layer which showed a significant impact on the binding 
interaction energy differences and the stabilities of the carbapenems inside the active pocket of LdtMt2.  The 
study concluded90 that the theoretical binding free energies obtained reflected the same trend as that of the 
experimental observations.   
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2.7 Conclusive remarks and perspectives 
Understanding the structure and function of transpeptidases in the Mtb responsible for its survival, 
especially in its non-replicating form, is essential for the development of anti-TB agents to permanently 
inactivate it.  Two biosynthetic pathways have been reported to inactivate both penicillin binding proteins 
and the non-classical transpeptidase in the presence of a β-lactam class of antibiotics via the serine and 
cysteine catalytic sites, respectively.  Studies have shown that most of the cross-links were generated by 
LDTs when compared to that created by penicillin binding proteins, thereby making the former a major 
target to impede the biosynthesis of Mtb peptidoglycan.  The transpeptidases enzymes are required to 
catalyze the polymerization of peptidoglycan (PG) cell wall of Mycobacterium tuberculosis.  Since Mtb 
cannot survive without PG, inhibiting its synthesis can be a powerful way to kill Mtb. Indeed, there is a 
powerful precedent to this approach.  More than 50% of antibiotics used today to treat bacterial infections 
in humans belong to the β-lactam class.  The β-lactams exert their activity by inhibiting PG synthesis by 
inhibiting the classical transpeptidases, namely DDTs.  Unlike in other bacteria where DDTs play a major 
role, the LDTs play dominant role in the synthesis of PG in Mtb.  Therefore, if inhibition of DDTs has 
resulted in 50% of antibiotics in use today, one can be hopeful that inhibiting LDTs can also produce 
effective drugs to treat bacterial infections, especially to treat Mtb infections.  Equally important is that 
since β-lactams have not been routinely used to treat TB, even the MDR-XDR strains are susceptible to this 
class of drugs.  The main conclusion of the landmark paper by Hugonnet et al, in 200991 in the journal 
Science was the carbapenems were effective against MDR and XDR-TB strains.  Now we know that 
carbapenems are effective largely because they inhibit the unique LDTs in Mtb.  Also, it is highly relevant 
here to note that in a recent publication Cohen et al92 demonstrated the MDR-XDR strains are paradoxically 
susceptible to β-lactams.  The first set of anti-mycobacterial antibiotics such as isoniazid and rifampicin are 
no longer effective in combating Mtb strains that are multidrug resistant.  This has led to the urgent need to 
elucidate the survival mechanisms of these enzymes inherent in Mtb.  The mechanism of inactivation of 
this mycobacterium using β-lactam derivatives drugs (carbapenems) involves the acylation of the serine 
and cysteine catalytic sites for DDTs and LDTs respectively.  However, it seems that only LdtMt2 has been 
well studied in terms of the bioactivities using its natural substrate and FDA approved drugs. 
Crystallography structures have been deposited in a protein data bank for further investigation 
computationally, which could advance the course of drug design.  It is important to note that relatively few 
crystal structures have been reported for both TB enzymes (10 for DDTs and 36 for LDTs), which limits 
the theoretical development of new TB drugs.  Thus, in order to permanently inactivate Mtb, all targets 
required for their survival needs to be investigated which could proffer adequate information leading to the 
development of potent anti-TB drugs.  
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Abstract 
Peptidoglycan is the exoskeleton of bacterial cells and is required for their survival and growth.  In 
Mycobacterium tuberculosis (Mtb), the bacteria that currently claims the most number of human lives each 
year, the final step of peptidoglycan synthesis involves generation of 4→3 and 3→3 transpeptide crosslinks 
catalyzed by D,D-transpeptidase and L,D-transpeptidase (Ldt) enzymes, respectively.  Unlike in most other 
bacteria, for Mtb, the majority of the cross-links are generated by L,D-transpeptidases.  Any Mtb strain that 
lacks a functional copy of an Ldt, namely LdtMt5, displays aberrant growth phenotype and is more 
susceptible to killing by cell wall perturbing agents including carbapenems which are considered the last 
resort antibiotics to treat resistant bacterial infections in humans.  Here, we used molecular dynamics (MD) 
and Quantum Mechanical (QM) simulations to probe the molecular interactions of LdtMt5 with 
carbapenems.  LdtMt5 complexes with three carbapenems, ertapenem (ERT), imipenem (IMI) and 
meropenem (MERO) were simulated.  The binding free energies (with entropy contributions) of the selected 
complexes were calculated from the MD trajectories using the MM/GBSA approach, the theoretical results 
revealed higher ∆Gbind for ERT—LdtMt5 and IMI—LdtMt5 than MERO—LdtMt5.  In comparison with LdtMt2  
Chapter Three – MD and QM/MM Studies 
52 
 
(experimental and computational results), it is clear that the corresponding interactions of these drugs are 
much weaker with LdtMt5.  To further understand the catalytic reaction mechanism of LdtMt5 with the 
selected carbapenems, the possible reaction pathway (thermodynamics and kinetics) was investigated using 
a two-layered ONIOM [B3LYP/6-31+g(d,p):Amber] model.  The high free energies of activation (∆G) for 
imipenem and meropenem, explain the reason behind inefficient binding of these carbapenems to LdtMt5.  
The inhibitor—enzyme precomplex computational model for L,D-transpeptidase 5 correctly reflects 
experimental observations.  This is the first computational project focusing on the elucidation of the 
interactions between carbapenems and LdtMt5.  These results provide a better understanding of how the 
antibacterial agents function and will potentially contribute to the discovery of more potent LdtMt5 
inhibitors.  
Keywords: L,D-Transpeptidase 5 (LdtMt5); Mycobacterium tuberculosis (Mtb); Carbapenems; Molecular 
docking; Molecular dynamics (MD); Quantum Mechanical (QM). 
3.1  Introduction 
Mycobacterium tuberculosis (Mtb), the bacteria that causes tuberculosis (TB), kills more people today than 
any other single bacteria1, killing about 2 million people annually and is the direct cause of death for many 
HIV patients2.  About one-third of the human population is sub-clinically infected with Mtb3.  Mtb is much 
more resistant to antibiotics than most other bacteria4, 5 and thus require the design of new and efficient 
drug regimens.  After entering into the lung, the bacteria often remains in a dormant state until the host’s 
immune system is compromised and activation of the disease occur6.   
Peptidoglycan is a major component of the Mtb cell wall. It is a macromolecule composed of cis-linked 
glycan chain with short peptide side chains that are crosslinked by transpeptide bridges7.  In addition to 
conferring cell shape, mechanical strength and integrity of the cell wall, peptidoglycan is vital for the normal 
physiology of the bacterial cell.  The final step of peptidoglycan biosynthesis involves bonding peptide 
sidechains with transpeptide linkages.  Mtb peptidoglycan contains both the classical 4→3 linkages and the 
non-classical 3→3 linkages, which are formed by D,D and L,D-transpeptidases, respectively8, 9.  
Carbapenems belong to the β-lactam family, the most widely used class of antibiotics to treat infections in 
humans.  Recent studies have demonstrated that carbapenems selectively inhibit the 3→3 crosslinks11, 
while classical penicillins inhibit 4→3 crosslinks10.  The combination of carbapenems and penicillins is 
speculated to result in coordinated disruption of the mycobacterial cell wall and subsequent killing of the 
pathogen7.  
The 3→3 crosslink L,D-transpeptidases (Ldts) by-pass the classical penicillin binding proteins (PBPs)11 
thus making them attractive targets for the development of new drugs for the treatment of multidrug-
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resistant tuberculosis11-13.  In Mtb, 80% of the peptidoglycan layer has been reported 14, 15 to be crosslinked 
by L,D-transpeptidases.  Therefore, Ldts that generate these linkages are potentially attractive targets 
against which to develop new drugs to treat drug-resistant TB. 
Mtb genome encodes five Ldt paralogs, namely LdtMt1 to LdtMt5.  Except for LdtMt3, these proteins were 
found to be active in vitro peptidoglycan crosslinking assays.  LdtMt2 has been extensively studied 
experimentally16-19 as well as computationally20-27.  However, very little is known about the activity and 
interactions of LdtMt5 with inhibitors.  It was experimentally observed that in terms of the binding affinities 
of the selected carbapenems, carbapenems are weaker binders against LdtMt5
28 in comparison to LdtMt2
16, 24, 
25, 29, 30.  Herein, our group is attempting to unravel these differences, using a computational comparison 
between these two enzymes.     
The reaction mechanism of  LdtMt2 with its natural substrate was investigated using hybrid quantum 
mechanics/molecular mechanic (QM/MM) molecular dynamic (MD) simulations, followed by umbrella 
sampling23.  It was concluded that the mechanistic process for joining of the m-A2pm3 residue with m-
A2pm3’, involves two stages: acylation and deacylation16.  During the acylation stage, two steps were 
observed: the first is a thiolate/imidazole ion-pair in the zwitterionic form and the second a nucleophilic 
attack on the carboxyl carbon of the substrate along with the breaking of the peptide bond.  In the 
deacylation stage, the acyl-enzyme undergoes a nucleophilic attack on the carboxyl carbon by the amine 
group of the second substrate.  The free energy calculations confirmed the experimentally proposed 
mechanism and identified16 the acylation as the rate-limiting step. 
The inhibition of LdtMt2 by carbapenems was subsequently studied using hybrid quantum 
mechanics/molecular mechanics (QM/MM) molecular dynamics (MD) simulations and an umbrella 
sampling approach22 to investigate the inactivation of LdtMt2 by the carbapenems, meropenem and 
imipenem. They studied a four-membered ring transition state and the theoretical energetics obtained from 
the study followed the same trend of reported experimental data31.  This activity order was confirmed by 
using density functional tight binding/molecular mechanics (DFTB/MM) to calculate the potential free 
energy surface for the reaction mechanism described22.   
Later, the mode of interactions of several carbapenem inhibitors inside the active pocket of  LdtMt2  targeting 
the cell wall of Mtb was theoretically studied using MM/GBSA and SIE binding free energy methods21.   
The average ligand-protein binding free energies in these pre-covalent complexes calculated from their MD 
simulation followed the same order as the experimental bioactivity data.  The isothermal titration 
calorimetry experiments (ITC) revealed16, 21 free binding energies for the covalently bonded inhibitors of 
9.97 and 8.30 kcal mol-1 for imipenem and meropenem against LdtMt2, respectively.   In other words, these 
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studies demonstrated that there is a direct correlation between the binding energies calculated in the pre-
covalent complexes and the free energies of the subsequent covalently bonded inhibitor—LdtMt2 complexes.  
A mechanistic study and acylation step model of the β-lactam ring of the carbapenems with LdtMt2 was 
performed by Fakhar et al.24 using DFT methods.  Four possible reaction pathways with different transition 
states (TS) models were proposed as four membered-rings (TS-4, TS-4-His and TS-4-water) and a six-
membered ring (TS-6-water).  The thermochemical quantities for the proposed models indicated that the 
activation barrier of TS-6-water model was considerably lower and therefore more favourable than the other 
TS models24.   
Subsequently, the flap dynamics of LdtMt2 and the impact of induced conformational changes of flap region 
within the binding process was studied using molecular dynamics simulations 24 in explicit solvent.  
Dynamic cross-correlation matrix (DCCM) analysis demonstrated significant anti-correlated motions in 
imipenem/LDTMt2 flap whereas ertapenem and meropenem binding induced a shift to correlation motion 
within flap units.  The MM-GBSA method 25  revealed lower values of ∆Gbind for MERO—LdtMt2 and 
ERT—LdtMt2 than IMI—LdtMt2.    
Despite several theoretical studies on LdtMt2, to the best of our knowledge, there has been no computational 
study on the inhibition mechanism of LdtMt5 in the presence of carbapenems.  For the first time, Brammer 
and co-workers reported 28 the crystal structures of LdtMt5 with meropenem (PDB code:4ZFQ
28 and its apo 
form (PDB code: 4Z7A28.  This crystal structure showed that a covalent bond has formed between Cys360 
and the β-lactam ring of carbapenems.  An experimental study using ITC demonstrated that the interaction 
of meropenem with LdtMt5 is not associated with significant heat exchange
28.  Similar results were observed 
for imipenem and ertapenem.  No adduct was detected by mass spectrometry after 5 hours incubation of 
meropenem and LdtMt5.  It was concluded that meropenem will acylate LdtMt5 over an extended incubation 
period as the X-ray structure of covalently bonded meropenem—LdtMt5 complex was reported
28.  They did 
not rule out the possibility that LdtMt5 is more rapidly inactivated by this class of β-lactams in vivo, 
particularly in the event of LdtMt5 requiring a protein-protein interaction for productive catalysis
28.  It is 
notable that the meropenem—adduct LdtMt5 structure
28, the hairpin and loop (Figure 3.1)  are partially 
disordered, so modelling of the missing portion was performed.  The modeled structure of the LdtMt5 in 
complex with meropenem use for this study is presented in Figure 3.1.  
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Figure 1 The modelled structure of MERO—LdtMt5 with displaying active site residues and loop regions. 
The β-hairpin flap (312-330) and Lc loop (338-358) are highlighted in yellow and active site pocket in CPK 
form [HIS342 (287), THR357 (302), ASN358 (303) and CYS360 (305)] and meropenem (inhibitor) are 
presented in stick form. 
 
Despite inefficient in vitro inactivation of LdtMt5 by carbapenems,  LdtMt5 knock-out strains of Mtb displayed 
aberrant growth, and are susceptibility to crystal violet, osmotic shock, and selected carbapenem 
antibiotics,28 making this enzyme also an important target for drug development against TB.  LdtMt5 is the 
only paralog of LdtMt2 that is not instantly inhibited in vitro by carbapenems
28, 32.  
The weaker inhibition of LdtMt5 by carbapenems (compared to other L,D-transpeptidases) has not been 
addressed at the molecular level;  this motivated us to undertake the present study.  It is likely that the 
reduced suceptibilty13 can be understood from the comparison of the dynamic behaviour of carbapenem-
enzyme complexes25.  The chemical structures of the selected carbapenems are presented in Figure 3.2. 
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Figure 3.2 Chemical structures of the selected carbapenems; 1: ertapenem, 2: imipenem and 3: meropenem. 
Herein, the dynamics of the selected carbapenem derivatives (ertapenem, imipenem and meropenem) 
complexed with LdtMt5 were investigated by performing 60 ns MD simulations in an explicit solvation 
model.  The binding energies of the carbapenems to the LdtMt5 were calculated using MMGBSA binding 
free energy method.  The involvement of the β-hairpin flap28 and Lc loop28 present in the enzyme and 
potential relationship of the flap dynamics to the binding affinities of the compounds in the LdtMt5 active 
site, were also analyzed.   
Since studies in our laboratory revealed a six-membered ring transition state including one water molecule 
(TS-6-water) for the inactivation of lactams by transpeptidase24, a TS-6-water reaction pathway for LdtMt5 
with meropenem and imipenem was also investigated.  The choice of these two carbapenems for the 
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mechanistic study was based on the reported inhibitory function and known experimental binding affinities 
for LdtMt2
33.  In order to probe the presumed natural substrate (SUB) for LdtMt5, we used the native 
tetrapeptide substrate L-Ala1-D-iso-Glu2-mesoDAP3-D-ala4,34 the substrate known for LdtMt2
16. 
3.2  Materials and methods  
The following approaches were used to investigate the inhibition mechanism of L,D-transpeptidase 5 from 
Mycobacterium tuberculosis in the presence of the selected β-lactam carbapenems (Figure 3.2). The 
inhibitor/enzyme complex was prepared using a docking method, followed by visual inspection of the 
inhibitor pose and comparison to the meropenem/LdtMt5 crystal structure
28.   This was followed by 
molecular dynamics simulations/MD trajectory analyses and QM/MM mechanistic studies.  Furthermore, 
the dynamics35 of the β-hairpin flap (312-330) and Lc loop (338-358) (Figure 3.1) on the catalytic binding 
mechanism of LdtMt5 were analyzed to assess whether there is a correlation between flap/loop opening and 
closing and the observed binding affinities of the different inhibitors.  Note that the flap/loop regions form 
part of the active pocket28.   
To achieve these objectives we determined the root mean square deviation (RMSD) to ascertain the stability 
of the system during the simulation.  The root mean square fluctuation (RMSF) was calculated to give the 
flexibility of the residues over the simulation period.   
3.2.1  Inhibitor/Enzyme structural preparation  
The 3D crystal structure of the LdtMt5 in complex with meropenem (PDB code:4ZFQ
28) was obtained from 
the Protein Data Bank36.  The missing residues of the LdtMt5 enzyme were modelled using MODELLER 
v9.1537.  As for the various protonation states of the enzyme, it was experimentally revealed that the LdtMt5 
optimally hydrolyzes nitrocefin at pH >928, however, the difference in its inhibitory activity is insignificant 
in comparison with that of LdtMt2, which favourably causes the hydrolysis of nitrocefin at pH 7
16.  An 
accurate assignment of the protonation states of all the enzyme residues at pH 7 was assigned by 
recalculating the standard pKa values of the titratable amino acids using the empirical PropKa web server38.  
The protonation states of the titratable residues of the LdtMt5 at pH 7 which was used for the modelling, 
were the same as pH 9 (Table S1), this was also confirmed 28 by experiments.  
3.2.2  Preparation of the inhibitor-enzyme complex  
The prepared structure of LdtMt5 was used as the starting structure for molecular docking, the active site of 
the enzyme was defined based on the crystal structure of the meropenem adduct28.  Meropenem, imipenem 
and ertapenem which were placed in the identified active pocket of LdtMt5
28 and were then subjected to 
redocking using flexible AutoDock Tools software39.  The charges of the ligands were computed with 
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Gasteiger partial charges for all atoms.  The number of rotatable bonds was 7, 9 and 9 for meropenem, 
imipenem, ertapenem respectively, which are below the cut-off of 10 rotatable bonds40, 41.  
The AutoGrid map was employed to set the proper size of the grid box.  AutoDock tools1.5.639 was 
employed to determine the proper size of the grid box for the potential binding site.  The grid box was 
determined as center (X=3.9; Y= -39.5; Z=12.1) and dimension (X=45; Y=45; Z=45) with the grid spacing 
of 0.375 Å for each of the following atom types: A C H HD N OA and SA representing all probable atom 
types in the target enzyme for the potential binding site. The Lamarckian Genetic algorithm42 was used for 
molecular docking analysis43 using the AutoDock 4.2 program 39.  The obtained docked poses and binding 
energies of the selected ligands complexed with LdtMt5 were visually inspected to ensure the expected 
drug/enzyme interactions are in accordance with experiment28.  
 
3.2.3  Molecular dynamics (MD) simulations 
The best docked pose of the selected carbapenems in the active site of LdtMt5, in terms of the observed 
interactions and more negative docked binding energies, were subjected to MD calculations.  The hydrogen 
atoms were added to the complexes using the Leap module as implemented in AMBER14 molecular 
dynamics package44.  The AMBER force field 99SB44 and the general AMBER force field (GAFF)45 were 
employed to describe the protein and inhibitors, respectively.  The complexes were neutralized by adding 
the required number of ions (Na+) before solvation.  The system (99835 atoms for both ertapenem  and 
imipenem, while  99852 atoms for meropenem complexes) was solvated in a truncated octahedral cell of 
TIP3P46 water molecules, extending 10 Å outside the protein on each side, thereafter, the parameter and 
topology files were saved for molecular dynamics simulations. Using the SHAKE algorithm 47, all bonds 
were constrained to hydrogen (H) atoms.  The two minimization steps were performed using 5000 frames 
of steepest decent minimization followed by 10000 of conjugated gradient minimization to remove the 
overlapping of atoms.  Afterwards, the minimized systems were heated up from 0 to 300 K with solute 
restrained during 300 ps and then 50 ps of density equilibration with weak restraints on solutes and 2000 
ps of constant pressure equilibration at 300 K were performed.  A total of 60 ns MD simulations for each 
ERT—LdtMt5, IMI—LdtMt5 and MERO—LdtMt5 complexes were performed at a constant temperature of 300 
K and a constant pressure of 1 atm using Particle Mesh Ewald method48.  The time step of 2 fs was used 
for all simulations.  The MD trajectories were analyzed using CPPTRAJ module49 implemented in 
AMBER14 software on GPUs with 24 shared processors using CHPC cluster.  To further validate the 
consistency and reliability of the MD simulations, two more MD runs with different starting structures 
(random seed and starting from different sets of atomic coordinates and velocities) were performed.  
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3.2.4  Principal component analysis (PCA)  
Principal component analysis (PCA) is a mathematical tool which describes the atomic positional 
fluctuations during MD trajectories.  PCA can be used to separate a protein’s conformational space into one 
subspace which contains only a few degrees of freedom that dictate the motions relevant for protein function 
and the remaining subspace which contains irrelevant local fluctuations of the protein50.  
The PCA was performed on the backbone atoms of all the 60 ns MD trajectories by constructing the 
covariance matrix of the C-α atom displacement.  The principal component analysis describes the 
eigenvectors and eigenvalues, which represents the direction of motions and the amplitudes in those 
directions of the protein, respectively51.  The ions and solvent molecules were stripped and CPPTRAJ 
module implemented in AMBER14 suite was used to perform the PCA and the porcupine plot of protein 
motion was created by NMWiz GUI for ProDyPrody52 in VMD53.     
3.2.5  Binding free energy calculations 
The binding free energy, ∆Gbind, of the ligands to their receptors has been calculated with the MM/GBSA 
method54, 55.  The MM-GB/SA method applies the Generalized Born (GB)56 solvation model to compute 
the electrostatic component of the solvation binding free energies. The binding free energy (∆G) of the 
protein-ligand complex is computed as:  
∆𝐺𝑏𝑖𝑛𝑑 = 𝐺𝐶𝑎𝑟𝑏𝑎𝑝𝑒𝑛𝑒𝑚𝑠—𝐿𝑑𝑡𝑀𝑡5 - 𝐺LdtMt5 - 𝐺𝑐𝑎𝑟𝑏𝑎𝑝𝑒𝑛𝑒𝑚𝑠           (1) 
In equation 1, 𝐺𝐶𝑎𝑟𝑏𝑎𝑝𝑒𝑛𝑒𝑚𝑠—𝐿𝑑𝑡𝑀𝑡5  is the absolute free energy of the complex, 𝐺LdtMt5 is the absolute 
free energy of the protein, and 𝐺𝑐𝑎𝑟𝑏𝑎𝑝𝑒𝑛𝑒𝑚𝑠 is the absolute free energy of the carbapenems. The individual 
components of ∆𝐺𝑏𝑖𝑛𝑑 are defined by:       
∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣 - T∆S           (2) 
Where 𝐸𝑀𝑀 is the molecular mechanics energy of the system expressed as the sum of the internal energy 
(bonds, angles, and dihedrals), 𝐸𝑖𝑛𝑡, electrostatic energy, 𝐸𝑒𝑙𝑒, and van der Waals term, 𝐸𝑣𝑑𝑤, as : 
𝐸𝑀𝑀 = 𝐸𝑖𝑛𝑡 + 𝐸𝑒𝑙𝑒 + 𝐸𝑣𝑑𝑤                    (3) 
∆𝐺𝑠𝑜𝑙𝑣 is the solvation energy which is divided into the polar (∆𝐺𝐺𝐵) and non-polar (∆𝐺𝑆𝐴) contributions 
as follows: 
∆𝐺𝑠𝑜𝑙𝑣 = ∆𝐺𝐺𝐵 + ∆𝐺𝑆𝐴                                        (4) 
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The  ∆𝐺𝐺𝐵 is refered to the electrostatic contribution to solvation and is obtained from GB solvation model. 
The second term, ∆𝐺𝑆𝐴, is the non-polar contribution to solvation-free energy that is linearly dependent on 
the solvent accessible surface area (SASA) as: 
∆𝐺𝑆𝐴 = γSASA + b                     (5) 
∆𝐺𝑆𝐴 was calculated using AMBER14’s default parameters for γ and b.  The MM-GBSA binding free 
energies and per residue binding free energy decomposition were determined by extracting 1000 snapshots 
at 10 ps interval from the last 10 ns production MD trajectories of the simulation for each complex.  The 
entropy contributions were calculated using normal mode analysis57, 58 by extracting 100 snapshots from 
the MD trajectories. 
3.2.6  Per-residue binding free energy decomposition analysis 
Per-residue binding free energy decomposition analysis21, 59 around 25 Å from the inhibitor was used to 
measure the detailed contribution of each active residue to the total binding free energy profile between the 
carbapenem inhibitors and LdtMt5 at the atomic level.  
3.2.7  QM/MM Mechanistic studies 
The input structure for QM/MM calculations was taken from the 1000 snapshots from the last 10 ns of the 
MD simulation. Then, a precomplex system was generated in the presence of a water molecule included in 
the active site for the 6-membered ring model based on the model reported before24, 60.  A two-layered 
ONIOM method61-63, implemented in Gaussian 0964 was used for all the QM/MM calculations on GPUs 
using CHPC cluster. In our ONIOM [B3LYP/6-31+g(d,p):Amber] model, the system was divided into two 
layers: a “high layer”, treated at the QM level, and a “low layer”, treated at the classical MM/Amber level.  
Prior to optimization, QM region, water and all residues within 6 Å around the active pocket were relaxed 
while others were held fixed48 using TAO-ONIOM toolkit65.   
The QM (high layer) region comprised of 65 atoms (imipenem, Cys360 of LdtMt5 and one water molecule) 
or 54 atoms (meropenem, Cys360 of LdtMt5 and one water molecule) with B3LYP 6-31G(d) level of theory 
(Figure 3.3).  The remaining part of the enzyme was treated as the low (MM) layer with the AMBER force 
field.   B3LYP/6-31+G(d) was used to obtain the 6-membered ring transition state structures and all 
transition state calculations were confirmed by vibrational frequency calculations using normal mode 
analysis66, 67 with one imaginary frequency.  The intrinsic reaction coordinates (IRC) calculations 68, 69 were 
performed to obtain the minimum energy path for the reaction mechanism.  Full optimization of the 
transition state, reactant and products obtained from the IRC calculations were performed using B3LYP/6-
31+G(d).  Single-point energy calculations with different functionals (B3LYP, MO6, wb97X) and a larger 
6-311+G(2d,2p) basis set were then performed on the optimized structures of the transition state, reactant 
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and product. These functionals were reported to be excellent for thermodynamics and kinetics 
calculations70-75.   
 
Figure 3.3 3D Structural representation of the meropenem—LdtMt5 pre-complex system used for ONIOM 
(B3LYP/6-31+G(d,p):Amber) calculations with the specified QM and MM regions.  The atoms in tubes are 
treated at the QM level, while the atoms in line display style at the MM layer.  The distance between the 
nucleophilic sulfur atom and the electrophilic carbonyl carbon is approximately 3.27 Å.  The minimized 
3D structures (PDB format) for all inhibitor—LdtMt5 complexes are provided as supplementary information. 
 
The inclusion of water to facilitate lactam cleavage is transferring the proton from R-SH to the lactam 
nitrogen.  This removes the need for His287 to abstract the proton as is postulated in the literature16, 24.  
 
3.3  Results and discussion 
Starting structures were obtained from a docking procedure, followed by 60 ns MD simulation of the free 
enzyme and the carbapenem—LdtMt5 complexes.   
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3.3.1  Molecular docking  
The docked conformations with the most negative binding energies and with a similar pose to the X-ray 
structure (PDB code: 4ZFQ)28 (Figure 3.4) were used as starting structures for the rest of this study.  To 
ensure the consistency of the selected docked conformations with the experimentally reported crystal 
structure (4ZFQ)28, the structural alignment of 4ZFQ with the selected docked complexes were visually 
compared.  The resulting structure in Figure 3.4 confirms the close proximity of carbonyl group involved 
in the β-lactam ring of the docked conformer with the sulfur atom (3.27 Å) of the catalytic cysteine residue 
Cys360 which is comparable with our earlier observation 21 for carbapenem—LdtMt2 (3.32 Å).  The close 
distance of this carbonyl group to the sulfur atom, indeed, indicates the possibility of a nucleophilic attack 
followed by subsequent covalent bond formation16, 21.  
 
Figure 3.4 The 3D conformation for meropenem in complex with LdtMt5 enzyme obtained by molecular 
docking. The 3D conformation for other selected carbapenems is provided in the supplementary 
information (Figure S1). The minimized 3D structures for all inhibitor—LdtMt5 complexes are provided in 
the supplementary information. 
3.3.2  Molecular dynamics simulations 
Analyses were made from the MD trajectories performed.  
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3.3.3  RMSD analysis 
The root mean square deviation with respect to the backbone heavy atoms of the protein structure was used 
to measure the deviation from the starting structure, as well as the complex stability over 60 ns MD 
trajectories.  The average values of the protein backbone RMSD for ERT—LdtMt5, IMI—LdtMt5 MERO—
LdtMt5 and free—LdtMt5, were 1.9, 1.6, 2.8 and 2.3 Å, respectively.  Despite the observed variations, 
reasonable convergence in the RMSD plot was obtained particularly after 40 ns (Figure 3.5), which 
indicates possible conformational changes during the MD trajectories.   All four complexes are found to be 
below this threshold suggesting reasonable stability of the complexes during the MD trajectories. 
 
Figure 3.5 Time evolution of the RMSD from the initial structures in the production MD simulations of  
Free—LdtMt5 (blue), ERT—LdtMt5 (black), IMI—LdtMt5 (red)  and MERO—LdtMt5 (green) during 60 ns MD 
simulation time The minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are provided 
as supplementary information.    
To further validate the consistency and reliability of the MD simulations, two more MD runs with different 
starting structures (random seed and starting from different sets of atomic coordinates and velocities) were 
performed (Figure S8).  The comparable complex fluctuation within these three MD runs confirmed the 
reliability of the MD simulations to be taken for further trajectory analyses. 
64 
 
3.3.4  RMSF analysis 
Given the RMSD result, it is also of interest to assess the RMS per residues, i.e., root mean square 
fluctuation (RMSF) of the protein backbone.  This allows for the evaluation and comparison of the amino 
acid residue flexibilities (Figure 3.6).  The nature of these movements is analysed in subsequent sections.  
Knowing that the β-hairpin flap and loop regions display the principal residual fluctuations among Mtb 
L,D-transpeptidases13, the focus of the RMSF analysis is on these segments of the enzyme.  As evident 
from the RMSF plot (Figure 3.6), the residues involved in the β-hairpin flap (312-330) and Lc loop (338-
358) of LdtMt5 for ERT—LdtMt5 and IMI—LdtMt5  showed higher rigidity around these regions compared to 
MERO—LdtMt5.   It can be inferred that the higher residual fluctuations of the MERO—LdtMt5 leads to the 
decrease in inhibitor binding.  In general, there appears to be no correlation between these results and the 
calculated binding free energies (Table 3.1).   
 
Figure 3.6 RMSF plot of the backbone atoms versus the residue numbers for Free—LdtMt5 (blue), ERT—
LdtMt5 (black), IMI—LdtMt5 (red) and MERO—LdtMt5 (green) during 60 ns MD simulation time.  The 
minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary 
information.    
IMI—LdtMt5 is the only complex that is more rigid than the free enzyme, although IMI—LdtMt5 is not the 
best inhibitor based on binding free energies (Table 3.1).  In previous studies on the flap dynamics study 
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of LdtMt2 enzyme complex from Mtb with the substrate and the same carbapenems by Fakhar et al.
25, the 
two complexes with the best binding energies (MERO—LdtMt2 and ERT—LdtMt2) were more rigid than the 
free enzyme. 
3.3.5  Binding free energy analysis 
Previous experimental studies16 indicated the existence of an inhibitor-enzyme precomplex.  Our group has 
demonstrated before20, 22, 23, 76 that the calculated energies of these precomplexes are in general agreement 
with experimental bioactivities16-18, 29, 32.  As mentioned before, attempts to determine the binding free 
energies of these carbapenems reacting with LdtMt5 using ITC, revealed
28 that none of them showed any 
significant heat exchange upon complexation.  Here we report the binding free energy (∆Gbind) for the 
selected inhibitors complexed to LdtMt5, using the MM-GB/SA method and normal mode analysis with 
MMPBSA.py77.  According to the calculated results presented in Table 3.1, ∆𝐺𝑏𝑖𝑛𝑑  for ertapenem, 
imipenem and meropenem in complex with LdtMt5 were -28.29 kcal/mol, -25.52 kcal/mol and -18.34 
kcal/mol respectively.  The results for the ERT—LdtMt5 and IMI—LdtMt5 complexes demonstrate larger 
binding free energies compared to MERO—LdtMt5, which will be further interrogated with per-residue 
decomposition energy (Figure 3.7) and hydrogen bonding analysis (Table 3.2).  
Table 3.1. Calculated binding free energies and its components for the inhibitors—LdtMt5 precomplex using 
MM-GBSA method and normal mode analysis.  The energy components are in kcal/mol.  The minimized 
3D structures (PDB format) for all inhibitors—LdtMt5 complexes are provided as supplementary 
information (Figures S2, S3 and S4). 
Complex ∆𝐸𝑣𝑑𝑤 ∆𝐸𝑒𝑙𝑒 ∆𝐺𝑔𝑎𝑠 ∆𝐺𝑝𝑜𝑙𝑎𝑟 ∆𝐺𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 ∆𝐺𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 -TΔS ∆𝐺𝑏𝑖𝑛𝑑 
ERT—LdtMt5 -28.6 -50.1 -78.6 54.9 -4.6 50.4 28.5 -28.3 
IMI—LdtMt5 -21.6 131.7 110.1 -132.5 -3.1 -135.6 29.1 -25.5 
MERO—LdtMt5 -30.2 -35.7 -65.9 51.2 -3.7 47.6 15.6 -18.3 
SUB—LdtMt5 -32.9 226.2 193.3 -215.3 -5.3 -220.6 23.2 -27.2 
    
ERT—LdtMt5 and MERO—LdtMt5 follows the same trends in terms of the energy components (negative and 
positive values) across the table while the different trends for IMI—LdtMt5 and SUB—LdtMt5 may be 
ascribed to the chemical structure of bulkier cyclo-aliphatic side chains of MERO–LdtMt5 and ERT–LdtMt5 
in contrast to the linear-aliphatic side chains in IMI–LdtMt5 and SUB—LdtMt5, Figure 3.2 
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By decomposing the binding free energy, ERT—LdtMt5 (-50.07 kcal/mol) and MERO—LdtMt5 (-35.72 
kcal/mol) have the largest electrostatic energy changes upon binding in both gas phase (ΔEele) and GB 
solvent (ΔGpolar), while IMI—LdtMt5 (131.68 kcal/mol) has the lowest.  Although IMI—LdtMt5 has the least 
favourable van der Waals energy change upon binding, the electrostatic energy change compensates 
significantly.  A potential explanation for this is the destabilizing effect of GLU284 as shown in the per-
residue energy contribution in Figure 3.7 for IMI—LdtMt5.  The non-polar contribution to the solvation free 
energy for ERT—LdtMt5 (-4.58 kcal/mol) is more negative than that of IMI—LdtMt5 (-3.09 kcal/mol) and 
MERO—LdtMt5 (-3.65 kcal/mol), this correlates with the lipophilic nature (LogP) of these compounds (-
1.72, -2.74 and -2.71 respectively) as expected.  However, non-polar contributions for all inhibitors are 
small.  This contribution is overcome by the polar contribution of solvation free energy for ERT—LdtMt5 
and MERO—LdtMt5.  The enthalpic and entropic contributions are related.  The increase in enthalpy energy 
of ERT—LdtMt5 (-56.75 kcal/mol) and IMI—LdtMt5 (-56.64 kcal/mol) leads to tighter binding, which 
corresponds to the more negative entropy values observed for ERT—LdtMt5 (-28.46 kcal/mol) and IMI—
LdtMt5 (-29.12 kcal/mol).  This high entropy contribution restricts the mobility of the interacting molecules.  
The entropy contribution of MERO—LdtMt5 (15.62 kcal/mol), the lowest, appears to be a result of the 
shorter and more rigid carbapenem side chain.  Also, the binding free energies of the complexes are linked 
to the SASA (Figure S7) which indicates the solvent exposed surface of the protein and hence the folding 
of exposed parts of the protein78.  ERT bound LdtMt5 has a smaller SASA, which could support the highest 
negative binding free energy observed while the IMI and MERO complexes each demonstrated larger 
SASA, with weaker binding free energy.   
The PCA (Figure 3.11) also supports the highest binding free energy observed for ERT—LdtMt5 with least 
correlated motion around the β-hairpin flap and Lc loop regions, followed by IMI— LdtMt5, while the more 
correlated motion was seen for MERO—LdtMt5 and consequently, its lower binding free energy.  
Furthermore, average binding affinities of LdtMt5 complexes (-28.29 and -25 kcal/mol for Ertapenem and 
Imipenem respectively Table 2) were found to be less than that for LdtMt2 complexes [experimental
16, 18, 29 
and computational results20, 22, 76 results (-37.91 and -40.42 kcal/mol for Ertapenem and Imipenem 
respectively)], as expected.   
3.3.6  Per-residue decomposition energy analysis 
The key features regarding the residue-based contributions to the binding free energies for the complexes 
were examined.  These results provide a better description of the separate contributions to the total binding 
free energy.  In particular, the per-residue energy decomposition was performed for the inhibitor—LdtMt5 
complexes including the active pocket residues.  The β-hairpin flap and LC loop residues in each complex 
fall in this range.  A total of 1000 snapshots was extracted from the last 10 ns of MD trajectories (at 10 ps 
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intervals) for all three complexes and were decomposed using per residue decomposition energy analysis 
implemented in the MMPBSA.py77 script.   According to Figure 3.7, the largest contributions were those 
of the residues ARG297 and GLU339; ARG297, ARG301 and ASN337; ARG297, PHE340, ASN358 and 
CYS360 for ERT—LdtMt5, IMI—LdtMt5 and MERO—LdtMt5, respectively.  The X-ray structure of 
meropenem complexed to LdtMt5 illustrates the importance of these aforementioned key residues.  CYS360, 
HIS342, ASN358 and THR357 are active site residues, according to previous13 experimental findings.  
ARG297, ASN298, ARG301, MET316, ASN318 and GLU328 are residues involved in the β-hairpin flap 
region, while ASN337, GLY338, GLU339 and PHE340 form significant interactions with the 
meropenem13.  These interactions for the selected carbapenem complexes were also observed in the per-
residue decomposition energy and hydrogen bond analyses (Table 3.2, Figures 3.7, S4, S5 and S6). 
 
Figure 3.7 The plot of per-residue decomposition analysis for ERT—LdtMt5, IMI—LdtMt5 and MERO—
LdtMt5 complex from 1000 snapshots extracted from the last 10 ns MD trajectories. The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information.   
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The role of some other important residues was explained13 from the crystal structure of the meropenem-
complex.  The two residues at the ends of loop LC which interact with the PG stem in the outer cavity of 
LdtMt2
16, HIS352 and TRP340, are said to be substituted with ASN358 and MET346, respectively, in LdtMt5.  
ASN358 replaces this conserved motif histidine, HIS352 in LdtMt2, that participates in recognition of the 
donor PG stem16, and, in LdtMt5, participates in recognition of the meropenem adduct.  The meropenem 
core13 lies with its most apolar side facing a hydrophobic patch formed by GLY338, the aliphatic portion 
of the side chain of GLU339, and PHE340 at the inner cavity.  The C-terminal portion of the main chain of 
loop LC GLY359 provides apolar contacts with the other side of the carbapenem core.  Some hydrophilic 
interactions were also observed between the carbapenem core and LdtMt5 which include ASN358, the main 
chain nitrogen atom of CYS360 hydrogen bond to the carbonyl of the opened penem ring.  The GLU328 
forms hydrogen bonds to the meropenem hydroxyethyl group and mediates the interaction between the 
meropenem core carboxylate and the carboxylate of GLU33913.  Our theoretical result (Figure 3.13) aligns 
with the experimental observations13 for meropenem in the complex with LdtMt5.  Also, it is interesting to 
observe that more interactions were seen for ERT—LdtMt5 and IMI—LdtMt5 for ARG297, ARG301, 
ASN337 and GLU339, in comparison to MERO—LdtMt5. A similar trend was also observed for SUB—
LdtMt5 as represented in Figure S6. 
3.3.7  Tip-tip distance analysis of the enzymes’ hairpin/loop  
Tip-tip distance analysis allows for a better understanding of the nature of flexibility in the studied 
complexes. Due to major structural differences displayed by the β-hairpin and loop LC among M. 
tuberculosis L,D-transpeptidases28, and the observed structural changes upon meropenem adduct formation 
suggest that their mobility and flexibility could play a role in the catalytic mechanism28.  The flap/loop 
dynamics during the entire 60 ns MD simulation using the tip-tip center of mass distance analysis between 
three center of mass tip points  on the β-hairpin flap residues (PRO319, ALA320, ALA321) and three facing 
points at the loop LC residues (GLY349, ALA350, GLN351) of the enzyme in the four selected complexes 
and free LdtMt5 (Figure S2) were studied and analyzed.   
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Figure 3.8 The three center of mass tip-tip distances of the β-hairpin flap and three facing points at the loop 
LC of ERT—LdtMt5. PRO319-GLY349 D1: 13.32 Å PRO319-ALA350 D2: 13.34 Å PRO319-GLN351 D3: 
12.18 Å ALA320-GLY349 D4: 12.77 Å ALA320-ALA350 D5: 13.24 Å ALA320-GLN351 D6: 11.30 Å 
ALA321-GLY349 D7: 9.37 Å ALA321-ALA350 D8: 10.29 Å ALA321-GLN351 D9: 9.20 Å. The 
minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary 
information.   
Distance analysis enabled us to identify which of the residues best describe the β-hairpin and loop LC 
dynamics.  The same approach25 was used earlier to study β-hairpin flap dynamics of LdtMt2 from Mtb.  The 
present study (Figure 3.9) revealed that in the case of  ERT—LdtMt5, the lowest average tip-tip center of 
mass distances correspond to ALA321—GLN351 D9: (9.20 Å) with the maximum and minimum values, 
14.89 Å and 3.5 Å and ALA320-GLN351 D6: (11.30 Å) with the maximum and minimum values, 18.53 Å 
and 4.1 Å, respectively (Figure 3.9 and Table S2).  Comparing these tip-tip center of mass distances with 
the open and closed conformations for the different complexes, suggested that these distances [ALA321—
GLN351 and ALA320—GLN351] are the most effective tip reference to measure the flap opening (in the 
range of 10-12 Å) and closure (around 5-7 Å) 
25 complex conformations (Table S2 and S3).   Over 60 ns 
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MD simulation, both the β-hairpin flap and the Lc loop regions reveal flap continuous opening and closing.  
This suggests the simulation time (60 ns) is long enough.  This was also experimentally observed 
experimentally and is reported to play a significant role in the catalytic mechanism28.     
 
Figure 3.9 The plot of the center of mass tip-tip distances between ALA321—GLN351 residues for the 
ERT—LdtMt5, IMI—LdtMt5 and  MERO—LdtMt5 over the 60 ns MD simulations.  The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information.      
It can be seen in Figure 3.10 that the average center of mass tip distances between the residues ALA321—
GLN351 in ERT—LdtMt5 is 9.2 Å, IMI—LdtMt5, 14.79 Å  and MERO—LdtMt5, 15.06 Å.  This result is in 
reasonable correlation with the calculated binding free energies; as ertapenem with the best binding affinity 
adopts the most compact flap conformation, while the weakest inhibitor (meropenem) exhibits the least 
compact conformation.     
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Figure 3.10 Histogram distribution of center of mass tip-tip distance [ALA321-GLN351] distances for 
ERT—LdtMt5, IMI—LdtMt5 and MERO—LdtMt5 over the 60 ns MD trajectories.  The minimized 3D 
structures (PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information.      
Comparison of the average distances for the free LdtMt5 with the complexes revealed the highest values for 
all considered tip–tip distances for the free enzyme (Table S3).  The average distances measured indicates 
that the ligand binding induces significant flap dynamics towards the formation of closed flap conformation 
which is insignificant for the free enzyme.  This similar phenomenon was also observed in our earlier 
study25 on SUB–LdtMt2 and free LdtMt2 from Mycobacterium tuberculosis.  
 
3.3.8  Principal component analysis (PCA) 
PCA is a useful approach in the detection of important motion in biomolecules ranging from proteins to 
nucleic acids and discovering molecular motions that are biochemically relevant79.  The concerted 
conformational motions in ERT—LdtMt5, IMI—LdtMt5 and MERO—LdtMt5 complexes were studied 
79 using 
PC analysis based on eigenvectors and eigenvalues of the covariance matrix. PCA as shown in Figure 3.11, 
revealed that the presence of carbapenems inside the enzyme (LdtMt5) induce a significant impact on the 
motions of the β-hairpin flap and Lc loop regions (Figure 3.1) for the complexes.  The ERT—LdtMt5 
complex showed less correlated motion around the flap and Lc loop regions, which can be attributed to its 
higher binding free energy compared to other complexes.   This reduced and correlated motion as compared 
to IMI—LdtMt5 and MERO—LdtMt5 in these regions appears to suggest a more rigid conformation.   
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Figure 3.11 The first principal components (PC1) collective motions for the obtained predominant 
eigenvectors using principal component analysis over the 60 ns MD trajectories for ERT— LdtMt5, IMI—
LdtMt5 and MERO—LdtMt5.  The minimized 3D structures (PDB format) for all inhibitor- LdtMt5 complexes 
are provided as supplementary information. 
3.3.9  Hydrogen bonding Analysis  
Hydrogen bonding interactions are particularly important for proteins, as they provide the organization for 
distinct folding and the selectivity in the protein-ligand interfacing that supports molecular recognition80.  
The hydrogen bonding interactions between the carbapenems and the active residues of LdtMt5, their 
percentage occupancy throughout the MD simulations were investigated and the results listed in Table 3.2.  
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Table 3.2. The hydrogen bonds between carbapenems and active site residues for ERT—LdtMt5, IMI—
LdtMt5 and MERO—LdtMt5 complexes over the simulation time. 
Complex Acceptor Donor Occupancy (%) Distance (Å)a Angle (o)a 
ERT—LdtMt5 LIG362-O3 ASN358-HD21-ND2 12.8 2.8 156.0 
 LIG362-O ASN358-H-N 4.2 2.9 154.5 
 LIG362-O2 ASN358-HD21-ND2 3.3 2.9 151.6 
 LIG362-O3 ASN358-HD22-ND2 1.9 2.9 156.2 
 LIG362-O ASN358-HD21-ND2 0.8 2.9 156.0 
      
IMI—LdtMt5 LIG362-O4 ASN358-HD21-ND2 1.1 3.0 162.0 
 ASN358-OD1 LIG362-H2-O2 0.9 2.9 153.7 
 LIG362-O2 ASN358-HD21-ND2 0.6 2.9 149.4 
 LIG362-O2 ASN358-HD22-ND2 0.6 2.9 153.6 
 ASN358-O LIG362-H2-O2 0.5 2.9 156.3 
 ASN358-ND2 LIG362-H2-O2 0.1 2.9 154.3 
      
MERO—LdtMt5 LIG362-O2 ASN358-HD22-ND2 0.5 2.9 147.5 
 LIG362-O3 ASN358-HD21-ND2 0.1 2.9 160.4 
 ASN358-OD1 LIG362-H3-O3 0.1 2.9 154.4 
    aThe hydrogen bonds were determined by the acceptor…donor atom distance of < 3.0 Å and acceptor…  
H-donor angle of >140 A˚. LIG362 = ERT, IMI and MERO for each complex.  The minimized 3D structures 
(PDB format) for all inhibitor- LdtMt5 complexes are provided as supplementary information.    
 
Generally, we observed prevalent hydrogen bond interactions between ASN358 with the ERT—LdtMt5, 
IMI—LdtMt5 and MERO—LdtMt5 complexes.  This contact was also observed between the carbapenem core 
and LdtMt5 from experimental findings
13.  The greater occupancy seen in ERT—LdtMt5 (Table 3.2) is in 
reasonable correlation with its higher binding free energy compared the other two complexes.  
3.3.10  Thermochemical analysis  
The relative free energies of activation for the reaction mechanism of LdtMt5 in the presence of imipenem 
and meropenem are presented in Table 3.3 for the systems.  The reaction energy profile for the obtained 
activation energies using M06/6-311++G(2d,2p) from Table 3.3 are presented in Figure 3.12 and the 
results will be explained based on this functional.  M06 functional gave the lowest ∆G values for enzymatic 
reactions.81  ∆G for the 6-membered ring transition state of imipenem and meropenem is 52.23 kcal/mol 
and 98.96 kcal/mol respectively.  This shows that imipenem is more reactive against LdtMt5 than 
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meropenem.  These results follow the same order as the molecular dynamics calculated binding free 
energies for the imipenem (-25.52 kcal/mol) and meropenem (-18.34 kcal/mol) precomplexes in this study.  
The calculated ∆G values for imipenem (-7.43 kcal/mol) and meropenem (-8.65 kcal/mol) with LdtMt2 
obtained by Silva et al.20 also followed the same order.  This confirms the experimentally observed result 
that imipenem reacts faster with LtdMt2 than meropenem.
24 
The ∆G value for the products (covalently bonded inhibitor complex) of imipenem (4.09 kcal/mol) and 
meropenem (22.33 kcal/mol) in our study followed the same trend that was experimentally observed for 
LdtMt2 against imipenem and meropenem by Erdemli et al.
33   
Our results (Table 3.3) also reveal that the 6-membered ring transition state mechanism obtained in this 
study has considerable higher activation energy than that of the 6-membered ring TS of LdtMt2 obtained 
previously24, 60 in our group.    
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Table 3.3. The thermochemical parameters of 6-membered ring reaction pathways of LdtMt5 obtained in ONIOM (B3LYP/6-31+g(d,p):Amber) using 
different density functionals.  The ∆E, ∆G, ∆H (kcal/mol) and ΔS (cal/mol/K). 
Inhibitors   B3LYPa M06a ωB97Xa 
    ∆E ∆G ∆H ΔS ∆E ∆G ∆H ΔS ∆E ∆G ∆H ΔS 
  R 0 0 0 0 0 0 0 0 0 0 0 0 
Meropenem TS 93.77 91.08 91.55 -0.47 101.65 98.96 99.43 -0.47 124.04 121.35 121.82 -0.47 
 
Pr 17.81 12.14 10.5 1.64 28 22.33 20.67 1.66 31.96 26.29 24.65 1.64 
 
R 0 0 0 0 0 0 0 0 0 0 0 0 
Imipenem TS 80.07 53.29 47.02 6.27 79.01 52.23 45.96 6.27 85.67 58.89 52.62 6.27 
  Pr 30.14 6.16 2.27 3.89 28.07 4.09 0.2 3.89 30.76 6.78 2.89 3.89 
 
R 0 0 0 0 0 0 0 0 0 0 0 0 
Natural 
substrate 
TS 67.04 66.22 64.82 1.39 71.23 70.4 69.01 1.09 76.02 75.19 73.8 1.39 
 
Pr 14.59 13.42 12.33 1.09 17.65 16.48 15.39 1.39 20.24 19.07 17.98 1.09 
aEnergies relative to reactant for total electronic energy (ΔE) and activation free energy (ΔG, with thermal correction) using B3LYP, M06, ωB97X/6-
311++G(d,p):AMBER//B3LYP/6-31G(d,p):AMBER. R = reactant, TS = transition state and P = product. The minimized 3D structures (PDB format) 
for all inhibitor- LdtMt5 complexes are provided as supplementary information.     
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For the activation energies, the entropy contribution of imipenem suggests that it experiences less 
restriction in the active site, in comparison to the other two cases.  Meropenem experiences the largest 
entropy penalty.  This observation is due to the differences in the respective side chains.  Imipenem has 
an aliphatic side which is much less sterically hindered, while the bulky side chain of meropenem is 
much more restricted in the active site.20  Also, imipenem has been reported as showing a lower entropy 
penalty (ΔS) compared to meropenem with LdtMt2, which is in agreement with Erdemli et al.
33.   
 
Figure 3.12 Gibbs free energy pathway of 6-membered ring mechanism of inhibition of L,D-
transpeptidase (LdMt5) by meropenem obtained using the ONIOM [M06/6-311++G(2d,2p):Amber] 
method. 
The free energy of activation observed for the natural substrate with LdtMt5 is 70.4 kcal/mol, which is 
approximately 40.0 kcal/mol higher than the corresponding activation energy for LdtMt2
82.  This is an 
indication that this specific natural substrate is perhaps not the correct one for LdtMt5.  While LdtMt2 uses 
the native tetrapeptide substrate L-Ala1-D-iso-Glu2-mesoDAP3-D-ala4,34 the exact substrate for LdtMt5 
is not known.  β-lactam antibiotics are known to structural and chemical mimics of peptidoglycan 
substrates and therefore bind to the enzymes as suicide substrates83, 84.  The fact the LdtMt2 binds strongly 
to carbapenems is indicative of this class of antibiotics closely mimicking the natural substrate of this 
enzyme.  The weaker binding of LdtMt5 to carbapenems suggests that the native substrate of this enzyme 
is likely to be different from that of LdtMt2.  While L-Ala1-D-iso-Glu2-mesoDAP3-D-ala4 is the most 
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abundant substrate in the peptidoglycan of Mtb14, bacteria are known to incorporate a range of 
modification including non-canonical D-amino acids in their peptidoglycan85.  It is possible that LdtMt5 
is involved in incorporating such amino acids or modifying the peptidoglycan with as yet unknown 
chemical decorations.  Additional studies will be necessary to unveil the native substrates and activity 
of LdtMt5.  
3.4 Conclusion     
Due to the relatively weak in vitro inhibition of LdtMt5 by carbapenems in comparison to its LdtMt2 
paralog, a theoretical comparative study into the key interactions between active residues of these 
enzymes with carbapenems is if great importance.  Herein, the essential factors that contribute to the 
binding and inhibition efficiency of the LdtMt5 in the presence of the three carbapenems, ertapenem, 
imipenem and meropenem were investigated.  Molecular docking was applied for the starting structures 
of the carbapenems in the active pocket of LdtMt5 based on the reported single crystal X-ray structure 
of MERO—LdtMt5.  Afterwards, the complexes were simulated using the molecular dynamics approach 
implemented in Amber.  The dynamics of the β-hairpin flap and Lc loop presence in LdtMt5 and their 
effect on the binding free energies were monitored through tip-tip distance analysis.  The binding free 
energies (including entropy contributions) of these complexes were calculated from the MD simulation 
using MM/GBSA approach, the theoretical results revealed the best ∆Gbind for ERT—LdtMt5 followed 
by IMI—LdtMt5 then MERO—LdtMt5.  Furthermore, per residue free energy decomposition and the 
hydrogen bonding interactions between the inhibitors and this protein were analysed to identify the 
essential residual interactions in the carbapenem complexes.  The theoretical results revealed 
interactions between the carbapenems and the following residues are important which were also 
observed experimentally: ARG297, MET316, GLU328, GLY338, GLU339, CYS360, HIS342, 
ASN358 and THR357. 
It is important to note that a similar previous study with LdtMt2 with the same inhibitors
25 also did not 
reveal much correlation between the calculated binding free energies and the quantities calculated 
(RMSF and Rg).  This may also be expected for the current study as efforts to determine the 
experimental binding free energies28 with these drugs failed due to weak inhibition of LdtMt5.  The 
average tip-tip distances of the β-hairpin flap and the Lc loop were analysed.  The average tip-tip 
distances revealed that the distances between ALA321 and GLN351 as well as ALA320 and GLN351 
are the most sensitive parameter that appears to correlate with the calculated binding free energies (best 
binding energy display the most rigid complex structure).  Finally, the carbapenem—LdtMt5 complexes 
showed similar residual fluctuations from the RMSF analyses to what was reported for LdtMt2, despite 
the fact that carbapenem complexes withLdtMt2
16, 25 undergo fast acylation (determined with ITC 
analysis).  However, the fluctuations for LdtMt5 were found to be much larger for LdtMt5 complexes, 
especially at the binding site, indicating weaker binding of carbapenems.  Furthermore, average binding 
affinities of LdtMt5 complexes were found to be less than that for LdtMt2 complexes, as expected.  In 
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addition to this, the distance analyses suggested that the opening of the flaps in LdtMt5 complexed with 
the inhibitor is more pronounced in comparison to that observed for LdtMt2 complexed form.  Overall, 
the stability of the carbapenem-LdtMt5 complexes may be perturbed by higher fluctuations of the β-
hairpin flap and loop LC.  Moreover, the interactions of carbapenems with major binding site residues 
such as HIS342 and CYS360 were found to be weak for LdtMt5 complexes.  The relative higher free 
energies of activation obtained from the mechanistic studies also support the weak binding of LdtMt5 
against the selected carbapenems.  In, addition, this study showed that the existing inhibitors have high 
activation energies suggesting their poor mode of reaction, and thus a need to find new β-lactam 
compounds against this target. Derivatives of the existing inhibitors will first be subjected 
computational studies and then validated with experimental bioassays. The higher free energy of 
activation observed with L-Ala1-D-iso-Glu2-mesoDAP3-D-ala4 against LdtMt5 could suggest that the 
native substrate of this enzyme is likely to be different from that of LdtMt2.  This study, therefore, 
confirms that the computational inhibitor-enzyme precomplex model20, 23, 76 for transpeptidases 
correctly reflects experimental observations.  
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Abstract 
Virtual screening is a useful in silico approach to identify potential leads against various targets.  It is 
known that carbapenems (doripenem and faropenem) do not show any reasonable inhibitory activities 
against L,D-transpeptidase 5 (LdtMt5) and also an adduct of meropenem exhibited slow acylation.  Since 
these drugs are active against L,D-transpeptidase 2 (LdtMt2), understanding the differences between 
these two enzymes are essential.  In this study, a ligand-based virtual screening of 12766 compounds 
followed by molecular dynamics (MD) simulations was applied to identify potential leads against 
LdtMt5.  To further validate the obtained virtual screening ranking for LdtMt5, we screened the same 
libraries of compounds against LdtMt2 which had more experimentally reported and calculated binding 
energies.  The observed consistency between the binding affinities of LdtMt2 validates the obtained 
virtual screening binding scores for LdtMt5.  We subjected 37 compounds with docking scores ranging 
from -7.2 to -9.9 kcal mol-1 obtained from virtual screening for further MD analysis.  A final set of 
compounds (n=10) from four antibiotic classes with ≤ -30 kcal mol-1 Molecular Mechanics/Generalized 
Born Surface Area (MM-GBSA) binding free energies (ΔGbind) were characterised.  The outcome of 
this study provides insight into the design of potential novel leads for LdtMt5.  
Keywords: Virtual Screening; Molecular dynamics (MD); Mycobacterium tuberculosis (Mtb); L,D-
transpeptidase 5 (LdtMt5); Molecular Mechanics/Generalized Born Surface Area (MM-GBSA). 
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4.1 Introduction  
The alarming rise of multi and extensively drug-resistant tuberculosis (TB) has become a serious global 
health threat 1.  The emergence of resistant strains is partly due to poor patient compliance with the 
extensive treatment regimen 2, 3.  Thus, the identification of new anti-TB leads, particularly LdtMt5, that 
can shorten the treatment regimen and target the resistant TB strains are urgently needed.  
Mycobacterium tuberculosis possesses a peptidoglycan (PG) layer that encapsulates the cytoplasmic 
membrane and is essential for cellular growth and viability 4.  The peptidoglycan structure of Mtb from 
a stationary-phase culture revealed a high content (80%) of nonclassical 3→3 cross-links generated by 
L,D-transpeptidation 5, whereas the classical 4→3 cross-links are predominantly formed by the D,D-
transpeptidation activity of penicillin-binding proteins (PBPs) during the exponential phase of growth 
6-9.  L,D-transpeptidases (Ldt) and PBPs are structurally similar 10 and contain the catalytic active-site 
cysteine and serine residues, respectively 11.  Five Ldt paralogues have been identified for Mtb, LdtMt1 
to LdtMt5.  The reported experimental and theoretical studies revealed that both LdtMt1 and LdtMt2 can be 
inactivated by carbapenems, a class of β-lactam antibiotics 5, 6, 8, 12.  The enzymes, LdtMt1 and LdtMt2 also 
have distinct functions in vivo 5, 9 and it has been shown that LdtMt1 may have a role in adaptation to the 
non-replicative state of the bacilli 5,  while LdtMt2 is essential for virulence in a mouse model of acute 
infection 9.  For Mtb, LdtMt5 is required for properly maintaining cell wall integrity 
4 and a more recent 
study also revealed that four L,D paralogues, with the exception of LdtMt3, are active in vitro 
peptidoglycan cross-linking assays, and that all but LdtMt5 are inhibited by carbapenems 
7. 
The single crystal X-ray structure of the extra-cellular portion of LdtMt5 was recently published 
4.  
Modest enhancement in susceptibility of Mtb to certain carbapenems (doripenem and faropenem) was 
observed presumably due to synthetic lethality, as these β-lactams may inactivate other targets.  
Meanwhile, a meropenem-adduct crystal structure was formed which supports very slow acylation of 
LdtMt5 over many days.  The structures of apo-LdtMt5 and its meropenem-LdtMt5 (Figure 4.1) 
demonstrate that, despite the overall structural similarity to LdtMt2, the LdtMt5 active site residues are 
different 4.  
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Figure 4.1 The rendering of MERO-LdtMt5 crystal X-ray structure.  Shown is a β-hairpin flap (312-330) 
and Lc loop (338-358) and active site pocket in CPK form [HIS287 (342), THR302 (357), ASN303 
(358) and CYS305 (360)] and meropenem (inhibitor) in stick form 13 
The presence of a structurally divergent catalytic site and a proline-rich C-terminal subdomain suggest 
that this protein may have a distinct role in PG metabolism, perhaps involving other cell wall anchored 
proteins.  Also, Mtb lacking a functional copy of LdtMt5 displays aberrant growth and is more susceptible 
to killing by osmotic shock, select carbapenem antibiotics and crystal violet 4.  The β-lactam and 
oxazolidinone compounds will most likely be able to form covalent bonds with the catalytic cysteine 
of LdtMt5 probably due to the carbonyl and amide functional group in the structural backbone.  Hence, 
in case any promising inhibitors from the other classes are identified, they will most likely act as 
competitive 14 inhibitors.   
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Figure 4.2 2D scaffold structures of (1) β-lactam (2) Diarylquinoline (3) Oxazolidinone (4) Rifamycin 
(5) Quinolone classes of TB antibiotics 
Carbapenems gave insignificant binding of LdtMt5 experimentally using isothermal titration calorimetry 
(ITC).  Carbapenems are considered the last resort antibiotics to treat resistant bacterial infections in 
humans 15-22.  This fact motivated us to perform a virtual screening of five classes of known TB 
antibiotics (Figure 4.2).  Virtual screening with both AutoDock Vina and Schrödinger Maestro software 
programs was performed as a benchmark for the automated docking.  Molecular dynamics and binding 
free energy studies were performed on each of the screened compounds from the five classes of anti-
TB agents.  To the best of our knowledge, a computational model to identify and rank the different anti-
TB agents against LdtMt5 has not yet been reported.   
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4.2 Materials and methods 
The following in silico approaches were used to screen five classes of known TB antibiotics (Figure 
4.2) against LdtMt5.  The automated docking process was performed using Autodock Vina 
23 and 
Schrödinger Maestro24 programs which implement the quasi-flexible docking method to perform the 
screening 25.  The docked energies followed by visual inspection of the inhibitor pose was performed to 
ensure the close proximity of the selected compounds with the catalytic cysteine.  This was followed 
by molecular dynamics simulations/MD trajectory analyses using CPPTRAJ module 26 implemented in 
Amber 14 27 package on GPU accelerated PMEMD engine. 
4.2.1 System preparation 
The 3D crystal structure of the meropenem-bound LdtMt5 (PDB code: 4ZFQ
13) was retrieved from the 
Protein Data Bank 28.  The missing residues (the β-hairpin flap is missing having the loop LC and the 
ex-CTSD being disordered)13 of the LdtMt5 enzyme were refined using MODELLER v9.15
29.  
Assignment of the protonation states of the enzyme residues at pH=7 was performed by recalculating 
the standard pKa values of the titratable amino acids using the empirical propKa server 30, similar to a 
study on LdtMt2 
31.  These protonation states of the titratable residues were used for the virtual screening 
and for the subsequent modelling. 
The chemical compounds used for the screening were retrieved from the ZINC32 database.  This 
database is available for free download (http://zinc.docking.org) in different formats usable for 
computational studies32.  Compounds from five classes of known TB antibiotics were subjected for the 
initial screening-based on their mode of action.  Each scaffold of the five classes was drawn using the 
2D Sketcher tool implemented in ZINC GUI.  A structural similarity index of 99% was set for all 
compounds except for rifamycin in which ligand mining could only be performed at a similarity index 
of 50%.  All the screened compounds obeyed  Lipinski’s rule33 of drug-likeness to filter the compound 
molecules and Veber’s criteria for oral bioavailability of drug candidates34.  The considered Lipinski’s 
parameters 33 are as follows: molecular weight; xlogP; net charge; rotatable bonds; polar surface area; 
hydrogen donors; hydrogen acceptors; polar and apolar solvation (Table 4.1). 
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Table 4.1 Physiochemical properties set for all screened compounds. 
 
4.2.2 Virtual screening using AutoDock Vina  
AutoDock Vina is a program for molecular docking and virtual screening.  The prepared 3D structure 
of LdtMt5 
13 in PDB format was converted to pdbqt format using raccoon 23, likewise, the library of 
compounds downloaded from ZINC database in the mol2 format was converted to pdbqt format.  
Virtual Screening using automated docking involves the preparation of the receptor (this includes 
assigning of Kollman charges 35 and Gasteiger partial charges 36 to all atoms and assignment of AD4 
types to atoms of the protein structure), ligands and a config file in which grid center, a grid box size, 
and a docking run number are assigned.  AutoDock tools1.5.6 37 was employed to determine the proper 
size of the grid box for the potential binding site for the lead compounds and the receptor grid center 
was set on Cys305 (360) (active site reactive residue) 13.  The grid box was determined as a a centre 
(X=3.9 Y=-39.5 Z=12.1) and dimension (X=45 Y=45 Z=45) with the grid spacing of 0.375 Å were 
considered for each of the following atom types: A C H HD N OA and SA representing all probable 
atom types in the target enzyme.  Created finally, was a conf.txt file which includes receptor in pdbqt 
format, a grid center with x, y, z coordinates, a grid box size in Ǻ, and a docking run number of 10.  The 
virtual screening was carried out using the python script, VS.bash executable on AutoDock Vina 
software on CPU Ubuntu on Dell computer.  Docked results were ranked based on the binding affinities 
and visual inspection to ensure an acceptable drug/enzyme interaction is present.  Visual inspection of 
the selected ligands inside the enzyme was performed using the Discovery Studio 38 software program. 
4.2.3 Virtual screening using Schrödinger Maestro 
Schrödinger Maestro software program was applied for the docking studies.  Protein/ligand preparation 
and virtual screening were all performed in the Maestro 11.2 graphical user interface 24.  The Protein 
Preparation Wizard 39 of the Schrödinger Maestro software program was used to prepare the 3D protein 
Parameter Minimum Maximum 
Molecular weight (g/mol) 32 500 
xlogP -4.00 5 
Net charge -5 5 
Rotatable bonds 0 10 
Polar surface area (Å2) 0 140 
Hydrogen donors 0 5 
Hydrogen acceptors 0 10 
Polar solvation (kcal mol-1) -400 1 
Apolar solvation (kcal mol-1) -100 40 
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structure.  The pre-processing of the protein was performed which includes assigning of bond orders; 
adding of hydrogens; creating zero-order bonds to metals; creating disulphide bonds; deleting 
crystallographic waters beyond 5.00 Å from hetero groups and generating hetero states using Epik40 pH 
7.0+/-2.0.  In the 3D protein structure refinement, the alignment of H-bonds was done using PROPKA 
pH: 7.0 and waters with less than three hydrogen bonds to non-waters were removed.  Restrained 
minimization was performed to converge heavy atoms to RMSD of 0.30Å. 
The 2D compound sketches were imported onto the Schrödinger Maestro project table and they were 
converted into a 3D model using the pre-set option.  The LigPrep module 24 was used to refine the 
structures using default parameters.  Ionization was performed to generate possible states at target 
pH:7.0+/-2.0 using Epik 40 and tautomers were generated.  The compounds were subjected to OPLS3 41 
(optimized potentials for liquid simulations) force field for energy optimisation.  For ligand preparation, 
the system was set to retain specified chiralities to 10 per ligand and the output format was Maestro 
from Schrödinger software program.  The grid box was positioned at the centre and the receptor grid 
centre was set on Cys305 (360) (active site reactive residue) 13 with grid spacing minimum distance of 
1 Å and a maximum distance of 3.5 Å.  The XYZ coordinates were -31.88; 23.5 and -46.48 respectively.  
Default settings of Maestro 11.2 were used for other parameters such as constraints, rotatable groups, 
and sites. 
Using a predetermined receptor grid, quasi-flexible docking 14, 25, 42 was performed via the Glide 43 mode 
of Schrödinger Maestro (Schrödinger, Inc).  The system was set to resume post-docking minimization, 
setting the number of poses per ligand to 5.  For filtering, default settings were employed and this 
includes applying the Epik state penalty parameters 24 for docking and the scaling of ligand van der 
Waals radii for nonpolar atoms using the scaling factor 0.80 44, 45 and partial charge cut-off 0.15 44, 45.  
Ligand docking was done using the three incremental stages of ranking accuracy i.e. high throughput 
virtual screening (HTVS), Glide simple precision (SP) and Glide extra precision (XP) 24.   
The difference with these programs lies in the docking algorithm in which Schrödinger Maestro uses 
the Glide module which employs the Monte Carlo algorithm 46 that makes random moves and accepts 
or rejects each conformation based on Boltzmann probability while AutoDock Vina utilizes the 
AutoDock module.  This program applies the genetic algorithm 47, which maintains a selective pressure 
towards an optimal solution, with randomized information exchange permitting exploration of the 
search space 25.  However, both software modules (Glide and AutoDock) identify multiple top-ranked 
docked poses per ligand.  They both use hierarchical algorithms that are an exhaustive systematic search 
for the best ligand conformations within the protein active site, therefore visual inspection for one best 
conformation per ligand, based on known interactions was performed to identify a single best 
conformation per ligand for MD simulations. 
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4.2.4 Molecular dynamics simulation 
MD simulations were performed to investigate the stability and dynamics of the 37 complexes using 
the AMBER 14 package on GPUs with 24 shared processors using CHPC cluster.  The ff99SB 48 
force field was used to describe the protein whereas the general AMBER force field (GAFF) 49 was 
used for the ligand.  System solvation for the complexes was performed in a 10 Å cubic box using the 
TIP3P water model.  To neutralize the system negative value, sodium ions were added accordingly.  
The protein-ligand complexes were parametrized by the Leap 49 module of the Amber14 package.  All 
simulations were performed using a 2fs timestep (based on a study with similar protein size) and the 
rest of the process was also based on the same study 31.  The partial Mesh Ewald (PME) 50 summation 
method was used to calculate the electrostatic forces with space cut-off of 12 Å.  Using the SHAKE 
algorithm 51, all bonds were constrained to hydrogen (H) atoms.  A two-stage energy minimization 
process, which is characterised by 2500 steps of steepest decent minimization and 2500 steps of the 
conjugated gradient was carried out to get rid of steric clashes.  The solute molecule was first restrained 
at 500 kcal mol-1 whereas the water molecules and the ions were relaxed.  The harmonic restraint was 
removed on the second stage thus the whole system was relaxed.  Heating of the system to a constant 
temperature of 300 K followed with a restraint of 10 kcal mol-1 A-2 for 200 ps, to keep the solute fixed.  
Density equilibration for 50 ps was performed and MD simulations ran at a constant temperature and 
pressure (1atm).  The LdtMt5-ligand (37 complexes) were simulated for 20 ns 
52.  The post-dynamics 
trajectory analysis including the radius of gyration (Rg) and root mean square deviation (RMSD) was 
evaluated on the top 5 β-lactams with ≥ 30 kcal/mol.  In addition to that, triplicate MD simulations were 
also performed with varying initial atomic coordinates to validate the simulations.  
4.2.5 Binding free energy calculation 
MM-GBSA is a widely accepted method to compare the binding affinities and to gain rational insights 
about inhibitors by analysing the binding mechanism [53].  The average binding free energies (ΔGbind) 
of the protein-ligand complexes was calculated for the last 10 ns using MM-GBSA method [54].  
Counter ions and water molecules were removed.  Entropy penalty (-TΔS) for the complexes was 
obtained using normal mode analysis (nmode).  The PTRAJ and CPPTRAJ modules [26] were used to 
analyse the MD trajectories.  
4.3 Results and discussions  
4.3.1 Data set preparation  
A total of 12766 antibacterial lead compounds in five categories listed in Table 4.2 were obtained from 
the ZINC database were screened.  
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Table 4.2 The selected five categories of antibacterial compounds from the ZINC database 
Class Mode of action Number of screened 
compounds  
β-lactam Cell wall biosynthesis (inhibition of 
transpeptidase and inhibition of β-lactamase by 
clavulanic acid) 
2707 
Diarylquinoline ATP synthesis inhibition (subunit c of ATP 
synthase) 
4309 
Oxazolidinone Protein synthesis inhibition 3065 
Rifamycin RNA synthesis inhibition (inhibition of RNA 
polymerase). 
2678 
Quinolone DNA synthesis inhibition (inhibition of gyrase). 
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4.3.2 Ligand-based virtual screening and docking   
Structural parameters were set to filter the compounds for screening based on Lipinski’s rule-of-five 
(Table 1).  Virtual screening of ligands was performed on a  set of 98 docked poses and then considered 
for further visual inspection of the interaction 14 to determine the optimal ligand conformation per 
compound in the active pocket of LdtMt5.  A total of 46 top-ranked poses was obtained using AutoDock 
Vina, (Table 4.3) and 52 from Schrödinger Maestro (Table 4.4). From there a total of 37 compounds, 
(13 from AutoDock Vina, Table 4.3 and 24 from Schrödinger Maestro Table 4.4), were selected for 
MD simulations and binding free energy calculations. Further MD analysis was carried out on the best 
5 β-lactams with the binding free energy of   ≥ 30.0 kcal/mol.   Figure 4.3 shows the virtual screening 
workflow down to the final 5 β-lactams compounds. 
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Figure 4.3 Virtual screening workflow to the ten final lead compounds and then more elucidation on 
five best β-lactams. 
The docking (consensus) scores for AutoDock Vina of the 10 top-ranked compounds across all classes 
lie between -7.4 and -9.0 kcal mol-1 (Table 4.3).  The Schrödinger Maestro top-ranked docking scores 
were also considered, and the values are between -7.2 and -9.9 kcal mol-1 (Table 4.4).  The docking 
scores of both software programs seem to be within the same range and both software programs 
optimize the ligand conformation during docking.   
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Table 4.3 The top 10 ligands per class based on the highest docked energies were chosen for AutoDock 
Vina against LdtMt5 (The optimal ligands in the active pocket, highlighted in blue, were selected for 
further MD analysis) 
Antibiotic class Ligand Identity Docking score (kcal 
mol-1) 
β-lactam 
1 ZINC 01662030 -8.4 
2 ZINC 02475683 -8.4 
3 ZINC 02475684 -8.4 
4 ZINC 01662029 -8.3 
5 ZINC 02462884 -8.3 
6 ZINC 03791246 -8.3 
7 ZINC 01412853 -8.3 
8 ZINC 01385054 -8.2 
9 ZINC 01412838 -8.2 
10 ZINC 01412839 -8.2 
Rifamycin 
1 ZINC 19569373 -8.6 
2 ZINC 03197606 -8.4 
3 ZINC 14828615 -8.4 
4 ZINC 01551761 -8.4 
5 ZINC 13125731 -8.2 
6 ZINC 13125732 -8.2 
7 ZINC 14693083 -8.2 
8 ZINC 15216498 -8.2 
9 ZINC 33832153 -8.2 
10 ZINC 39227187 -8.2 
Oxazolidinone 
1 ZINC 03921583 -8.7 
2 ZINC 03921580 -8.5 
3 ZINC 00586642 -8.4 
4 ZINC 00003190 -8.3 
5 ZINC 00594969 -8.3 
6 ZINC 03785925 -8.3 
7 ZINC 03921504 -8.3 
8 ZINC 05774946 -8.2 
9 ZINC 03791902 -8.2 
10 ZINC 03921352 -8.2 
Diarylquinoline 
1 ZINC 00022457 -9.0 
2 ZINC 00022456 -8.7 
3 ZINC 00057310 -8.2 
4 ZINC 00075863 -8.2 
5 ZINC 00097351 -8.2 
6 ZINC 00152025 -8.2 
7 ZINC 00236246 -8.1 
8 ZINC 00254016 -8.1 
9 ZINC 00118842 -8.0 
10 ZINC 00192295 -8.0 
Quinolone 
1 ZINC 80595608 -8.0 
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2 ZINC 80595598 -7.9 
3 ZINC 80595612 -7.9 
4 ZINC 78317542 -7.6 
5 ZINC 80595606 -7.6 
6 ZINC 79236395 -7.4 
AutoDock Vina top-ranked docking scores were considered, and the values are between -7.4 and -9.0 
kcal mol-1 
 
 
Table 4.4 The Schrödinger Maestro top ligands per class based on the highest Glide docking score 
against LdtMt5 (The optimal ligands in the active pocket, highlighted in blue, were selected for further 
MD analysis) 
Antibiotic class Ligand Identity Glide XP GScore (kcal 
mol-1) 
β-Lactam 
1 ZINC 03788344 -9.9 
2 ZINC 03788344 -9.7 
3 ZINC 03788344 -9.4 
4 ZINC 03788344 -9.2 
5 ZINC 03808350 -8.8 
6 ZINC 03788344 -8.9 
7 ZINC 03808351 -8.7 
8 ZINC 03808352 -8.7 
9 ZINC 03826440 -8.4 
10 ZINC 03826440 -8.4 
11 ZINC 03788344 -8.4 
12 ZINC 03785001 -8.2 
13 ZINC 03785029 -8.2 
14 ZINC 03808350 -8.1 
15 ZINC 03784242 -7.9 
Rifamycin 
1 ZINC 06483425 -9.3 
2 ZINC 06483423 -9.3 
3 ZINC 06483425 -9.2 
4 ZINC 06483423 -9.2 
5 ZINC 13532137 -8.0 
6 ZINC 59077219 -7.9 
7 ZINC 59077220 -7.9 
8 ZINC 59077221 -7.9 
9 ZINC 59077222 -7.9 
10 ZINC 59077219 -7.9 
11 ZINC 59077220 -7.9 
12 ZINC 59077221 -7.9 
Oxazolidinone 
1 ZINC 00108966 -8.0 
2 ZINC 00108966 -8.0 
3 ZINC 00108973 -8.0 
4 ZINC 00108973 -8.0 
5 ZINC 00108966 -7.9 
6 ZINC 00108966 -7.9 
7 ZINC 00108973 -7.9 
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Schrödinger Maestro top-ranked docking scores were considered, and the values are between -7.2 and 
-9.9 kcal mol-1. The class Quinolone was eliminated for further MD analysis because of its low docking 
score of -3.7 kcal mol-1 
4.3.3 Binding free energy analysis 
Our group has reported that MD studies provide comparable binding free energies for LdtMt2 with 
several inhibitors 31 to experiment.  Based on the calculated docking scores, the complexes showing the 
best score and best ligand conformations within the protein active site were subjected to further 
molecular dynamics simulations using the AMBER14 package.  A similar protocol was carried out by 
John et al. and Islam et al. 52, 53.  With a cut-off predicted binding energy (ΔGbind) of ≤ -30 kcal mol-1, a 
final set of lead compounds (n=10) (marked in bold) from four antibiotic classes was selected from 
Tables 4.5 and 4.6.  
  
8 ZINC 00108973 -7.9 
9 ZINC 00052567 -7.5 
10 ZINC 00052568 -7.5 
11 ZINC 02512954 -7.3 
12 ZINC 02512954 -7.2 
13 ZINC 00108966 -7.2 
14 ZINC 00108966 -7.2 
Diarylquinolone 
1 ZINC 00096619 -8.1 
2 ZINC 00002447 -7.7 
3 ZINC 00002447 -7.7 
4 ZINC 00007109 -7.5 
5 ZINC 00060410 -7.7 
6 ZINC 00060410 -7.7 
7 ZINC 00060410 -7.7 
8 ZINC 00060410 -7.7 
9 ZINC 00060410 -7.7 
10 ZINC 00060410 -7.7 
Quinolone 
1 ZINC 80595598 -3.6 
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Table 4.5 Binding free energies method and their corresponding components using MM-GBSA method 
for compounds screened against LdtMt5 in AutoDock Vina program. 
ZINC 
ID 
ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation  -TΔS ΔGbind 
β-lactam 
0247568
3 
-59.68 -9.72 -69.41 27.7 -6.82 20.88 -31.01 -48.52 
0246288
4 
-54.07 -8.97 -63.03 22.7 -6.42 16.28 -27.53 -46.75 
0379124
6 
-26.26 -
123.11 
96.85 -112.62 -3.1 -155.72 -18.6 -18.86 
Rifamycin 
1469308
3 
-42.27 -5.81 -48.07 22.49 -3.97 18.52 -2.03 -29.95 
1312573
2 
-30.71 -7.55 -38.26 18.27 -2.96 15.31 -15.55 -22.95 
1312573
1 
-28.75 -5.52 -34.27 19 -2.92 16.09 -20.68 -18.18 
Oxazolidinone 
0577494
6 
-30.17 -0.5 -30.67 8.68 -3.93 4.75 -20.58 -25.92 
0000319
0 
-32.67 -4.89 -37.57 15.9 -3.39 12.51 -17.07 -25.06 
0059496
9 
-26.73 -0.41 -26.32 9.77 -3.14 6.63 -3.58 -19.7 
Diarylquinolone 
0002245
6 
-47.08 -4.08 -51.15 -14.65 -5.36 9.28 -18.42 -41.87 
0002245
7 
-44.53 -5.72 -50.25 -16.46 -5.01 11.45 -23.61 -38.8 
0019229
5 
-35.19 -2.46 -37.65 14.48 -3.22 11.26 -21 -26.39 
Quinolone 
7831754
2 
-30.55 -
278.11 
-308.64 290.44 -3.91 286.52 -18.06 -22.12 
7923639
5 
-31.66 -
154.13 
-185.77 167.67 -3.79 163.88 -14.87 -21.89 
Compounds in bold are the best binders within the -30 kcal mol-1 ≤ screening threshold and compounds 
in normal text are below the threshold  
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Table 4.6 Binding free energies and their corresponding components using MM-GBSA method for 
compounds screened against LdtMt5 in Schrödinger Maestro. 
ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation -TΔS ΔGbind 
β-lactam 
03784242 -
28.18 
-
154.51 
-182.69 160.28 -4.08 156.20 -21.11 -26.49 
03785029 -
27.18 
-153.7 -180.88 159.8 -4.03 155.77 -24.48 -25.11 
03785344 -
19.65 
-
333.09 
-352.74 339.3 -3.43 335.87 -18.24 -16.87 
03785001 -
30.57 
-
175.27 
-205.83 179.63 -4.48 175.15 -16.06 -30.68 
03808350 -
30.12 
-
136.81 
-166.93 150.41 -4.72 145.69 -19.04 -21.23 
03808351 -
33.59 
-
188.02 
-221.61 191.16 -4.87 186.29 -27.84 -35.32 
03808352 -
34.38 
-167.3 -201.68 174.86 -5.36 169.5 -26.19 -32.18 
03826440 -
26.83 
-
176.63 
-203.45 184.25 -4.36 179.9 -18.32 -23.56 
Rifamycin 
06483423 -
37.88 
-10.71 -48.59 26.03 -4.57 21.45 -17.91 -27.14 
06483425 -39.5 -11.34 -50.85 27.31 -4.77 22.53 -11.67 -28.31 
13532137 -
46.38 
-12.24 -58.62 26.57 -5.16 21.41 -19.39 -37.21 
59077219 -9.81 -98.27 -108.1 103.06 -1.73 101.34 -14.14 -6.77 
59077220 -
17.38 
-
173.77 
-191.17 176.93 -3.29 173.64 -22.4 -17.53 
59077221 -
20.37 
-92.93 -113.32 104.55 -3.23 101.32 -17.38 -11.99 
59077222 -33.2 -
164.92 
-196.14 176.58 -4.28 172.3 -22.59 -23.84 
Oxazolidinone 
00052567 -
26.43 
-
304.35 
-330.78 315.3 -4.06 311.24 -22.5 -19.54 
00052568 -
32.74 
-307.5 -340.24 316.29 -4.38 311.91 -9.02 -28.33 
00108966 -
30.59 
-4.15 -34.74 12.44 -3.84 8.6 -18.77 -26.13 
00108973 -
43.19 
-3.93 -47.12 14.93 -5.02 9.91 -23.21 -37.21 
02512954 -
21.99 
-
331.59 
-353.58 332.66 -3.29 329.37 -20.23 -24.21 
Diarylquinolone 
00002447 -
44.45 
-
257.63 
-302.08 270.09 -5.69 264.4 -22.68 -37.68 
00007109 -
22.67 
-3.16 25.83 -3.16 12.22 9.45 -20.51 -16.38 
00060410 -
28.61 
-4.13 -32.74 12.17 -3.48 8.69 -14.97 -24.05 
00096619 -
34.15 
-4.99 -39.13 15.42 -4.18 11.24 -15.17 -27.89 
Compounds in bold are the best binders within the -30 kcal mol-1 ≤ screening threshold and compounds 
in normal text are below the threshold 
 
Two different classes of compounds were obtained as the best binders from utilizing the two docking 
programs.  AutoDock Vina identified two lead compounds in terms of highest binding, both 
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monobactams and these compounds showed greater predicted binding energies compared to the three 
carbapenems which were identified using Schrödinger Maestro (Table 4.7). 
 
Table 4.7 Identified lead compounds with their antibacterial class, ZINC ID, calculated binding 
energies and the corresponding chemical structure, ten in total 
Class ZINC ID ΔGbind (kcal mol−1) Structure 
β-lactam 02475683 -48.52 
 
 
02462884 -46.75 
 
03808351 -35.32 
 
03808352 -32.18 
 
03785001 -30.68 
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Diarylquinolone 00022456 -41.87 
 
00022457 -38.8 
 
00002447 -37.68 
 
Oxazolidinone 00108973 -37.21 
 
Rifamycin 13532137 -37.21 
 
Compounds in bold were screened by AutoDock Vina 23 and compounds in the normal text were 
screened by Schrödinger Maestro 24 
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The final set of compounds (n=10) had all parameters within the Lipinski’s and Veber’s constraints of 
drug-likeness (Table 4.8).  It is noteworthy that all the screened compounds revealed a topological polar 
surface area (tPSA) > 150 Å2, which is an indication of a high bioavailability 54.  
Table 4.8 Drug-like properties of the 10 potential lead from the ZINC database 
Compounds in bold were screened by AutoDock Vina and compounds in the normal text were screened 
by Schrödinger Maestro. Representations: * β-lactam; ˠ Diarylquinolone; ˟ Oxazolidinone; ʱ Rifamycin 
 
In light of the experimentally reported covalently bound interactions between L,D-transpeptidases and 
β-lactams, the subsequent section of this study focuses on better understanding of the binding 
interactions between the β-lactam class and LdtMt5.  To validate the virtual screening ranking and to 
compare the binding affinities, selected carbapenems known to inhibit LdtMt2 were screened for both 
LdtMt2 and LdtMt5 (Table 4.9).  According to the consistent trend observed in Table 9 in terms of the 
binding energies, the docking scores obtained seem to be valid. 
Table 4.9 Comparison of the calculated binding energies for carbapenems on LdtMt5 versus the 
calculated and experimental 55, 56 binding energies for LdtMt2 
Carbapenem LdtMt2 ΔGexp 
(kcal mol-1) 
LdtMt2 ΔGdocked 
(kcal mol-1) 
LdtMt5 ΔGdocked  
(kcal mol-1) 
Biapenem -9.055 -6.7 -6.2 
Imipenem -9.856 -6.5 -5.5 
Meropenem -8.256 -7.1 -6.3 
Tebipenem -9.455 -6.6 -6.0 
The ZINC IDs for biapenem, imipenem, meropenem and tebipenem are 03784073, 03830927, 
03808779 and 04072129 respectively 
  
ZINC ID xlogP Apolar 
desolvation 
(kcal mol-1) 
Polar 
desolvatio
n (kcal 
mol-1) 
H 
bond 
dono
rs 
H bond 
acceptor
s 
Net 
charge 
tPSA 
(Å2) 
Molecular 
weight 
(gmol-1) 
Rotatable 
bonds 
*02475683 4.37 11.33 -14.54 0 10 0 124 489.415 4 
*02462884 4.53 12.58 -14.66 0 8 0 105 445.406 4 
*03808351 -0.76 -8.64 -92.33 4 7 0 117 342.417 5 
*03808352 -0.76 -8.61 -86.43 4 7 0 117 342.417 5 
*03785001 4.73 1.62 -34.23 1 3 1 24 384.371 4 
ˠ00022456 4.06 1.31 -14.65 0 5 0 64 324.343 2 
ˠ00022457 4.49 1.62 -14.46 0 5 0 64 338.37 2 
ˠ00108973 0.69 -1.15 -18.45 1 6 0 67 267.329 4 
˟00002447 1.43 -1.02 -53.74 4 6 1 96 333.408 7 
ʱ13532137 0.92 -3.03 -13.32 5 7 0 127 318.281 2 
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4.3.4  Trajectory analyses of β-lactam-LdtMt5 complexes 
4.3.4.1  Root mean square deviation (RMSD) analysis 
RMSD is a measure of accuracy, comparing the differences between predicted values and observed 
values of a model 57.  The average values of the β-lactam-LdtMt5 complexes (A-E) (Figure 4.4) are 1.88, 
1.75, 1.35, 2.25 and 1.55 Å respectively which lies in the accepted range of <2.5 Å 14 for stable 
simulation.   
 
Figure 4.4 Time evolution of the root mean square deviation (RMSD) of the β-lactam- LdtMt5 
complexes of A 02475683-LdtMt5 (black), B 02462884-LdtMt5 (red), C 03808351-LdtMt5 (green), D 
03808352-LdtMt5 (blue) and E 03785001-LdtMt5 (yellow) during 20 ns MD trajectories 
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4.3.4.2  Analysis of the radius of gyration (Rg) 
The radius of gyration is defined as the moment of inertia of the C-α atoms from its centre of mass and 
it is used as an indicator of structural compactness of the protein-ligand complex 58, 59.  Figure 4.5 shows 
the Rg plots for the β-lactam-LdtMt5 complexes over a 20 ns trajectory.  The average Rg values for 
complex A (02475683-LdtMt5), B (02462884-LdtMt5), C (03808351-LdtMt5), D (03808352-LdtMt5) and E 
(03785001-LdtMt5) reveal great overall similarity.  The values are 29.65 Å, 29.60 Å, 29.83 Å, 30.25Å 
and 29.60 Å respectively. 
 
Figure 4.5 The radius of gyration (Rg) of the β-lactam-LdtMt5 complexes of A 02475683-LdtMt5 (black), 
B 02462884-LdtMt5 (red), C 03808351-LdtMt5 (green), D 03808352-LdtMt5 (blue) and E 03785001-
LdtMt5 (yellow) during 20 ns MD trajectories 
4.3.4.3 Binding free energy (∆Gbind) analysis of β-lactam-LdtMt5 complexes 
In this study, the calculated binding energies of β-lactam derivatives (meropenem and imipenem) 
against LdtMt2 from previous studies 
31, 60 were used to validate the selection of lead compounds which 
demonstrated the best binding affinity for LdtMt5.  The calculated binding free energies (∆Gbind) of the 
selected β-lactam-LdtMt5 complexes were obtained using the MM-GBSA method,  1000 snapshots at 10 
ps interval was extracted from the last 10 ns production MD trajectories.  The entropy (-TΔS) 
contributions were calculated using normal mode analysis 61, 62 by extracting 100 snapshots from the 
MD trajectories due to computation cost.  The contributing binding components upon complexation, 
namely, ΔEvdw, ΔEele, ΔGgas, ΔGpolar, ΔGnonpolar and ΔGsolvation are shown in Table 4.10.  The results reveal 
the binding free energies (∆Gbind) of -48.52 kcal mol-1 and -46.75 kcal mol-1 for complex A (02475683-
LdtMt5) and complex B (02462884-LdtMt5) respectively.  The binding free energies of complexes C 
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(03808351-LdtMt5), D (03808352-LdtMt5) and E (03785001-LdtMt5) are -35.32 kcal mol-1, -32.18 kcal 
mol-1 and -30.68 kcal mol-1, all between -30 kcal mol-1 and -40 kcal mol-1.  It was observed that 
compounds with a greater binding affinity (A and B) are characterised by a more negative van der Waals 
value and they are less electronegative as compared to the other compounds (C-E). 
Table 4.10 Calculated binding free energies and their corresponding components using MM-GBSA 
method for the selected β-lactam-LdtMt5 complexes. 
Compound ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvati
on 
-TΔS ΔGbind 
A 02475683 -59.68 -9.72 -69.41 27.7 -6.82 20.88 -31.01 -48.52 
B 02462884 -54.07 -8.97 -63.03 22.7 -6.42 16.28 -27.53 -46.75 
C 03808351 -33.59 -188.02 -221.61 191.16 -4.87 186.29 -27.84 -35.32 
D 03808352 -34.38 -167.3 -201.68 174.86 -5.36 169.5 -26.19 -32.18 
E 03785001 -30.57 -175.27 -205.83 179.63 -4.48 175.15 -16.06 -30.68 
Compounds in bold were screened by AutoDock Vina and compounds in the normal text were screened 
by Schrödinger Maestro   
4.3.4.4 Residue-inhibitor interaction analysis 
To further elucidate the possible intermolecular hydrogen bonding and electrostatic interactions 
between β-lactam-LdtMt5 complexes, we used LigPlot program 
63.  The active site of LdtMt5 is defined 
by four conserved residues (His287 (342), Thr302 (357), Asn303 (358) and Cys305 (360)) 13.  Figure 
4.6 shows the schematic representations of core amino acid residues interaction modes between the β-
lactam compounds (A-E) and LdtMt5.  It is important to note that the residue-inhibitor interaction of 
compound A with LdtMt5 demonstrates close hydrogen bond interaction between the ligand and two 
active site residues Asn303 (358) and Cys305 (360), which can be a possible explanation to the highest 
binding free energy observed.  Compound B interact with the residue Asn263 (318) and a water 
molecule which is within the active site (Figure 4.6) and binding free energies (Table 4.10) of both 
compounds (A, B) are within the same range.  Common among all 3 compounds (C-E) is the interaction 
with residue Arg242 (297).  Compound C has other interactions with residues Glu284 (339) and Gly304 
(359).  Val244 (299) is a common residue between compound D and E while each compound interacts 
with Gly304 (359) and Asn243 (298) respectively.  The other 3 compounds (C-E) also fall in a similar 
binding free energies range (Table 4.10) and they are unique in that they interact with different residues, 
although not with any of the active site residues. 
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Figure 4.6 2D schematic representations of the hydrogen and hydrophobic interactions between LdtMt5 
residues and the selected β-lactam compounds, ZINC ID (A) 02475683, (B) 02462884, (C) 03808351, 
(D) 03808352, and (E) 03785001.  All structures are average conformations generated from the last 10 
ns snapshots of each MD system 
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Results from virtual screening and docking studies demonstrated that several lead compounds from 
different classes of antibiotics potentially tend to bind to the active pocket of LdtMt5.  The binding free 
energies also demonstrate the favourable binding potential of our lead compounds to LdtMt5.  It is known 
that β-lactams, specifically carbapenems, form covalent bonds with the catalytic cysteine (305) residue 
of LdtMt5 due to the carbonyl functional group in the structural backbone.  However, results from the 
model as highlighted by the residue-inhibitor interaction analysis seem to suggest that other compounds 
may interact differently with LdtMt5.  Instead of forming covalent interaction, other potential inhibitors 
of LdtMt5 may perform competitive inhibition instead.  It is also important to note that the closer the 
inhibitor interacts with the active site residues, the higher the binding affinity it may have as 
demonstrated compound A (Figure 4.6). 
4.4 Conclusion 
In this study, virtual screening of compounds from ZINC database against LdtMt5 was investigated with 
AutoDock Vina and Schrödinger Maestro software programs.  The obtained docking scores presented 
a reasonable number of lead compounds which can be utilised as potential drug candidates against 
LdtMt5.  Despite the lack of overlap on the screened compounds using these two different software 
programs, both provided reasonable binding scores.  The observed exclusiveness of each program to a 
certain class of compounds strongly suggests that the effectiveness of a computational technique is 
subject to the software program utilised.  To improve the chances of getting a ‘lead compound’, different 
programs with alternative search algorithms need to be employed for the screening of compound 
libraries.  It is essential to verify virtual screening results with MD free energy calculations as was 
demonstrated before 14.  The screened lead compounds were subjected to the MM-GBSA approach.  A 
final set of compounds (n=10) from four antibiotic classes with ≤ -30 kcal mol-1 were obtained. 
The computational model presented in this study is robust in that its accuracy was validated on both the 
docking stage as well as on the MD simulations stage.  Such benchmarking offers baseline comparisons 
of experimental and computational data from a paralog of the enzyme under study which brings about 
comparable extrapolations applicable to the natural system.  The model as expressed through the 
docking affinities and binding energy calculations from MD simulations demonstrated strong binding 
ligands.  It should also be noted, however, that the residue-inhibitor interaction analysis further revealed 
that apart from the already known interactions, other compounds interact with other active site residues 
of the target.  This certainly paves the way to explore other β-lactam binding mechanisms and expresses 
the importance of molecular dynamics simulations in revealing other possible interactions within the 
active site of other transpeptidases.  We, therefore, conclude that pharmacophore-based virtual 
screening and molecular dynamics simulations are essential tools which will continue to play a 
significant role in drug design and identification of novel ligands.   
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Abstract 
Tuberculosis (TB) is one of the world’s deadliest diseases caused by the bacterium, Mycobacterium 
tuberculosis (Mtb).  The L,D-transpeptidase enzymes catalyze the most dominant 3 → 3 peptidoglycan 
cross-links of the Mtb cell wall and specific β-lactam antibiotics have been reported to inhibit its action.  
Carbapenems inactivate L,D-transpeptidases by acylation, although differences in antibiotic side chains 
modulate drug binding and acylation rates.  Herein, we used a two-layered our Own N-layer integrated 
Molecular Mechanics ONIOM method to investigate the catalytic mechanism of L,D-transpeptidase 5 
(LdtMt5) by β-lactam derivatives.  LdtMt5 complexes with six β-lactams, ZINC03788344 (1), 
ZINC02462884 (2), ZINC03791246 (3), ZINC03808351 (4), ZINC03784242 (5) and ZINC02475683 
(6) were simulated.  The QM region (high-level) comprises the β-lactam, one water molecule and the 
Cys360 catalytic residue, while the rest of the LdtMt5 residues were treated with the AMBER force field.  
The activation energies (ΔG#) were calculated with B3LYP, M06-2X and ωB97X density functionals 
with 6-311++G(2d, 2p) basis set.  The ∆G# for the acylation of LdtMt5 by the selected β-lactams were 
calculated as 13.67, 20.90, 22.88, 24.29, 27.86 and 28.26 kcal mol-1 respectively.  Several of the 
compounds showed an improved ∆G# when compared to the previously calculated for imipenem and 
meropenem for the acylation step for LdtMt5.  This model provides further validation of the catalytic 
inhibition mechanism of LDTs with atomistic detail.  
Chapter Five – ONIOM QM/MM Study 
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5.1  Introduction 
The understanding of the enzyme-catalysed reactions mechanisms is essential to the study of biochemical 
processes.  Possibly, an improved understanding can add to the development of novel inhibitors with greater 
therapeutic potential1.  In Mtb Peptidoglycan is required for major cell division, growth and recovery 
from dormancy.  This is a metabolically inactive state that allows the mycobacteria to endure hostile 
physical-chemical situations or nutrient malnourishment2.  This inactive state subsequently leads to 
latent infection which affects one-third of the world’s population2.  The β-lactam antibiotics, an 
effective therapeutic category of antibacterial3 agents for the inhibition of transpeptidases, which are 
required in cell wall biosynthesis4.  Majority of the cross-linkage has been reported to occur via 3→3 
linkages catalysed by L,D-transpeptidases which bypass the D,D-transpeptidase activity of penicillin-
binding proteins (PBPs), leading to high-levels of resistance to the drugs5-8.  The second type of cross-
linkage occurs via 4→3 linkages catalysed by D,D-transpeptidase (also PBPs).  This group of 
antibacterial drugs inactivate both transpeptidase enzymes2, 3, 5, 9-12.  Carbapenems are one group of β-
lactam antibiotics showed to have inactivated L,D-transpeptidase activity2, 5, 10-12.  As is the case for all 
cysteine proteases13, L,D-transpeptidases hydrolyse the peptide bonds by two catalytic processes that 
are required to start enzyme acylation by the second last peptide of the donor stem leading to the release 
of the C-terminal residue.  This is tailed by deacylation of this acyl-enzyme intermediate by an acceptor 
stem10, 14.   
Unique to Mtb, the majority of the cross-links are generated by L,D-transpeptidation reaction, making 
this enzyme essential in the adaptation of Mtb to the stationary phase5.  Combined inhibition of both 
transpeptidases (L,D and D,D) will permanently hinder the synthesis of the peptidoglycan sheet and 
therefore, destroy the bacteria15.  Erdemli and co-workers10 proposed mechanism of acylation of L,D-
transpeptidase to be built on cysteine protease mechanism.  This mechanism for LdtMt2 proceeds in two 
phases.  Firstly, is the acylation step, where the Cys352 thiolate is produced via abstraction of proton 
bonds on the acyl carbon of the substrate resulting in a tetrahedral intermediate.  Secondly, in the 
deacylation step, additional peptide stem goes into the catalytic pocket and binds to the residues with 
the side chain amide of the m-A2pm3′ residue.  In this step, His336 plays the role of the catalytic base 
via abstraction of a proton from the amine group of the mA2pm3′ residue, which in turn makes an attack 
(nucleophilic) on the carbonyl carbon of the acyl-enzyme10. 
Computational applications have been employed to investigate this mechanism, which corroborates 
experimental observations for the catalytic mechanism of L,D-transpeptidase 2, a commonly studied 
enzyme from Mtb16, 17.  The first computational study on the inhibition mechanism of L,D-
transpeptidase 2 was carried out using a hybrid DFTB/MM potential16.  The peptidoglycan fragment 
bound with the initial coordinates of the extramembrane portion of LdtMt2  (ex-LdtMt2) (PDB code: 
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3TUR) was replaced in silico, for the natural substrate.  Based on the results obtained, the formation of 
His336-imidazolium/Cys354-thiolate initiated a four-membered ring acylation step.  This is then 
followed by a single step attack of Cys 354 on the carbonyl carbon of the substrate. The aforementioned 
is the rate-limiting step, and it agrees with the experimental results for cysteine proteases.  The attack 
on the acyl-enzyme complex by the amine group of the subsequent substrate and results in the formation 
of  3→3 peptide bond (deacylation step) 16.  Fakhar et al.17 using a β-lactam model investigated the 
acylation of the β-lactam ring by LdtMt2 in Mtb with B3LYP/6-31 + G(d).  The acylation mechanism 
employed four-membered and six-membered ring transition states.  The calculated thermochemical 
quantities for the proposed models specified that the activation free energy for the six-membered ring 
transition states model was significantly lower in comparison to other models17. 
The crystal structure of LdtMt5 was recently solved both for apo (PDB code: 4Z7A
12) and meropenem 
bound (PDB code: 4ZFQ12).  Any Mtb strain with a deletion of LdtMt5 displays abnormal growth 
phenotype and is more vulnerable to killing by cell wall perturbing agents including carbapenems which 
are considered the last resort antibiotics to combat resistant bacterial infections in humans12.   
Herein we have investigated the acylation reaction of some selected β-lactam derivatives from our on-
going virtual screening against LdtMt5 via a 6-membered ring mechanism.  These results we hope will 
provide a reasonable computational model for designing new anti-Tuberculosis drugs.  This present 
work will adopt the protocol reported by Fakhar et al.17.  The selected β-lactams are shown in Figure 
5.1.  A water molecule will be evaluated as well as the active pocket of LdtMt5 at the quantum mechanical 
(QM) level, and the other portion of the enzyme at molecular mechanics (MM) level.  Compounds 1, 
3, 4 and 5 are carbapenems while compounds 2 and 6 are monobactams. 
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Figure 5.1 2D structures of the selected β-lactam derivatives. 
5.2  Computational methods  
A 6-membered ring transition state mechanism18, 19 for the acylation of carbapenems by LdtMt5 (from 
Mtb) was investigated with a water molecule within the active pocket.  QM/MM (ONIOM20) method 
calculations were applied.  The influence of catalytic water has been reported to play a vital role in 
enzymatic reactions17 using the ONIOM method20.   
5.2.1  System preparation  
The crystal structure of meropenem-LdtMt5 complex (Figure S1) was retrieved from protein data bank
21 
(PDB code: 4ZFQ, 2.8 Å resolution)12.   Meropenem was removed and complexed with the selected β-
lactam derivatives from the ZINC database22 as described in our on going virtual screening study.  The 
β-lactams were docked into the active site of LdtMt5 using AutoDock Vina and Schrodinger Glide 
programs. The ff99SB 23 force field was applied for the protein whereas the general AMBER force field 
(GAFF) 24 was used for the ligand.  System solvation for the complexes was performed in a 10 Å cubic 
box using the TIP3P water model.  To neutralize the system, counterions were added accordingly.  The 
protein-ligand complexes were parametrized by the Leap 24 module of the Amber14 package.  All 
simulations were performed using a 2fs timestep based on a study with similar protein size 25.  The 
partial Mesh Ewald (PME) 26 summation method was used to calculate the electrostatic forces with 
space cut-off of 12 Å.  Using the SHAKE algorithm 27, all bonds were constrained to hydrogen (H) 
atoms.  A two-stage energy minimization process, which is characterised by 2500 steps of steepest 
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decent (partial geometric minimization) and 2500 steps of the conjugated gradient (full geometric 
minimization) was carried out to eliminate steric clashes.  The solute molecule was first restrained at 
500 kcal mol-1, whereas the water molecules and the ions were relaxed.   
The starting structure was obtained from the previously minimized structure, upon deletion of all water 
molecules beyond a shell of 6 Å around the inhibitor-enzyme complexes. All counterions that were in 
far distant from the active site were removed. A similar approach has been reported before 28, 29.   
Prior to optimization in ONIOM, the TAO ONIOM toolkit30, 31 was utilized to generate the starting 
structure (for each system) containing the Cys360, β-lactams and the water molecule (QM/MM regions) 
around 6 Å around the active site while others more than 6 Å were held fixed 30, 31. This was done to 
prevent fictitious changes and instabilities in the geometries. The obtained structures showed a 
sufficiently close distance between inhibitor, Cys360 and water molecule for a nucleophilic attack to 
occur 32. QM/MM calculations implemented in Gaussian 0920 were used to investigate the mechanism 
of the reaction.  The cysteine catalytic active site (Cys360), all the selected β-lactams and the water 
molecule were placed at a high layer [B3LYP/6-31+G(d)4] while the other residues were at the low 
layer (AMBER) for geometry optimization. To obtain the transition state for each system, constrained 
interatomic distances (Figure 5.3) similar to those previously reported28 for LdtMt2 were applied.   All 
transition state calculations were verified by vibrational frequency calculations exhibiting only one 
imaginary frequency.  The intrinsic reaction coordinate (IRC) calculations were computed to determine 
the reaction pathway. A full unconstrained geometry optimization of the obtained transition states, 
reactant and product from IRC were performed. Single-point energy calculations were performed on 
the optimized structures of the transition states, reactant and product, resorting to the electronic 
embedding scheme with the different functionals (B3LYP, MO6, wb97X) and 6-311+G(2d,2p) basis 
set. These functionals have been reported to give reproducible results for thermodynamics and kinetics 
calculations33-35.  The frontier orbital (HOMO, LUMO) for β-lactams (1-6) complexed with LdtMt5 were 
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obtained using  B3LYP/6 31G(d,p).  The donor-acceptor interactions in the systems were evaluated 
using the natural bond orbital (NBO) calculations. 
 
 
Figure  5.2 2D structure of the 6-membered ring transition states starting structures obtained using 
constraints with ONIOM (B3LYP/6-31+G(d):AMBER), where a =1.64 Å, b = 2.14 Å, c =1.60 Å, d = 
1.58 Å, e = 1.3 Å, f = 1.3 Å.  The TS optimized coordinates of all enzyme-inhibitor complexes are 
provided in the supplementary material) 
5.2.3  Second-order perturbation analysis 
NBO analysis is used to interpret the extent and function of intermolecular orbital interactions in the 
molecular system, principally charge transfer36, 37.  The second-order perturbation theory is applied to 
estimate the energetic importance of all interactions between filled donor and empty acceptor NBOs. 
For each donor NBO (i) and acceptor NBO (j), the stabilization energy E(2) associated with 
delocalization is estimated as: 
𝐸2 = ∆𝐸𝑖𝑗 = 𝑞𝑗
𝐹(𝑖,𝑗)2
𝜀𝑗−𝜀𝑖
 
Where 𝑞𝑗 is the donor orbital occupancy, 𝜀𝑖 and 𝜀𝑗 are diagonal matrix elements and 𝐹(𝑖, 𝑗) is the off-
diagonal Fock matrix element. 
5.2.4  Frontier molecular (FMO) orbitals 
The electronic interaction between the donor and acceptor as well as the electron transfer in the 
molecular system principally relies on the spatial position of the FMO38.  The kinetic characteristics of 
reactants and reactions are assessed by considering only FMO interactions39.  To achieve this, the 
highest occupied molecular orbitals (HOMOs) and lowest unoccupied molecular orbitals (LUMOs) 
energies and the molecular orbital contributions were calculated using DFT40-42.   
 
 
a 
b 
c 
d 
e 
f 
ZINC03788344 
Cys360 
117 
 
5.3 Results and discussion 
5.3.1 Mechanistic study 
The activation free energies, enthalpies and entropies of the selected compounds, complexed with LdtMt5 
for the 6-membered ring reaction pathway of the acylation are listed in Table 5.1.  To investigate the 
accuracy and sensitivity of different functionals and method used, single point energy calculations of 
the respective structures (reactants, transition states and products) were performed using electronic 
embedding with B3LYP, M06-2X and ωB97X with 6-311++G(2d, 2p) basis set which have been 
reported to perform reasonable for kinetic and thermodynamic analysis33-35.  In our previous study, the 
critical catalytic role of water, known to play a vital role in reaction mechanism has been demonstrated9, 
17.  The kinetic parameters obtained from the proposed model with water (TS-6-water) showed a lower 
activation barrier when compared with the model without water in LdtMt2
17. The catalytic behaviour of 
the acylation of Cys360 in LdtMt5 with one water molecule in the binding pocket against the selected β-
lactams compounds was investigated.  As shown in Table 5.1, the lowest activation energy (∆G#) is 
obtained with B3LYP/6-311++G(2d,2p) basis set, and thus our elucidation will be based on the results 
from this functional. The 6-membered ring transition state ∆G# of compounds 2-6 differs by about 1 
kcal mol-1 while compound 1 showed the lowest activation barrier (Table 5.1).  A comparison of the 
ΔH values of the transition states for compounds 1-6 revealed that they are consistent with the results 
obtained for the calculated ∆G#.  
Our results also reveal that our proposed 6-membered ring transition state mechanism is comparable to 
the activation energies of the 6-membered ring TS of LdtMt2 achieved previously
28 in our group using 
the same functional and basis set.  In addition, the results revealed that this TS model with thermal 
corrections has a smaller value (between 14 and 28 kcal mol-1) for LdtMt5 compared to the ∆G# 19.98 
and 24.55 kcal mol-1 for a similar concerted pathway for imipenem and meropenem complexed with 
LdtMt2
28.  Meanwhile, a higher  ∆G# 53.29 and 91.08 kcal mol-1 for imipenem and meropenem against 
LdtMt5 respectively was previously observed
43.  Meropenem and imipenem were tested experimentally 
against LdtMt5, both drugs were reported to show slow acylation which indicates possibly higher 
activation energies.  
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Table 5.1 Relative energy, ∆H (kcal mol-1) and ΔS (kcal mol-1) of LdtMt5 for the 6-membered ring reaction pathway of the acylation step obtained in ONIOM 
model using different density functionals at 6-311++G(2d,2p):AMBER. 
aEnergies relative to reactant for total electronic energy (ΔE) and activation free energy (ΔG#, with thermal correction) using B3LYP, M06, ωB97X/6-
311++G(d,p):AMBER//B3LYP/6-31G(d,p):AMBER. R = reactant, TS = transition state and Pr = product.  (The TS optimized coordinates of enzyme-inhibitor 
complexes are provided in the supplementary material) 
Compounds 
  
  
R 
B3LYPa M06a ωB97Xa 
  
1 
  
∆E ∆G# ∆H ΔS ∆E ∆G# ∆H ΔS ∆E ∆G# ∆H ΔS 
0 0 0 0 0 0 0 0 0 0 0 0 
TS 17.36 13.67 13.41 0.26 21.71 18.03 17.77 0.26 23.08 19.39 19.13 0.26 
Pr -19.39 -19.36 -18 -1.36 -18.75 -18.72 -17.35 -1.37 -18.94 -18.91 -17.54 -1.37 
2 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 22.62 20.9 18.75 2.15 25.89 23.02 22.02 1.00 28.19 26.46 24.32 2.14 
Pr -19.66 -16.79 -19.75 2.96 12.12 14.99 12.03 2.96 13.66 16.54 13.57 2.97 
3 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 23.65 22.88 18.9 3.98 27.5 26.73 28.78 -2.05 28.69 27.92 23.95 3.97 
Pr -14.23 -12.96 -14.28 1.32 -11.6 -10.32 -11.65 1.33 -13.74 -12.47 -13.79 1.32 
4 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 25.01 24.29 21.68 2.61 27.33 26.62 24.01 2.61 30.77 30.05 27.44 2.61 
Pr -6.26 -4.69 -4.93 0.24 -4.48 -2.91 -3.16 0.25 -5.26 -3.68 -3.93 0.25 
5 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 29.3 27.86 25.62 2.24 32.15 30.71 28.47 2.24 34.12 32.69 30.44 2.25 
Pr -9.88 -8.46 -8.41 -0.05 -7.69 -6.27 -6.22 -0.05 -9.11 -7.68 -7.64 -0.04 
6 
  
R 0 0 0 0 0 0 0 0 0 0 0 0 
TS 28.33 28.26 21.54 6.72 33 32.91 26.2 6.71 38.22 38.14 31.42 6.72 
Pr -24.68 -23.23 -22.06 -1.17 -21.83 -20.38 -19.22 -1.16 -20.18 -18.73 -17.57 -1.16 
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Based on the results shown in Table 5.1 and Figure 5.3, compound 1 is the most reactive inhibitor in 
comparison to the other compounds.   
 
Figure 5.3 Gibbs free energy pathway for the 6-membered ring mechanism of inhibition of L,D-
transpeptidase (LdtMt5) by the β-lactams compounds obtained at (ONIOM) B3LYP/6-
311++G(2d,2p):AMBER, extrapolated from Table 1.  See Fig. 1 for the structure of the inhibitors. 
5.3.2 Frontier molecular orbitals and electrostatic potential mapping 
The difference in the LUMO-HOMO, also known as the energy gap helps to characterize the chemical 
reactivity and kinetic stability of a molecule44.  The frontier molecular orbitals (LUMO-HOMO) of the 
β-lactams plot is shown in Figure S3.  This energy gap for the studied compounds calculated by 
B3LYP/6-31G(d,p) is presented in Table S1.  The order of reactivity ranges from the lowest to highest 
in the order 2 < 1 < 3 < 4 < 5 < 6.  This order relatively follows the same order base on the ΔG# of the 
covalently bonded product formed after the acylation (Table 5.1), which indicates how fast or slow the 
kinetics of the reaction are.  Molecular electrostatic potential (ESP) calculations of the transition states 
structures were surface mapped and this parameter was then used to depict the size, shape, charge 
density and reactive sites of the molecules45, 46.  The mapped surface of the different compounds is 
presented in Figure 5.4.  The values of the electrostatic potential are signified by various colours; red 
denotes the regions of the most negative electrostatic potential, blue signifies the regions of the most 
120 
 
positive electrostatic potential and green represents the region of zero potential47.  Figure 5.4 gives a 
pictorial representation of the nucleophilic sites and relative reactivity of atoms.  It is evident in all the 
compounds that the site of nucleophilic attack between the Sγ and C3 atoms (red region) of cysteine 
and lactam ring respectively react with the electrophilic sites.  
 
 
Figure 5.4 Molecular electrostatic potential surface of the selected β-lactams—LdtMt5 calculated at the 
B3LYP/6-31 + G(d,p), mapped onto electron density (0.004 electrons per Å3) isosurfaces. The red 
regions correspond to the site most susceptible to nucleophilic attack. Blue and red regions represent 
positive and negative potential areas, respectively.   
5.3.3 Natural bond orbital (NBO) analysis 
Charge transfer, viz from a donor (bond or lone pair) to acceptor corresponding to a stabilizing donor-
acceptor interaction can be calculated using NBO analysis.  The charge transfer between the β-lactam-
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LdtMt5 complexes is of paramount importance.  The resulted donor, acceptor orbitals and energy of 
stabilization E2  is derived from the second-perturbation theory48, 49.  A larger E2 value indicates a 
stronger interaction between the electron-donors and electron-acceptors, i.e. the more donating 
tendency from donors to acceptors the greater the extent of conjugation of the whole system50.  In other 
words, a larger E2 value contributes to a lower energy.  The pictorial representation of the electron 
transfer for lactams—LdtMt5 complexes derived from this analysis is shown in Figure 5.5.  
 
Figure 5.5 Depiction of electron transfer for β-lactams/LdtMt5 complexes derived from second-order 
perturbation theory of NBO analysis.  The curved arrows (a, b and c) depict the direction of charge 
transfer from lone pair to antibonding (LP→σ*). (The TS optimized coordinates are provided in the 
supplementary material) 
As presented in Table 5.2, the 6-membered ring, stabilization energy E2 for the nucleophilic attack on 
the carbonyl group of compounds 4, 3, 5, 6, 2 and 1 by the thiol group of Cys360 are 8.01, 6.16, 5.49, 
3.40, 1.87 and 0.91 kcal mol-1 respectively. These values showed that the carbapenems have a more 
nucleophilic attack in comparison to the monobactam.  The E2 value of the 6-membered ring transition 
states for each complex from a lone pair (LP) of the Sγ atom of the donor to the acceptor (C3).  The 
concerted proton transfer to the β-lactam nitrogen (LP(Nβ)-LP*(He)) revealed compound 5 and 6 (1.64 
and 1.49 kcal mol-1, respectively) as the highest while compound 2 (1.00 kcal mol-1) the lowest.  The 
result follows a similar trend with the activation energies of compound 5 and 6 having lower activation 
energies.  
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Table 5.2 Second-order perturbation stabilization energies corresponding to the core intermolecular 
charge transfer interaction (Donor to Acceptor) of the LdtMt5 for 6-membered transition states of 
carbapenems obtained at B3LYP/6-311++G(d,p). 
Donor Acceptor E2(kcal/mol) 
1   
LP (Sγ) δ*(C3-O2) 0.91 
LP (H42)     δ*(N6-C7) 1.06 
2   
LP (Sγ) δ*(C3-O2) 1.87 
LP*(H21)     δ*(N2-C3) 1 
3   
LP (Sγ) δ*(C3-O2) 6.16 
LP*(H21)     δ*(N2-C30) 1.17 
4   
LP (Sγ) δ*(C3-O2) 8.01 
LP*(O-H21)     δ*(N2-C3) 0.14 
5   
LP (Sγ) δ*(C3-O2) 5.49 
LP (H41)     δ*(N5-C9) 1.64 
6   
LP (Sγ) δ*(C3-O2) 3.4 
LP* (H20)     δ*(N1-C4) 1.49 
 
5.4 Conclusion 
Due to the relatively weak in vitro inhibition of LdtMt5 by the carbapenems drugs currently employed, 
we used the β-lactam ring as a scaffold to screen similar compounds in the ZINC database to see their 
kinetic behaviour with this enzyme.  In this study, we investigated the acylation step of LdtMt5 by 
employing QM/MM (ONIOM) calculations.  The 6-membered ring mechanisms were investigated for 
the acylation reaction path of LdtMt5 with six selected β-lactams from the ZINC database.  The activation 
free energy (∆G#) obtained from the 6-membered ring TS reveal that all the β-lactams were 
thermodynamically favourable than previously calculated ∆G# for imipenem and meropenem 
complexed with LdtMt5.   Meropenem and imipenem were tested experimentally against LdtMt5, both 
drugs were reported to show slow acylation which indicates possibly higher activation energies. The 
obtained results are comparable to that observed for LdtMt2 albeit, for compound 1 the activation energy 
is considerably lower than that obtained for meropenem and imipenem in complexed with LdtMt2.  This 
suggests that compound 1 should, in theory, be a very potent inhibitor of LdtMt5.   
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The LUMO-HOMO energy gap values of the compounds are small suggestive of their structural 
stability.  ESP revealed that the site of reaction is chemically active sites viz the interaction of the lactam 
ring with the cysteine of LdtMt5.  It is important to stress that this study has in addition to the previous 
efficacy reported for carbapenems, the selected β-lactam derivatives showed a lower energy barrier 
difference found in acylation with these new derivatives against LdtMt5.  Consequently, these findings 
should be subject to experimental bioactivities of this enzyme, more specific binding thermodynamics 
assays i.e. isothermal titration calorimetry. Feedback from that will assist us to better validate our 
theoretical model and aid rational design of new compounds and potential drug candidates with higher 
inhibitory activity against Mtb.  
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CHAPTER SIX 
Conclusion 
Tuberculosis is one of the most deadly human infectious diseases and research in the area has led to 
significant and promising insights into combating this devastating disease1.  The incidence of the 
epidemics of HIV/AIDS, diabetes, and multidrug resistance have contributed to the susceptibility of TB 
globally.  Transpeptidases catalyze the polymerization of the peptidoglycan cell wall of Mtb and since 
mycobacteria cannot survive without PG, inhibiting its synthesis can be a powerful way to kill Mtb.  The 
genome of Mtb encodes five Ldt paralogs, namely LdtMt1 to LdtMt5.  Any Mtb strain that lacks a functional 
copy of an Ldt, namely L,D-transpeptidase 5 (LdtMt5), displays aberrant growth and this phenotype is 
more susceptible to killing by cell wall perturbing agents.  These include carbapenems, which are 
considered the last resort antibiotics to treat resistant bacterial infections in humans.  Carbapenems, a 
class of β-lactams, are more effective against LDTs responsible for the synthesis of PG in Mtb.  Despite 
incredible contributions worldwide on understanding the mechanism of L,D-transpeptidases inhibition 
(from Mtb) with respect to carbapenems, there are significant gaps yet to be addressed by researchers.   
In this thesis, the introductory chapter provides a summary of the necessary background for the rest of 
the thesis (Chapter one).  A detailed literature review (up to date) on the structure and function of L,D- 
and D,D-transpeptidase family of enzymes from Mycobacterium tuberculosis was presented in Chapter 
two.  The study summarizes the experimental and computational studies on L,D transpeptidases in Mtb 
that have been identified and validated.  The reported structures of L,D- and D,D-transpeptidases, as 
well as their functionalities, were reviewed and the proposed enzymatic mechanisms for L,D-
transpeptidases were summarized.  In addition, we provided bioactivities of known M. tuberculosis 
drugs against these enzymes based on both experimental and computational approaches.  In Mtb, 80% 
of the peptidoglycan layer has been reported 2, 3 to be crosslinked by L,D-transpeptidases.  Peptidoglycan 
is the exoskeleton of bacterial cells required for their survival and growth, therefore, Ldts that generate 
these linkages are potentially attractive targets for the development of new drugs to treat drug-resistant 
TB.  Among the five paralogs of Ldts present in Mtb, LdtMt2 is the commonly investigated.  LdtMt5 has 
been reported to be essential for proper maintenance of cell wall integrity of the bacteria but carbapenems 
showed negligible activity against it.   
Our group has previously studied the mechanism of carbapenems against LtdMt2
4-6.  In contrast to LdtMt5, 
carbapenems are very effective against LdtMt2.  This prompted us to investigate the inhibition mechanism 
of LdtMt5 against carbapenems using molecular dynamics and hybrid QM/MM methods.  The acylation 
mechanism of carbapenem—LdtMt5 in which the process occurs via a cyclic transition state (TS) as 
proposed earlier for L,D-transpeptidases7 was adopted for this study4. 
The first computational study was targeted at understanding the inhibition mechanism of carbapenems 
against LdtMt5 (Chapter three).  The binding free energies (including entropy contributions) of these 
complexes were calculated from the MD simulation using an MM/GBSA approach, the theoretical 
results revealed the best ∆Gbind for ERT—LdtMt5 followed by IMI—LdtMt5 then MERO—LdtMt5.  The 
Chapter Six - Conclusion 
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theoretical results revealed important interactions between the carbapenems on the following residues 
ARG297, MET316, GLU328, GLY338, GLU339, CYS360, HIS342, ASN358 and THR357 by per 
residue free energy decomposition and the hydrogen bonding analysis.  These interactions were also 
observed experimentally8.  In addition, the average binding affinities of LdtMt5 complexes were found 
to be less than that for LdtMt2 complexes, as expected.  Furthermore, the relative higher free energies of 
activation obtained from the mechanistic studies also support the weak binding of LdtMt5 against the 
selected carbapenems.  This study, therefore, confirms that the computational inhibitor-enzyme pre-
complex model for L,D-transpeptidase 5 correctly reflects experimental observations8 in terms of the 
activity and the free binding energies.   
In the second investigation, virtual screening of compounds from the ZINC database against LdtMt5 was 
investigated with AutoDock Vina and Schrödinger Maestro software programs (Chapter Four).  The 
obtained docking scores gave a reasonable number of potential lead compounds, which can be utilized 
as potential drug candidates against LdtMt5.  Despite the lack of overlap on the screened compounds 
using these two different software programs, both provided reasonable binding scores.  The two docking 
programs gave completely different results in terms of the specific drugs that were identified based on 
the respective scoring functions9.  Similar variations have been previously reported9-11.  In order to 
validate the docking results against a better method, the screened lead compounds were subjected to 
molecular dynamics simulations and free binding energies calculated using the MM-GBSA approach.  
The free binding energies of these compounds in this study against LdtMt5 showed better binding 
compared to meropenem and imipenem and are also comparable to those reported for LdtMt2 
experimentally7, 12, 13.  The outcome of this study provides insight into the design of potential novel 
leads for LdtMt5.   
The 6-membered ring mechanisms were investigated for the acylation reaction path of LdtMt5 with six 
selected β-lactams from the previous study (Chapter 4) using hybrid QM/MM calculations (Chapter 
five).  The activation free energy (∆G#) obtained from the 6-membered ring TS reveal that all the β-
lactams were more thermodynamically favourable than previously calculated ∆G# for imipenem and 
meropenem complexed with LdtMt5.  Meropenem and imipenem were tested experimentally against 
LdtMt5
8
, and both drugs were reported to show slow acylation, which indicates possibly higher activation 
energies.  The selected β-lactam derivatives against LdtMt5 showed a lower energy barrier difference for 
the acylation step than that calculated for meropenem and imipenem.  Consequently, these findings mean 
that bioactivity experiments on this enzyme, more specific binding thermodynamics assays (isothermal 
titration calorimetry) need to be undertaken.  This will assist in further validation of our theoretical model 
and aid rational design of new compounds and potential drug candidates with higher inhibitory activity 
against Mtb.  The entire work is thus summarized in this section (Chapter six) to provide an overall 
conclusion on the present study. 
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Future studies should include an adequately long molecular dynamics study of the enzyme with 
carbapenems to explore the significant loop regions responsible for the catalytic mechanism of the target 
as well as target-inhibitor interactions at the atomic level.  In addition, new β-lactams compounds should 
be computed against this enzyme with lower activation energies leading to improved bioactivity.  The 
computational model should be improved by introducing more water molecules around the active site 
of the Cys360 catalytic residues that will be treated at least at semi-empirical level. 
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Appendix 1. Supplementary material for Chapter 3 
 
Table S1  The protonation states of the titratable LdtMt5 residues at pH=7. 
Residues pKa 
GLU 58 4.56 
LYS 59 10.44 
ARG 60 12.42 
ARG 66 13.07 
ARG 70 13.17 
ASP 73 2.59 
ASP 77 4.04 
GLU 87 3.88 
ASP 90 2.49 
ARG 95 12.33 
LYS 104 10.58 
TYR 110 10.18 
ARG 112 12.5 
ASP 113 2.46 
ARG 114 12.67 
TYR 117 11.28 
GLU 121 3.81 
TYR 125 11.47 
ASP 126 4.03 
TYR 129 10.64 
HIS 138 7.16 
ASP 139 3.76 
LYS 141 10.64 
LYS 148 10.54 
LYS 156 10.29 
ASP 157 3.36 
ASP 181 3.06 
ASP 186 3.32 
LYS 187 10.63 
GLU 191 4.96 
ASP 199 4.03 
GLU 203 4.25 
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ASP 211 3.28 
GLU 212 4.77 
HIS 219 6.52 
GLU 224 4.62 
TYR 225 14.16 
TYR 226 13.69 
ASP 233 3.18 
ASP 235 4.26 
LYS 237 10.86 
ASP 245 3.14 
TYR 248 10.64 
ASP 252 3.63 
HIS 256 7.41 
ARG 261 13.52 
ARG 262 13 
ARG 273 13.1 
ASP 279 3.94 
ASP 285 2.52 
CYS 288 11.22 
ASP 294 2.28 
ARG 297 12.26 
ARG 301 12.54 
HIS 305 6.54 
GLU 309 3.8 
LYS 310 9.26 
ASP 313 3.6 
TYR 315 10.27 
TYR 323 9.5 
HIS 325 6.17 
GLU 328 4.67 
GLU 338 5.08 
HIS 342 6.48 
CYS 360 12.67 
GLU 366 4.65 
GLU 369 3.95 
TYR 371 13.94 
TYR 372 10.66 
TYR 377 12.18 
ASP 379 5.29 
GLU 382 4.62 
TYR 392 10.29 
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ASP 394 3.15 
ASP 396 3.84 
ASP 399 4.86 
ASP 403 2.37 
ASP 405 4.03 
  
 
 
Figure S1 The 3D conformations for (A) Imipenem and (B) Ertapenem (C) Natural substrate in 
complex with LdtMt5 enzyme obtained by molecular docking. 
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Figure S2   Histogram distribution of the tip-tip distances for ERT-LdtMt5, IMI-LdtMt5 and MERO-
LdtMt5 over the 60 ns MD trajectories: D1: PRO319-GLY349 D2: PRO319-ALA350 D3: PRO319-
GLN351 D4: ALA320-GLY349 D5: ALA320-ALA350 D6: ALA320-GLN351 D7: ALA321-GLY349 
D8: ALA321-ALA350 D9: ALA321-GLN351. 
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Table S2   Average, maximum and minimum values for the tip-tip distances for ERT-LdtMt5, IMI-
LdtMt5 and MERO-LdtMt5 over the 60 ns MD trajectories. 
ERT-LdtMt5 Flap tips 
Average 
distance(Å) Max. value Min. value 
 
PRO319-
GLY349 13.31875 18.5441 8.0934 
 
PRO319-
ALA350 13.3411 21.2384 5.4438 
 
PRO319-
GLN351 12.17885 19.5449 4.8128 
 
ALA320-
GLY349 12.76815 18.1888 7.3475 
 
ALA320-
ALA350 13.23585 20.3587 6.113 
 
ALA320-
GLN351 11.3033 18.5327 4.0739 
 
ALA321-
GLY349 9.369 14.3144 4.4236 
 
ALA321-
ALA350 10.29375 16.5666 4.0209 
 
ALA321-
GLN351 9.2049 14.8925 3.5173 
IMI-LdtMt5 Flap tips 
Average 
distance(Å) Max. value Min. value 
 
PRO319-
GLY349 18.74675 28.1251 9.3684 
 
PRO319-
ALA350 20.2258 29.9013 10.5503 
 
PRO319-
GLN351 18.6594 30.0674 7.2514 
 
ALA320-
GLY349 16.01705 25.9577 6.0764 
 
ALA320-
ALA350 17.74735 28.4055 7.0892 
 
ALA320-
GLN351 16.9422 28.4003 5.4841 
 
ALA321-
GLY349 13.4909 22.4313 4.5505 
 
ALA321-
ALA350 15.83605 24.7497 6.9224 
 
ALA321-
GLN351 14.7909 24.6841 4.8977 
MERO-LdtMt5 Flap tips 
Average 
distance(Å) Max. value Min.value 
 
PRO319-
GLY349 19.63605 31.2853 7.9868 
 
PRO319-
ALA350 19.9922 31.7357 8.2487 
 
PRO319-
GLN351 17.4153 29.4292 5.4014 
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ALA320-
GLY349 17.03175 29.4106 4.6529 
 
ALA320-
ALA350 17.66495 30.8501 4.4798 
 
ALA320-
GLN351 16.9422 28.4003 5.4841 
 
ALA321-
GLY349 15.65435 26.8576 4.4511 
 
ALA321-
ALA350 16.22155 28.1441 4.299 
 
ALA321-
GLN351 15.06445 26.4135 3.7154 
 
Table S3   Average, maximum and minimum values for the tip-tip distances for Free-LdtMt5 over the 
60 ns MD trajectories. 
Free- LdtMt5 Flap tips Average distance (Å) Max. value Min. value 
 
PRO319-
GLY349 20.30075 27.7099 12.8916 
 
PRO319-
ALA350 17.34275 24.6979 9.9876 
 
PRO319-
GLN351 16.49245 22.8007 10.1842 
 
ALA320-
GLY349 19.93465 27.7383 12.131 
 
ALA320-
ALA350 17.46865 24.5619 10.3754 
 
ALA320-
GLN351 16.06805 22.8366 9.2995 
 
ALA321-
GLY349 16.62965 24.41 8.8493 
 
ALA321-
ALA350 14.41665 21.1822 7.6511 
 
ALA321-
GLN351 13.102 19.5415 6.6625 
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Figure S3  The plot of per residue decomposition analysis of ERT—LdtMt5 complex. 
 
 
Figure S4  The plot of per-residue decomposition analysis of IMI—LdtMt5 complex. 
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Figure S5  The plot of per-residue decomposition analysis of MERO—LdtMt5 complex. 
 
 
Figure S6  The plot of per-residue decomposition analysis of SUB—LdtMt5 complex. 
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Figure S7   Solvent accessible surface area (SASA) of Free—LdtMt5 (blue), ERT—LdtMt5 (black), IMI—
LdtMt5 (red) and MERO—LdtMt5 (green) over the 60 ns simulation time.   
 
 
 
Figure S8   RMSD plot of backbone atoms of LdtMt5 over three 60 ns MD trajectories. 
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Figure S9  View of the binding site interactions observed for the minimized highest scoring MM-GBSA 
representative complex of each ligand: (A) meropenem, (B) imipenem, (C) ertapenem and (D) natural 
substrate. Where the protein residues numbers are in parenthesis as follows; LEU240(295), 
ARG242(297), ASN243(298), ARG246(301), GLU254(309), TYR256(311),  PHE259(314), 
MET261(316), SER262(317), ASN263(318), ALA265(320), ALA266(321), ILE271(326), 
GLU273(328), ALA276(331), ARG278(333), SER280(335), ASN282(337), GLY283(338), 
GLU284(339), PHE285(340), GLN296(351), VAL301(356), ASN303(358), GLY304(359), 
CYS305(360), ASP339(394).     
 
  
(A)                                                                                                                  (B) 
  
(C)                                                                                                                  (D)  
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Figure S10   2D structure of the 6-membered ring transition states obtained using constraints with 
ONIOM (B3LYP/6-31+G(d): AMBER).  (1): Carbapenem.  R1 = imipenem side chain, a =1.58 Å, b = 
2.32 Å, c =1.64 Å, d = 1.25 Å, e = 1.12 Å, f = 1.42 Å. (2): Carbapenem.  R1 = meropenem side chain, a 
=1.60 Å, b =2.52 Å, c =1.82 Å, d = 1.13 Å, e = 1.00 Å, f = 1.79 Å.  
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Figure S11   A pictorial representation describing the reactants, transition states and products of the 
complexes. 
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Fig. S12   Ligand RMSD plot for ertapenem (ERT), imipenem (IMI) and meropenem (MERO) over 60 
ns MD trajectories. 
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Appendix 2. Supplementary material for Chapter 4 
 
Table S1: A detailed summary of the binding energy calculations for the compounds in the other 
antibiotic classes  
ZINC ID ΔEvdw ΔEele ΔGgas ΔGpolar ΔGnonpolar ΔGsolvation -TΔS -ΔGbind 
Diarylquinolone 
00022456 -47.08 -4.08 -51.15 14.65 -5.36 9.28 -18.42 -41.87 
00022457 -44.53 -5.72 -50.25 -16.46 -5.01 11.45 -23.61 -38.8 
00002447 -44.45 -257.63 -302.08 270.09 -5.69 264.4 -22.68 -37.68 
Oxazolidinone 
00108973 -43.19 -3.93 -47.12 14.93 -5.02 9.91 -23.21 -37.21 
Rifamycin 
13532137 -46.38 -12.24 -58.62 26.57 -5.16 21.41 -19.39 -37.21 
Compounds in bold were screened by AutoDock Vina, and compounds in the normal text were screened 
by Schrödinger Maestro. 
 
Table S2: Distances in angstroms (Å) between the carbon atom of the carbonyl group of the β-lactam 
and the sulphur atom of the cysteine (CYS305 (360)) residue of the LdtMt5 active site 
 
β-lactam compound Distance before MD 
simulation (Å) 
Distance after    MD 
simulation (Å) 
A 7.164 5.442 
B 7.456 8.276 
C 4.077 7.929 
D 4.077 5.158 
E 5.327 5.486 
Triplicate MD simulations with varying initial atomic coordinates to confirm the stability of the initial 
simulation are shown in the figure below. 
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Figure S1: Time evolution of the root mean square deviation (RMSD) from MD simulations of one 
complexed structure at different velocities the during 20 ns MD simulation trajectory at 6ns (Data 3); 
12ns (Data 6) and 18ns (Data 9).   
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Appendix 3. Supplementary material for Chapter 5 
 
 
 
Figure S1  The 3D crystal structure of LdtMt5 (PDB code: 4ZFQ). 
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Figure S2. Optimized TS structures of (1) TS-6- ZINC03788344 and (2) TS-6-ZINC02462884 (3) TS-
6-ZINC03791246 and (4) TS-6-ZINC03808351 (5) TS-6-ZINC03784242 (5) TS-6-ZINC02475683  
obtained from an ONIOM (B3LYP/631+G(d): AMBER) calculation. 
 
 
1       2 
 
3       4 
 
5       6 
150 
 
Compound 1 (TS Coordinate) 
0 1 
 S-S             -1    2.73513600   -9.15245600    3.49405400 H 
 O-O            -1    0.11249900   -4.25111200    3.07908900 H 
 O-OH            -1    3.72473600   -2.47535800    1.72353400 H 
 O-OH            -1    0.09483700   -9.09991900    1.47570200 H 
 O-O             -1   -1.02610700   -7.30258100    1.86093000 H 
 N-N               0    1.72557300   -5.64749900    1.81104400 H 
 C-CM             0    3.14120000   -5.33838200    2.39501500 H 
 C-CT             0    2.63834400   -4.14055300    3.19443800 H 
 C-CT            -1    3.77939100   -6.54285600    3.09743400 H 
 C-C               0    1.20545300   -4.30674600    2.60110300 H 
 C-CA            -1    2.55633800   -7.48333500    2.82903500 H 
 C-CA            -1    1.40186500   -7.04480800    2.10807100 H 
 C-CT            -1    3.48809400   -2.85922300    3.06382600 H 
 C-CT            -1    4.09411300   -6.32786800    4.56735200 H 
 C-CT            -1    4.86675100   -3.13482900    3.66682500 H 
 C-C             -1    0.08172400   -7.79688700    1.84161600 H 
 H-HC            -1    3.76495000   -5.07157300    1.57085900 H 
 H-HC            -1    2.58484000   -4.39143500    4.28425600 H 
 H-HC            -1    4.68754300   -6.94193700    2.58158700 H 
 H-H1            -1    2.97024600   -2.02622700    3.59999000 H 
 H-HC            -1    4.37307800   -7.26556300    5.06441600 H 
 H-HC            -1    4.92333600   -5.61131400    4.69088800 H 
 H-HC            -1    3.22950500   -5.90434500    5.10586200 H 
 H-HC            -1    5.56219300   -3.51969400    2.90940800 H 
 H-HC            -1    5.30594300   -2.23101800    4.08969200 H 
 H-HC            -1    4.82846800   -3.88819900    4.47251800 H 
 H-HO            -1    2.87235600   -2.35896700    1.31844700 H 
 H-HO            -1   -0.79978100   -9.37150500    1.29060300 H 
 N-N               0   -0.11312600    0.15687800    2.87825400 H 
 H-H             -1   -0.91468300   -0.34106400    3.21799500 H 
 C-CT             0    0.33856400   -0.25048700    1.54053600 H 
 H-H1            -1    0.82349400    0.64867600    1.11962300 H 
 C-CT            -1    1.42545800   -1.37318200    1.45960200 H 
 H-H1            -1    1.99376900   -1.22304000    0.52385500 H 
 H-H1            -1    2.15066000   -1.14671300    2.26605900 H 
 S-SH             0    0.67383700   -2.95520900    1.02469900 H 
 H-H               0    1.28334100   -3.61273100   -0.25078500 H 
 C-C               0   -0.93400900   -0.46572200    0.65541200 H 
 O-O             0   -2.01671200   -0.40674200    1.18507500 H 
 O-O               0    1.60638200   -5.08340500   -0.72162200 H 
 H-H              -1    0.90381600   -5.35754400   -1.30954200 H 
 H-H              -1    1.63845000   -5.27921000    0.56347900 H 
 C-CT            -1    4.41201900   -9.64444500    3.15580800 H 
 C-CT            -1    4.44650900  -10.76822500    2.10968100 H 
 C-CT            -1    5.07653000  -10.20933700    4.41985100 H 
 H-H1            -1    4.96427400   -8.74637200    2.78797200 H 
 C-CT            -1    5.11670000  -11.91815800    2.79861300 H 
 H-HC            -1    5.02224000  -10.45941100    1.20183800 H 
 H-HC            -1    3.41482700  -11.04886100    1.78146900 H 
 H-H1            -1    5.97779600   -9.61189700    4.70563700 H 
 H-H1            -1    4.37073100  -10.20041300    5.28742100 H 
 H-H1            -1    4.44805800  -12.75340200    2.81219600 H 
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 N-N              -1    5.46084600  -11.61298300    4.06144100 H 
 H-H             -1    5.02388400  -12.42584700    4.44656100 H 
 C-CM            -1    6.38408800  -12.30313000    2.01304100 H 
 H-HC             0    7.39819200  -12.27169000    2.40319400 H 
 C-CM            -1    6.01227500  -12.58642000    0.54569600 H 
 H-HC            -1    5.01435500  -12.96956600    0.49820500 H 
 C-C              0    7.14253900  -13.22244300   -0.20465000 H 
 C-CT            -1    5.74820000  -14.75354200   -2.00158700 H 
 H-H1            -1    6.05194100  -15.70658700   -1.62165800 H 
 C-CT             0    7.51011800  -13.58157200   -3.88271600 H 
 H-H1             0    7.67684100  -12.78208600   -4.62996700 H 
 H-H              -1    5.98033600  -14.27526300   -5.24085800 H 
 C-C             0    7.60440800  -13.01444800   -2.47554600 H 
 N-N              0    6.96396900  -13.94259400   -1.51270300 H 
 N-N              -1    6.18591900  -14.14340800   -4.16560100 H 
 C-CT             0    5.46885300  -15.07693600   -3.39750000 H 
 O-O             -1    8.33197300  -13.16554500    0.13551300 H 
 H-H1             0    8.69067300  -12.94469600   -2.24349100 H 
 H-H1             0    5.58816000  -16.14529500   -3.66490100 H 
 H-H1            -1    4.44691800  -14.73809100   -3.47276100 H 
 H-H1             0    4.84991300  -14.39489200   -1.46535000 H 
 H-H              -1    7.19945300  -12.00584100   -2.14567100 H 
 H-H1             0    8.31823700  -14.33102800   -4.03191600 H 
 
Compound 2 (TS Coordinate) 
0 1 
 O               -1    1.50123800   -4.02014100    4.20143800 
 N                0    2.01921200   -5.95468800    2.42811400 
 C                0    3.54932600   -5.83623500    2.62400500 
 C                0    3.43705500   -4.49487200    3.32771600 
 C                0    1.92226800   -4.42987800    3.14878900 
 H               -1    3.95112300   -5.59141500    1.65578200 
 H               -1    3.26584700   -4.51816300    4.41139400 
 N                0    0.01271200   -0.20750000    2.63002500 
 H               -1   -0.89064200   -0.44390600    2.95226500 
 C                0    0.36120500   -0.64076300    1.33060000 
 H               -1    0.86550200    0.10703400    0.71247000 
 C               -1    1.35829400   -1.87116200    1.35912500 
 H               -1    1.91878000   -1.89939500    0.40579900 
 H               -1    2.10814300   -1.56376000    2.11375900 
 S                0    0.61744600   -3.46643500    1.69515700 
 H                0    0.92802300   -4.40313100    0.51133300 
 C                0   -0.96133000   -0.86531100    0.53882200 
 O                0   -2.02257000   -0.67746000    1.09204300 
 O                0    1.25530500   -5.62944300    0.05237100 
 H                0    0.42302800   -6.11903800   -0.04833600 
 H                0    1.67595100   -5.83159200    1.09393800 
 C                0    1.29948800   -7.17796900    2.71564400 
 C                0    1.01261900   -8.05096500    1.64609200 
 C                0    0.87377900   -7.53505100    3.99505600 
 C                0    0.26256600   -9.20355000    1.85942400 
 H                0    1.39886300   -7.84967500    0.65387000 
 C                0    0.16319900   -8.72323100    4.23008800 
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 H                0    1.13743700   -6.88138800    4.81061600 
 C                0   -0.16620600   -9.53799400    3.14232900 
 H                0    0.01871400   -9.84739000    1.02048900 
 H                0   -0.74352700  -10.44531700    3.30388100 
 C                0   -0.22084200   -9.13611900    5.62883900 
 H                0    0.65645500   -9.46501800    6.20026800 
 H                0   -0.67657100   -8.30375600    6.16804500 
 H                0   -0.93698300   -9.96417100    5.61680600 
 C                0    4.08976600   -7.04102400    3.35333700 
 C                0    4.43762800   -8.19614100    2.63496800 
 C                0    4.04929100   -7.11681100    4.75472200 
 C                0    4.73987700   -9.39300500    3.28583500 
 H                0    4.47377700   -8.15543900    1.54981500 
 C                0    4.32750800   -8.31011200    5.42467100 
 H                0    3.78359400   -6.24641000    5.34578900 
 C                0    4.66384400   -9.42748300    4.67203500 
 H                0    5.01637300  -10.28943000    2.74203300 
 H                0    4.29428600   -8.37297600    6.50780100 
 F                0    4.93830900  -10.59446100    5.31395500 
 C                0    3.87761100   -2.39591500    4.32087000 
 C                0    3.92707500   -1.02373700    3.82732800 
 C                0    4.33520800   -2.47920200    2.03568200 
 C                0    4.28670100   -1.04208700    2.48130600 
 N                0    4.14302100   -3.24612200    3.19503300 
 O                0    4.51809100   -2.92151300    0.91981400 
 O                0    3.67211200   -2.78909000    5.44527500 
 C                0    4.63325500    0.13245800    1.83444000 
 H                0    4.94692200    0.16938300    0.79887100 
 C                0    3.73111900    0.15248800    4.52306300 
 H                0    3.28324400    0.13248700    5.50907200 
 C                0    4.18485500    1.32999900    3.93259300 
 H                0    4.16108900    2.27209600    4.46058000 
 N                0    5.48292500    2.36267800    2.12624700 
 O                0    5.76565000    3.25959200    3.17273600 
 H                0    5.86569500    4.11294500    2.71593300 
 C                0    4.73565200    1.27698300    2.64686800 
 O                0    6.70961500    1.87414400    1.60802600 
 H                0    7.16889600    1.42442800    2.35198 
Compound 3 (TS Coordinate) 
0 1 
 O               -1    1.06484900   -4.43612200    2.82225100 H 
 N                0    2.90408400   -5.52374100    1.66931200 H 
 C                0    4.24262000   -5.02273200    2.16740000 H 
 C                0    3.57058800   -3.86971500    2.94664300 H 
 C                0    2.18567600   -4.36792200    2.38620100 H 
 H               -1    4.80524400   -4.60380800    1.31737500 H 
 H               -1    3.51837300   -4.04043300    4.00851400 H 
 N                0    0.05904100   -0.16766500    2.43907200 H 
 H               -1   -0.75476900   -0.70210100    2.67819400 H 
 C                0    0.48136800   -0.41936900    1.08738800 H 
 H               -1    0.75695800    0.50695600    0.52017600 H 
 C               -1    1.73935300   -1.34247600    0.94590600 H 
 H               -1    2.26712600   -1.12866000   -0.00160700 H 
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 H               -1    2.40748500   -0.94287000    1.73389200 H 
 S                0    1.49421900   -3.09011100    0.57341200 H 
 H                0    2.44389000   -3.84070600   -0.47149900 H 
 C                0   -0.77852100   -0.88489800    0.30785600 H 
 O                0   -1.81662300   -1.07695300    0.89898300 H 
 O                0    2.89069300   -5.00836100   -0.78602100 H 
 H                0    2.18087800   -5.43788600   -1.29406900 H 
 H                0    2.86185400   -5.40023600    0.27565000 H 
 C                0    4.25124200   -2.49936600    2.84584400 H 
 H                0    3.53939700   -1.74170300    3.20421000 H 
 C                0    5.49055000   -2.45776000    3.73723300 H 
 H                0    5.25024600   -2.76071100    4.75675200 H 
 H                0    6.25695400   -3.13520300    3.34802100 H 
 H                0    5.90666900   -1.44951000    3.74991500 H 
 O                0    4.72175400   -2.18819600    1.54639600 H 
 H                0    3.97807100   -2.27541000    0.92819400 H 
 C                0    2.64631500   -6.85142000    2.25930400 H 
 H                0    2.12149500   -6.71909100    3.21147600 H 
 H                0    2.00813000   -7.45589000    1.60856800 H 
 C                0    4.97512200   -6.23648500    2.81362600 H 
 C                0    4.04638400   -7.46551100    2.41523100 H 
 H                0    5.92622300   -6.37517200    2.29214800 H 
 H                0    4.39545400   -7.68372400    1.41169800 H 
 C                0    4.09255200   -8.79149100    3.16085200 H 
 C                0    5.17358300   -9.70814300    2.95113600 H 
 C                0    3.01849800   -9.19366600    3.93801600 H 
 C                0    5.13860700  -11.00330800    3.55158700 H 
 C                0    6.29663700   -9.38011700    2.12271500 H 
 C                0    2.98900700  -10.45902900    4.54672400 H 
 H                0    2.16376500   -8.54216400    4.07599100 H 
 C                0    6.22650500  -11.94543600    3.31072300 H 
 C                0    4.02736600  -11.34371300    4.35873600 H 
 C                0    7.30259500  -10.26411400    1.87897600 H 
 H                0    6.35374300   -8.39960600    1.66529600 H 
 H                0    2.13465100  -10.74069800    5.15572400 H 
 C                0    7.31145000  -11.57249600    2.46165700 H 
 C                0    6.24512100  -13.23502700    3.89504700 H 
 H                0    3.97123700  -12.31727700    4.83065100 H 
 H                0    8.11231300   -9.97560000    1.21893200 H 
 C                0    8.37877800  -12.49160700    2.22599900 H 
 C                0    7.28134500  -14.11434800    3.65980100 H 
 H                0    5.43845900  -13.55075300    4.54583900 H 
 C                0    8.34802100  -13.73919800    2.82559600 H 
 H                0    7.27465100  -15.09794000    4.12084300 H 
 H                0    9.16362200  -14.43612800    2.64851100 H 
 C                0    9.57401300  -12.13212600    1.36426400 H 
 H                0    9.99056800  -11.16832400    1.67987800 H 
 H                0   10.36011000  -12.88322800    1.53597300 H 
 C                0   10.10806100  -11.22284200   -0.86135700 H 
 C                0    8.52539000  -12.98894400   -0.72221000 H 
 C                0   10.16420100  -11.32213600   -2.20176600 H 
 H                0   10.68153500  -10.47896800   -0.31382500 H 
 C                0    8.53034300  -13.15542100   -2.05574700 H 
 H                0    7.88684900  -13.57709000   -0.07246900 H 
 C                0    9.44840700  -12.40104700   -2.98387400 H 
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 H                0   10.78391800  -10.61444900   -2.74750900 H 
 H                0    7.87941800  -13.90521100   -2.49424600 H 
 N                0    9.28211800  -12.01598500   -0.06890600 H 
 C                0    5.42003000   -6.26574700    4.27122300 H 
 O                0    4.96338700   -5.27415900    5.07262000 H 
 H                0    5.35056100   -5.45449900    5.95168500 H 
 O                0    6.16314800   -7.12259300    4.69318100 H 
 N                0   10.35259000  -13.36875300   -3.65908800 H 
 H                0   10.90915500  -12.88063100   -4.36303500 H 
 H                0   11.01663000  -13.71870200   -2.96755400 H 
 H                0    8.86833200  -11.95723100   -3.80740600 H 
 
Compound 4 (TS Coordinate) 
0 1 
 O               -1    0.13421400   -4.31300500    3.12795300 
 O               -1    3.74123500   -2.52915900    1.77849900 
 O               -1    0.11187900   -9.15373300    1.53073600 
 O               -1   -1.00906600   -7.35639900    1.91597900 
 N                0    1.80833000   -5.53082000    1.76046200 
 C                0    3.18591300   -5.34134800    2.45151400 
 C                0    2.65971800   -4.16812500    3.26857600 
 C               -1    3.79592800   -6.59663500    3.15262000 
 C                0    1.22619200   -4.30120200    2.65775400 
 C               -1    2.57342500   -7.53724800    2.88407200 
 C               -1    1.45355200   -6.76152600    2.13657200 
 C               -1    3.50518300   -2.91284800    3.11881300 
 C               -1    4.11120600   -6.38171200    4.62238500 
 C               -1    4.88410100   -3.18899800    3.72100100 
 C               -1    0.09882400   -7.85077700    1.89657700 
 H               -1    3.78185200   -5.12521700    1.62600700 
 H               -1    2.60104000   -4.44471100    4.33985600 
 H               -1    4.70460500   -6.99574600    2.63665600 
 H               -1    2.98774800   -2.08021500    3.65574100 
 H               -1    4.39021400   -7.31936300    5.11943300 
 H               -1    4.94035700   -5.66510600    4.74592900 
 H               -1    3.24654400   -5.95817000    5.16090400 
 H               -1    5.57919700   -3.57363600    2.96447700 
 H               -1    5.32301600   -2.28481900    4.14466800 
 H               -1    4.84547200   -3.94182700    4.52773200 
 H               -1    2.88941300   -2.41262900    1.37352500 
 H               -1   -0.78273900   -9.42532100    1.34564300 
 N                0   -0.07217700    0.12781000    2.86281200 
 H               -1   -0.93172200   -0.28723700    3.16295900 
 C                0    0.33372300   -0.16551900    1.53508800 
 H               -1    0.80645900    0.70249400    1.06460300 
 C               -1    1.40840000   -1.31943400    1.40453600 
 H               -1    1.97672400   -1.16920900    0.46881600 
 H               -1    2.13361900   -1.09286600    2.21101100 
 S                0    0.70744100   -2.93586500    0.98470200 
 H                0    0.97774200   -5.32091200   -1.20989100 
 C                0   -0.95429700   -0.39328100    0.69435900 
 O                0   -2.03191200   -0.35100400    1.24113200 
 O                0    1.69798300   -4.91233500   -0.70100500 
 H                0    1.75644400   -5.34826400    0.29446700 
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 H                0    1.36953700   -3.83445700   -0.26776800 
 S               -1    2.74966200   -9.18262200    3.53962700 
 C               -1    4.03820200  -10.03827800    2.65884400 
 C               -1    5.14185200  -10.46875900    3.61419500 
 C               -1    3.48646300  -11.28721300    1.98602200 
 H               -1    4.44017100   -9.32810000    1.89303800 
 C               -1    5.34059500  -11.96919300    3.45525300 
 H               -1    4.86015100  -10.22338600    4.66926700 
 H               -1    6.09114100   -9.92051000    3.39121700 
 H               -1    3.58126700  -11.20567100    0.87401600 
 H               -1    2.39781200  -11.40701200    2.21518100 
 H               -1    6.36118900  -12.18553200    3.05000800 
 O               -1    4.27270000  -12.48438300    2.50100200 
 N               -1    5.24035300  -12.64491000    4.75688900 
 H               -1    5.07771600  -13.62119400    4.61399600 
 H               -1    6.09311000  -12.51975800    5.26398100 
 
Compound 5 (TS Coordinate) 
0 1 
 O               -1    0.11611000   -4.25863600    3.07358000 
 O               -1    3.72473600   -2.47535800    1.72353400 
 O               -1    0.09483700   -9.09991900    1.47570200 
 O               -1   -1.02610700   -7.30258100    1.86093000 
 N                0    1.71771700   -5.64349300    1.80765400 
 C                0    3.13962500   -5.33624500    2.38077600 
 C                0    2.63219100   -4.14987900    3.19871800 
 C               -1    3.77939100   -6.54285600    3.09743400 
 C                0    1.20905300   -4.42316100    2.63601000 
 C               -1    2.55633800   -7.48333500    2.82903500 
 C               -1    1.40186500   -7.04480800    2.10807100 
 C               -1    3.48809400   -2.85922300    3.06382600 
 C               -1    4.09411300   -6.32786800    4.56735200 
 C               -1    4.86675100   -3.13482900    3.66682500 
 C               -1    0.08172400   -7.79688700    1.84161600 
 H               -1    3.76495000   -5.07157300    1.57085900 
 H               -1    2.58484000   -4.39143500    4.28425600 
 H               -1    4.68754300   -6.94193700    2.58158700 
 H               -1    2.97024600   -2.02622700    3.59999000 
 H               -1    4.37307800   -7.26556300    5.06441600 
 H               -1    4.92333600   -5.61131400    4.69088800 
 H               -1    3.22950500   -5.90434500    5.10586200 
 H               -1    5.56219300   -3.51969400    2.90940800 
 H               -1    5.30594300   -2.23101800    4.08969200 
 H               -1    4.82846800   -3.88819900    4.47251800 
 H               -1    2.87235600   -2.35896700    1.31844700 
 H               -1   -0.79978100   -9.37150500    1.29060300 
 N                0   -0.05550000    0.07324400    2.91133600 
 H               -1   -0.91468300   -0.34106400    3.21799500 
 C                0    0.34966800   -0.22120000    1.57806100 
 H               -1    0.82349400    0.64867600    1.11962300 
 C               -1    1.42545800   -1.37318200    1.45960200 
 H               -1    1.99376900   -1.22304000    0.52385500 
 H               -1    2.15066000   -1.14671300    2.26605900 
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 S                0    0.69711000   -2.95922200    0.86192200 
 H                0    1.45198100   -3.87670100   -0.26460600 
 C                0   -0.93979400   -0.43099100    0.72922300 
 O                0   -2.01826400   -0.40233300    1.28060800 
 O                0    1.62604500   -5.06703500   -0.64287400 
 H                0    0.80271400   -5.35607600   -1.07356500 
 H                0    1.64423500   -5.43966100    0.42499600 
 C                0    2.73760000   -8.98752200    3.05648600 
 C                0    3.30019300   -9.48238800    4.41689000 
 C                0    3.77780700   -9.58152800    2.03175900 
 H                0    1.77790700   -9.47548000    2.89470700 
 H                0    2.82965400  -10.45775000    4.64102000 
 H                0    3.09283700   -8.82291100    5.26125700 
 C                0    4.85484500  -10.28088400    2.88571700 
 H                0    3.28648600  -10.28061300    1.35073500 
 H                0    4.22222100   -8.79095300    1.42063000 
 H                0    4.63535600  -11.36184900    2.95772600 
 N                0    4.74117100   -9.60273600    4.18314200 
 H                0    5.21247500  -10.11348900    4.92756300 
 H                0    5.86484300  -10.16828100    2.47671300 
 
Compound 6 (TS Coordinate) 
0 1 
 N                0    2.43367500   -6.52887600    1.44291700 
 C                0    3.93374700   -6.59846400    1.26380300 
 C                0    4.04278400   -5.15322500    1.76688500 
 C                0    2.59708500   -5.13199200    2.29225500 
 H               -1    4.36465800   -6.57051800    0.22666700 
 H               -1    4.32826900   -4.88622700    2.75245700 
 N                0    0.06476100   -0.45786300    2.48974900 
 H               -1   -0.78677700   -0.89086400    2.77499800 
 C                0    0.46908800   -0.80651800    1.13032000 
 H               -1    0.95140000    0.09887600    0.67662500 
 C               -1    1.55336500   -1.92298200    1.01660600 
 H               -1    2.12167600   -1.77284100    0.08085900 
 H               -1    2.27856500   -1.69651200    1.82306300 
 S                0    1.26172700   -3.92746900    1.39631000 
 H                0    1.25859200   -4.84964500    0.00460600 
 C                0   -0.83293300   -0.95648500    0.27720600 
 O                0   -1.89812100   -0.87950300    0.84591300 
 O                0    1.06193300   -5.80268500   -0.64227100 
 H                0    0.25563600   -6.31160000   -0.69801600 
 H                0    1.82294400   -6.33192800    0.34715900 
 C                0    1.73280000   -7.68643000    2.01469800 
 C                0    1.85749200   -8.92189900    1.36732000 
 C                0    0.98112400   -7.57056400    3.17823800 
 C                0    1.25716300  -10.03619500    1.94459500 
 H                0    2.43381500   -9.03261300    0.44786500 
 C                0    0.43344200   -8.71425500    3.75120900 
 H                0    0.84704100   -6.58996800    3.62080500 
 C                0    0.55951000   -9.97035200    3.15699200 
 C                0    4.46739600   -2.77253600    1.25694600 
 C                0    5.35597700   -2.12701500    0.29478500 
157 
 
 C                0    5.15527200   -4.39223300   -0.31005000 
 C                0    5.91615700   -3.16524700   -0.46084000 
 N                0    4.29911400   -4.13344400    0.78564300 
 O                0    5.23285000   -5.42323200   -0.96420200 
 O                0    4.05129100   -2.34631200    2.31442400 
 C                0    7.20738300   -3.12514100   -0.89882600 
 H                0    7.66870500   -4.01000300   -1.32998800 
 C                0    5.93061000   -0.85677500    0.26369700 
 H                0    5.38576500    0.02459900    0.59987800 
 C                0    7.28730600   -0.82041100   -0.06656200 
 H                0    7.88627000    0.08340700    0.03655800 
 N                0    9.12871200   -2.39437200    0.29864700 
 C                0    7.91416400   -2.04074200   -0.36649500 
 C                0   -0.04768100  -11.19855400    3.75942100 
 H                0   -0.94228700  -11.50627100    3.20202900 
 H                0    0.65328900  -12.04143700    3.73981600 
 H                0   -0.34367800  -11.02981400    4.80060100 
 H                0   -0.11730200   -8.62073200    4.68399800 
 F                0    1.35849100  -11.22523500    1.31666700 
 C                0    4.68650000   -7.67400000    2.00239800 
 C                0    5.29314900   -8.71400800    1.27888400 
 C                0    4.80484800   -7.67740600    3.39878200 
 C                0    5.94355500   -9.74181900    1.96922500 
 C                0    5.44857500   -8.71407600    4.06824400 
 H                0    4.37032300   -6.84278700    3.94324000 
 C                0    6.01407700   -9.76953300    3.35337500 
 H                0    5.10124900   -7.99479600   -0.49608300 
 H                0    5.51052600   -8.70313500    5.15549500 
 H                0    6.51985100  -10.59312200    3.85326200 
 H                0    6.00656300  -10.96338900    0.44980000 
 O                0    6.56341800  -10.80106600    1.23263700 
 O                0    5.28854800   -8.84580700   -0.08283900 
 C                0    7.90566800  -10.55420700    0.74368800 
 H                0    7.89418100  -10.00170300   -0.19483600 
 O                0    9.45371100   -3.68489800   -0.10395600 
 H                0   10.40217700   -3.66181700   -0.25672100 
 O                0    8.55520500   -2.76932900    1.56710100 
 H                0    9.20081400   -2.44590900    2.20522400 
 H                0    8.46445800  -10.08478600    1.54649600 
 O                0    2.68948400   -5.02350800    3.56081600 
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Figure S3. The frontier molecular orbital (FMO) representing the LUMO-HOMO orbitals for  
6-membered ring mechanisms obtained using TDDFT/6-311++G(2d,2p).  The energy  
difference between LUMO and HOMO (energy gap) is represented in eV.  
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Table S1. Energetic parameters for the 6-membered ring mechanism obtained using TDDFT/6-
311++G(2d,2p).  The energy gap is represented in eV.  
Compounds EHOMO (eV) ELUMO (eV) ΔEgap (eV) 
1 -5.39 -4.3 1.09 
2 -5.85 -4.32 1.53 
3 -5.32 -4.05 1.27 
4 -5.83 -4.08 1.75 
5 -5.46 -3.7 1.76 
6 -4.19 3.96 0.23 
 
 
 
